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General introduction and Aim of the study
High-throughput identification of potential minor 
histocompatibility antigens by MHC tetramer-based 
screening: feasibility and limitations
Mixed functional characteristics correlating with TCR-ligand 
koff -rate of MHC-tetramer reactive T-cells within the naïve 
T-cell repertoire
Discovery of T-cell epitopes implementing HLA-peptidomics 
into a reverse immunology approach
Identification of clinically relevant minor histocompatibility 
antigens within the B-lymphocyte derived HLA-ligandome 
using a reverse immunology approach
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1     General introduction
Allogeneic hematopoietic stem cell transplantation
Allogeneic stem cell transplantation (alloSCT) is considered an effective curative therapy for 
various hematopoietic malignancies1-3. During this therapy patients receive a transplantation 
of multipotent hematopoietic stem cells derived from a genetically different donor. Pre-
transplantation, patients are conditioned with chemotherapy, irradiation and immune 
suppression to eradicate malignant cells and to allow engraftment of the donor derived 
stem cell graft. After conditioning, a donor hematopoietic stem cell graft is transplanted 
that can fully replace the damaged patient’s bone marrow. The efficacy of this therapy 
is affected by the pre-transplant doses of chemotherapy and irradiation. Conventional 
myeloablative conditioning includes intensive high-dose treatment aiming at complete 
eradication of malignant cells and prevention of graft rejecting by residual patient immune 
cells. This type of conditioning is associated with severe toxicity that can be potentially 
lethal. As a consequence, older and frailer patients who require a less toxic approach 
may receive non-myeloablative conditioning with lower-dose treatment4;5. This regimen 
is characterized by reduced intensity pre-transplantation treatment of patients aiming at 
sufficient immune suppression to allow donor stem cell engraftment and prevent graft 
rejection. Post-transplantation, durable engraftment of allogeneic hematopoietic stem cells 
may be achieved using both regimens followed by complete hematopoietic reconstitution 
within several weeks. Although both myeloablative and non-myeloablative conditioning 
aim at pre-transplant reduction of tumor burden, not all malignant cells can be eliminated. 
Residual malignant cells may remain in the patient and can lead to relapse of disease. 
As a consequence, both regimens rely on the graft versus leukemia (GvL) effect of donor 
immune cells to fully eradicate residual malignant cells.
Graft versus leukemia and graft versus host disease
The beneficial role of donor immune cells in controlling durable remission after hematopoietic 
stem cell transplantation was demonstrated when patients who developed graft versus host 
disease (GvHD) after alloSCT showed a lower leukemic relapse rate and an increased overall 
survival6;7. GvHD is a potentially life-threatening complication in which donor immune cells 
were demonstrated to attack healthy tissues of the host8;9. GvHD causes damage to many 
organs and especially targets the skin, gastrointestinal tract, liver and lungs. GvHD can be 
divided in two categories based on the onset of clinical manifestation. Whereas acute GvHD 
is usually observed within 100 days after transplant, chronic GvHD generally manifests later 
and may follow acute GvHD. Symptoms of acute GvHD can be divided in 4 grades depending 
on the severity of target organs inflammation whereas chronic GvHD has features more 
resembling autoimmune diseases. Although both types of GvHD may be treated with 
immune suppressive drugs this also increases the risk of infections and leukemic relapse. 
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 The role for T-cells in both GvL as in GvHD was demonstrated by the induction of 
remission in patients after withdrawal of immune suppression10;11. In addition, depletion of 
T-cells from the alloSCT graft was shown to be effective in reducing the incidence of GvHD 
but also resulted in an increased leukemic relapse rate12-16. More evidence that GvL was 
mediated by donor derived T-cells was provided by the induction of sustained remissions 
in patients with relapsed or persistent leukemia after alloSCT after treatment with donor 
lymphocyte infusion (DLI) from the original stem cell donor17. Although this form of 
immunotherapy, with unmanipulated T-cells, mediates GvL in various hematopoietic 
malignancies, the susceptibility of different types of malignancies to respond to DLI 
varies18-22. As T-cells play a crucial role in both the development of GvHD and GvL many 
strategies aim to minimize their role in GvHD while maintaining their beneficial GvL effect. 
By comparing different transplantation strategies in which donor grafts were used of either 
autologous, homozygous twin or allogeneic origin it was demonstrated that merely the 
presence of T-cells was not sufficient to mediate GvL and that a certain degree of genetic 
disparity between patient and donor was required23;24. The major determinant for the 
development of severe GvHD appeared to be disparities in genetic loci within the major 
histocompatibility complex (MHC), with an increased number of mismatched antigens 
predicting greater risk for GvHD. In humans, MHC is also called human leukocyte antigen 
(HLA). The percentage of T-cells within an individual T-cell repertoire that is capable to 
react with peptides presented in non-self HLA is high and ranges between 1-10%25;26. As 
a consequence, HLA-matched allo-SCT is preferable over HLA-mismatched allo-SCT to 
minimize the toxicity associated with more severe GVHD.
Human leukocyte antigens and antigen presentation
HLA-molecules are membrane-spanning heterodimers that are encoded by highly 
polymorphic genes and as a consequence are extremely variable in their primary 
structure. There are different classes of HLA and those that correspond to HLA class I are 
composed of a heavy α-chain and a β2 microglobulin. In contrast, HLA class II molecules 
are composed of a homogenous α- and β-chain. HLA-class I molecules present small 
cytosolic intracellular processed peptides, 8 to 11 amino acids in length, to CD8+ T-cells. 
HLA-class II molecules, which are structurally different, present peptides mainly derived 
from extracellular proteins, 12-25 amino acids in length, to CD4+ T-cells27. Peptides 
presented by HLA-class I molecules are the product of ubiquitinated proteins28;29. Ubiquitin 
is a small regulatory protein that post translation binds to proteins and regulates protein 
turnover as it signals for protein degradation in the proteasome30. Excessive or damaged 
intracellular proteins can be degraded via proteolysis in proteasomes, specialized protein 
complexes located in the cytoplasm. Protein degradation yields peptide fragments that are 
generally translocated by the transporter associated with antigen processing (TAP) into 
the lumen of the endoplasmic reticulum (ER), where they may be loaded onto an HLA-
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class I molecule if they bind into their peptide-binding pocket with sufficient affinity31.  The 
peptide-HLA complex is then guided through the ER to the cell surface for presentation 
to CD8+ T-cells32. Peptides derived from autologous proteins are continuously processed 
and presented at the surface of antigen presenting cells. The repertoire of peptides that is 
presented is restricted to self HLA-molecules and only represents a subset of the human 
proteome, all proteins produced from the human genome33. HLA-class I molecules are 
continuously expressed on all nucleated cells whereas expression of HLA-class II molecules, 
which are loaded with peptides generated by a different process called endocytosis, is 
more restricted to cells derived from the hematopoietic compartment, such as B-cells, 
monocytes, dendritic cells and macrophages, but can be induced in non-hematopoietic 
cells under inflammatory conditions34;35. Based on the extremely variable structure of 
HLA-molecules, it is very unlikely that two randomly selected, non-related, individuals will 
express identical HLA-molecules. As alloreactive T-cells, recognizing peptides in allo HLA-
molecules are present in high frequencies in peripheral blood, HLA-mismatched alloSCT 
may result in strong allo-HLA immunity36. Therefore, fully HLA-matched individuals, related 
or unrelated to the patient are ideal alloSCT donors.
T-cells and antigen recognition
The main mediators of GvHD and GvL are believed to be T-cells that play an important role 
in the adaptive immune response against various pathogens. T-cells are a subpopulation of 
lymphocytes that can be distinguished from other white blood cells by the presence of a 
T-cell receptor (TCR), through which they can distinguish self from mutated self and foreign 
antigenic peptides, presented in the context of HLA-molecules at the surface of antigen 
presenting cells37;38. The TCR is a transmembrane heterodimer consisting of a TCRα and a 
TCRβ chain that are linked with a disulfide bond and embedded in combination with the 
CD3 protein complex in the cell membrane. Each of these chains is composed of a variable 
and a constant region. The rearrangement of these chains during T-cell development and 
especially the random mutations in the extracellular complementarity-determining regions 
(CDR) within their variable regions establish a unique antigen-binding site for each TCR. 
The CD3 protein complex is composed of 3 different CD3 T-cell co-receptor chains (gamma, 
delta and epsilon) and a CD3 zeta-chain that can associate with the TCR and generate 
an activation signal upon antigen challenge. Together these molecules are called the TCR 
complex. The TCR of an individual T-cell is usually specific for a particular peptide-HLA 
complex. However, since a TCR can be activated by even a few crucial residues of the 
presented peptide, other peptides with high sequence similarities may also be recognized 
in a process called molecular mimicry39. Hematopoietic precursor cells are released from 
the bone marrow and thymus-homing progenitors migrate to the thymus to give rise to the 
T-cell lineage. After T-cell development in the thymus immune competent naïve T-cells are 
released in the periphery either committed to the CD4 or CD8 lineage that can home to 
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nonlymphoid tissues40;41. In the thymus positive selection takes place of T-cells expressing 
a TCR that is able to engage self-HLA molecules with low affinity that are tolerant for self 
peptides presented in the context of self-HLA42. Subsequently, T-cells with too high affinity 
to self-peptides in the context of self-HLA are eliminated through programmed cell death43. 
In the thymus, T-cells are not negatively selected towards peptides derived from mutated 
or non-self antigens.
 For activation of naïve CD8+ T-cells several simultaneous signals are required. First, 
the TCR should bind a non-self peptide presented by HLA class I molecules. This interaction 
is stabilized by an additional interaction of the CD8 co-receptor molecule with the HLA 
class I molecule. Secondly, binding of the CD28 co-stimulatory molecules to CD80 and 
CD86 expressed by the activated antigen presenting cells (APC) is essential. Helper T-cells, 
expressing a CD4 co-receptor are in addition important for optimal activation of naïve-CD8+ 
T-cells by the  induction of expression of CD80 and CD86 on the APCs and by the production 
of cytokines necessary for the proliferation of CD8+ T-cells. Upon activation, CD8+ T-cells 
will start to produce cytokines such as TNF-alpha and IFN-gamma and will be able to lyse 
the recognized target cells (e.g. infected cells, tumor cells) by a perforin, granzymes and 
granulysin mediated response 44;45. In addition, CD8+ T-cells can also induce apoptosis of 
target cells by binding with their surface expressed FAS ligand to FAS molecules at the 
surface of target cells. Specific antigen recognition results in a clonal expansion of antigen-
specific effector T-cells followed by a rapid contraction when the infection is cleared. After 
infection, memory T-cells survive that can initiate a faster and more efficient secondary 
immune response upon re-encounter with the antigenic peptides46;47.
 As described previously, T-cell activation is strictly regulated and multiple signals 
are simultaneously required to induce their effector function. To induce activation, the TCR 
complex needs to bind to non-self peptide presented on HLA of APC such as dendritic cells 
(DC). The strength by which a TCR interacts with a peptide-HLA complex is termed TCR 
affinity. Antigen engagement results in cross-linking of TCR and subsequent phosphorylation 
of immunoreceptor tyrosine-based activation motifs (ITAM) motifs on the proximal domain 
of the assembled CD3-TCR complex. This phosphorylation is mediated by protein kinases 
and initiates a cascade of signaling events that eventually results in translocation of 
transcription factors into the nucleus and transcription of effector molecules. As the affinity 
of a single TCR towards a single peptide-HLA complex is relative low, many TCR need to 
engage with their antigen and cross-link simultaneously to initiate T-cell activation. This 
results in TCR clustering in the immunological synapse, the interaction site between the 
APC and a T-cell. During the formation of this ring shaped structure, the TCR co-receptor 
molecules CD4 or CD8, co-stimulatory and adhesion molecules such as CD28, OX40, ICOS 
and LFA-1 are also recruited and clustered in protein islands and amplify the signaling 
process initiated by the TCR48;49. The affinity of the TCR for the presented peptide-HLA 
complex in combination with additional interactions via co-receptor, co-stimulatory and 
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adhesion molecules with their APC ligands, determines the overall strength by which a 
T-cell binds to a target cell, termed T-cell avidity.
 The activation of naïve T-cells is strictly regulated by the requirement of both 
TCR and co-stimulatory molecule stimulation. As a consequence, naïve T-cells can only be 
properly activated by professional APC that are frequently residing in the draining lymph 
nodes of infected organs50;51. Upon activation, naïve T-cells gain the capacity to migrate 
into the infected tissue and exalt their effector function.  In the absence of co-stimulation, 
TCR signaling alone will result in anergy of these cells52. In contrast, memory T-cells can be 
activated in the absence of co-stimulation. Although the molecular basis of this increased 
sensitivity remains unclear, both enhanced downstream signaling of TCR signaling and the 
expression of more and larger TCR oligomers at the cell surface enable the activation of 
these cells by every HLA-expressing cell53. As a consequence, memory T-cells can reside in 
peripheral tissues and epithelial cell layers, the main entry sites for pathogens, and enable 
long-term immunosurveillance to prevent secondary infections54-56. 
Minor histocompatibility antigens
Since T-cell mediated GvHD and GvL may also occur after fully HLA-matched alloSCT, 
disparities outside the MHC loci can also elicit T-cell reactivity. Detailed analyses of T-cell 
responses in patients responding to HLA-matched allo-SCT and subsequent DLI have 
demonstrated that the donor T-cells mediating both GVHD and GVL recognize minor 
histocompatibility antigens (MiHA)  presented in the context of HLA-class I and HLA-class 
II molecules on the surface of recipient cells57-65. These MiHA are immunogenic peptides 
derived from polymorphic proteins that differ between donor and recipient due to DNA 
sequence variations. The most frequent MiHA variations between two individuals are 
generated by single nucleotide polymorphisms (SNP) in the coding regions of the MiHA 
encoding genes66-68. When these SNP change the amino acid sequence of the protein 
they are called “nonsynonymous” while SNP that does not affect this sequence are called 
“synonymous”. Synonymous SNP in coding regions or those that are located in non-coding 
regions may still be responsible for T-cell recognition as peptides containing these SNPs 
may be produced due to differential protein synthesis caused by alterations in reading 
frame, gene splicing and messenger RNA stability69-72. As humans are diploid, two copies 
of each autosomal chromosome exist that both contain an allele of the MiHA encoding 
gene. If both alleles are identical, the MiHA is homozygously expressed. If the alleles are 
not identical for the SNP, the MiHA is heterozygously expressed. The minor allele frequency 
indicates the occurrence of the least common allele in a population. If an individual is 
homozygous for a given MiHA, there may be T-cells present within the T-cell repertoire that 
recognize the non-self alternative allelic variant of the MiHA with high avidity. If a donor if 
heterozygous for a given MiHA, T-cells that recognize both allelic variants of the MiHA are 
depleted from the T-cell repertoire in the thymus.
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 Variation in the DNA sequence of different individuals is common and is caused 
by spontaneous mutations, genetic recombination and driven by natural selection. To date, 
approximately 180 million SNP are listed in the bioinformatics NCBI dbSNP database that 
are mainly identified by the combined efforts of two massif whole genome sequencing 
consortiums73;74. On average, 3 million SNP were identified per individual genome. 
Consequently, two randomly selected individuals will be mismatched for hundreds of 
thousands of SNP. Despite these astonishing numbers, to date, only 50 MiHA have been 
identified by different molecular methods of which 44 are expressed at autosomal loci68;75. 
The ex vivo analysis of the recipient T-cell repertoire after allo-SCT for presence of T-cells 
directed against these MiHA revealed that the presence of these T-cells variable and some 
MiHA specific T-cells are more frequently observed than others76-79.
MiHA as relevant targets for adoptive immunotherapy
Currently, several strategies are exploited to generate MiHA-specific adoptive 
immunotherapy. As MiHA specific T-cells can both mediate GvL and GvHD, specificity is 
crucial. If donor derived T-cells recognize MiHA that are ubiquitously expressed on many 
tissues they may mediate both GvL and GvHD. However, if this response is directed 
against MiHA that are exclusively expressed on cells of the hematopoietic system, they 
may mediate GvL in absence of GvHD80. Donor-derived T-cells that target MiHA expressed 
on hematopoietic cells will selectively eradicate patient hematopoietic cells, including 
malignant cells. Hence, selective infusion of T-cells reactive with MiHA exclusively expressed 
on hematopoietic cells is considered an attractive immunotherapy to establish a potent 
GVL response in absence of GVHD81;82. However, a recent multicenter study demonstrated 
that although mismatching for hematopoietic restricted MiHA correlates with lower 
relapse rates, higher relapse-free survival and higher overall survival after allo-SCT, this 
was only observed in recipients with GvHD and not in those without GvHD. This indicates 
that adoptive immunotherapy should aim to enhance the GvL effect in a GvHD controllable 
manner83. 
 MiHA specific adoptive immunotherapy requires the ex vivo generation of 
sufficient numbers of donor derived high-avidity MiHA-specific T-cells. One way to achieve 
these numbers is by redirecting the specificity of donor T-cells by gene transfer of MiHA-
specific TCR. To prevent the induction of GVHD, the TCR genes should preferentially be 
transferred into donor T-cells with a known specificity that are unlikely to mediate GVHD, 
such as virus-specific T-cells84;85. Alternatively, sufficient number of MiHA specific T-cells 
can be achieved by repeated stimulation of donor T-cells with MiHA-peptide loaded or 
genetically MiHA gene transduced dendritic cells86-90.  Several clinical trials, using adoptive 
transfer of MiHA-specific T-cells have been performed thus far91;92. Although these therapies 
appeared to be relatively safe, clinical response is not always observed. A recent phase I 
trial, that included the adoptive transfer of MiHA-specific T-cells in patients with relapsed 
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leukemia, demonstrated the induction of a temporary complete morphologic remission in 
5 out of 7 patients92. Although promising, the assessment of the contribution of adoptively 
transferred MiHA-specific T-cells to the observed GvL response was complicated due to 
pre-therapy and concurrent administration of immunosuppressive agents.  Unfortunately, 
the infused cells failed to persist in vivo and as a consequence may not protect against 
future relapsed disease. The observed short life span of the introduced cells may be the 
result of extensive in vitro expansion culture protocols that result in short-lived terminally 
differentiated cells. Alternatively, MiHA specific T-cells may be isolated from the naïve T-cell 
repertoire, as these cells are not terminally differentiated upon expansion and may persist 
longer after infusion93. In a different immunotherapy approach the frequency of MiHA 
specific T-cells is increased by pre transplant vaccination of donors or by vaccinating patients 
after DLI with DCs that selectively present hematopoietic restricted MiHA peptides94-96. 
These strategies aim to stimulate long-term persistence of MiHA specific T-cell responses 
in vivo, and induce GvL without extensive T-cell manipulation. Although currently several 
MiHA specific immunotherapy strategies are exploited, a major limitation for broad clinical 
implementation of MiHA is the small number of identified MiHA derived from genes that 
are exclusively restricted to hematopoietic cells.
Strategies for the molecular identification of hematopoietic MiHA
Over the years, the discovery of MiHA is accelerated by the introduction of novel 
immunology approaches such as cDNA library screening97-99, genetic linkage analysis100;101, 
peptide elution from-HLA69;102;103, and genome-wide association studies64;104;105. Collectively, 
these methods use a forward immunology approach characterized by the isolation of 
activated T-cells from patients demonstrating a clinical response to DLI after allo-SCT 
and subsequent elucidation of the genomic locus and peptide sequence of the MiHA 
recognized. The intrinsic property of these methods is isolation of T-cells with antigen 
specificities which are not predefined. Stimulated by the emerging availability of public 
bioinformatics data on human genetic polymorphisms73;106, computer algorithms that 
predict peptide-HLA binding affinity, TAP transport, proteosomal cleavage and gene 
expression profiles107-110, an alternative method called “reverse” immunology is increasingly 
exploited to enhance the efficiency of characterizing hematopoietic MiHA with therapeutic 
potential. In this approach computational peptide predictions are the starting point and 
peptide candidates are subsequently screened for their capacity to induce a T-cell specific 
response111-113. This approach has the advantage to specifically screen for T-cells recognizing 
MiHA that are exclusively expressed by hematopoietic cells. Although this approach have 
been used extensively to discover tumor associated antigens (TAA), it only resulted in the 
identification of a few MiHA114;115. Thus far the numbers of immunogenic TAA and MiHA 
epitopes that were identified by reverse immunology approaches are in contrast with the 
large panel of candidate epitopes that can be generated using these algorithms. The overall 
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low efficiency may be explained by the observation that when such epitope predictions 
are solely based on computer algorithms that predict peptide-HLA binding affinity the vast 
majority of T-cell responses detected is directed against epitopes that are not naturally 
processed and presented and as a consequence these T-cells will not kill their target 
cells116-119. One possibility to evade this candidate selection problem is the identification of 
the HLA-associated peptidome of hematopoietic cells by mass spectrometric analysis. The 
implementation of HLA-peptidomics into a reverse immunology approach guarantees HLA-
restricted processing and presentation of eluted peptide candidates33;120;121.
 Although the generation of large panels of candidate epitopes is feasible, 
predicted MiHA can only be validated by the identification of high-avidity T-cells reactive to 
these antigens. The use of soluble fluorescently labeled major histocompatibility complex 
multimers (MHC-tetramers) has become a widely used approach to detect antigen-
specific T-cells in a diverse T-cell repertoire122. Whereas classical major histocompatibility 
complex multimer analyses are designed for the detection of immune responses to a few 
epitopes, large-scale screening of a multitude of different T-cell populations in a single 
sample is essential to keep up with demands to screen large predicted peptide libraries. 
The development of technology for high-throughput MHC-tetramer production makes 
it possible to screen for T-cell reactivity against large panels of potential MiHA by flow 
cytometry either by combinatorial coding or by extension of the number of fluorescent 
labels used for MHC-tetramer labeling123-127. In conclusion, differential tissue distribution of 
MiHA in patients may elicit high avidity donor derived T-cell reactivity that can mediate in 
GvL when the tissue distribution of the SNP is restricted to the malignant or hematopoietic 
compartment. If these MiHA are exclusively expressed on hematopoietic cells, these 
MiHA are attractive targets for adoptive T-cell therapy of patients with hematological 
malignancies. To date however, the number of known MiHA that form attractive targets 
for adoptive T-cell therapy remains limited. The development of efficient techniques to 
identify MiHA may increase the number of patients that may be treated with MiHA specific 
immunotherapy. In addition, future applications of MiHA specific immunotherapy may also 
benefit from increased knowledge of what source of T-cell populations should be uses 
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1     Aim of the study
Two decades ago, reverse immunology was postulated as an efficient and high-throughput 
approach for the identification of strongly immunogenic tumor antigens that could be used 
in immunotherapy. Encouraged by advances in T-cell culture techniques and the elucidation 
of structural components underlying the interaction of the T-cell receptor (TCR) of antigen 
specific T-cells with the peptide presenting major histocompatibility complex (MHC) on 
target cells, reverse immunology was expected to overcome the limitations of forward 
immunology approaches. Although promising, a typical reverse immunology approach in 
which the prediction of putative minor histocompatibility antigens (MiHA) candidates is 
the starting point and peptide candidates are subsequently screened for their capacity to 
induce a T-cell specific response appeared to be low efficient in identifying MiHA.
 In the past decade, rapid developments in the field of bioinformatics renewed 
the interest in using reverse immunology for MiHA discovery. The emerging availability of 
data on genome sequencing, human genetic polymorphism and gene expression profiles 
resulted in the prediction of large libraries of candidate MiHA for which the specific 
recognition by T-cell clones must be achieved in in vitro assays. In chapter 2, we investigate 
whether the genome-wide prediction of hematopoietic MiHA, coupled to the isolation of 
T-cell populations that react with these antigens is feasible using a novel technology for 
the high-throughput production of MHC-tetramers. Although the use of MHC-tetramers 
to detect antigen-specific T-cells in a diverse T-cell repertoire was already widely used, 
it was only after the development of UV-induced conditional ligand cleavage that this 
technology could be used on this scale. To this purpose a large set of putative HLA-A*0201 
binding hematopoietic MiHA is produced using various HLA-peptide binding algorithms. To 
allow high-throughput screening with a large set of MHC-tetramers in PBMC samples with 
low cell numbers, we first develop an approach to simultaneously isolate T-cells reactive 
with any of the MHC-tetramers by magnetic pull down, followed by in vitro expansion. 
Subsequently, flow cytometry analysis of antigen-specific T-cell responses in patients with 
various hematologic malignancies after allo-SCT, followed by functional testing of identified 
T-cell clones is used to assess the clinical value of predicted MiHA.
 Since the frequencies of antigen-specific T-cells in the naïve T-cell repertoire are 
very low, isolation of antigen specific naïve T-cells is challenging. In chapter 3 we aim to 
optimize the generation of naïve repertoire derived antigen-specific T-cell lines based 
on MHC-tetramer staining and magnetic-bead enrichment. To ensure their biological 
relevance, we select a variety of immunodominant cytomegalovirus (CMV) epitopes 
binding to various HLA-molecules (HLA-A1, A2, B7, B8 and B40). In this chapter we describe 
the functional heterogeneity of isolated CMV-specific T-cells within the total MHC-tetramer 
positive T-cell populations and focus on the predictive value of MHC-tetramer staining on 
T-cell reactivity as T-cells within a certain range of high avidity for their cognate ligand are 
believed to be most effective. We demonstrate that variations in the functional avidity of 
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the MHC-tetramer positive T-cells correlate with the structural avidity of their cell surface 
expressed TCR as measured by the dissociation kinetics of antigen specific TCR binding to 
monomeric peptide-MHC complexes.
 Although the rapid developments in the field of bioinformatics encourage the 
use of reverse immunology approaches, the gigantic amounts of data provided by gene 
sequence, expression and polymorphisms databases is overwhelming and may result 
in low efficient prediction of biological relevant MiHA. In chapter 4, we investigate the 
feasibility of implementing mass spectrometry based HLA-peptidomics into a reverse 
immunology approach as a reliable source for naturally processed and presented peptides. 
For this purpose HLA class I binding peptides are eluted from transformed B-cells, analyzed 
by mass spectrometry and matched with a database dedicated to identify polymorphic 
peptides. The resulting set of HLA-A*0201 binding MiHA candidates will be evaluated 
for their immunogenic potential in multiple selection steps. Based on these results we 
will develop an algorithm that can be exploited for the efficient identification of MiHA, 
that is used and further optimized in chapter 5 to study the clinically relevance of a new 
high priority set of eluted HLA-A*0201 and B*0702 MiHA candidates. In this study we will 
screen the T-cell repertoire of both healthy donors and patients that received an allo-SCT 
from a HLA-matched donor with a favorable SNP disparity for the availability of high avidity 
T-cells. Identified MiHA specific T-cells will be tested for their reactivity against primary 
hematopoietic malignant cells.
 Finally, the general discussion describes how our findings may contribute to 
the improvement of reverse immunology approaches for the identification of clinically 
relevant MiHA or other T-cell epitopes useful for adoptive T-cell therapies. In addition, 
novel technologies that have the potential to increase the efficiency of future reverse 
immunology based epitope discovery studies will be discussed.
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2     T-cell recognition of minor histocompatibility antigens (MiHA) plays an important role in the graft-versus-tumor (GVT) effect 
of allogeneic stem cell transplantation (allo-SCT). However, the 
number of MiHA identified to date remains limited, making 
clinical application of MiHA reactive T-cell infusion difficult. This 
study represents the first attempt of genome-wide prediction 
of MiHA, coupled to the isolation of T-cell populations that 
react with these antigens. In this unbiased high-throughput 
MiHA screen, both the possibilities and pitfalls of this approach 
were investigated. First, 973 polymorphic peptides expressed 
by hematopoietic stem cells were predicted and screened for 
HLA-A2 binding. Subsequently a set of 333 high affinity HLA-A2 
ligands was identified and post transplantation samples from 
allo-SCT patients were screened for T-cell reactivity by a 
combination of pMHC-tetramer-based enrichment and multi-
color flow cytometry. Using this approach, 71 peptide-reactive 
T-cell populations were generated. The isolation of a T-cell line 
specifically recognizing target cells expressing the MAP4K1IMA 
antigen demonstrates that identification of MiHA through 
this approach is in principle feasible. However, with the 
exception of the known MiHA HMHA1, none of the other T-cell 
populations that were generated demonstrated recognition 
of endogenously MiHA expressing target cells, even though 
recognition of peptide-loaded targets was often apparent. 
Collectively these results demonstrate the technical feasibility 
of high-throughput analysis of antigen-specific T-cell responses 
in small patient samples. However, the high-sensitivity of this 
approach requires the use of potential epitope sets that are not 
solely based on MHC binding, to prevent the frequent detection 
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Introduction
Patients with hematological malignancies can be successfully treated with HLA-matched 
allogeneic stem cell transplantation (allo-SCT) and subsequent donor lymphocyte infusion 
(DLI)1;2. The graft-versus-leukemia (GVL) effect of this successful immunotherapy is due 
to recognition by donor T-cells of minor histocompatibility antigens (MiHA) expressed on 
malignant hematopoietic recipient cells3-6. These MiHA result from genetic polymorphisms 
between donor and recipient that alter the HLA-associated peptide repertoire, and are 
therefore capable to elicit a potent T-cell response in the context of self-HLA7. Unfortunately, 
most MiHA are not solely expressed on hematopoietic cells but display a broad expression 
pattern in nonmalignant recipient tissues. As a consequence, DLI can induce or enhance 
graft-versus-host disease (GVHD), one of the main causes of transplant-related morbidity 
and mortality8;9. It is assumed that the selective infusion of T-cells reactive with MiHA 
exclusively expressed on recipient hematopoietic cells would help to separate the beneficial 
GVL effect from GVHD, and identification of MiHA with a hematopoietic expression pattern 
is therefore of interest.
 To date, the number of known MiHA that form attractive targets for antigen-
selective cell therapy remains limited. As a consequence of the requirement for both the 
relevant MiHA mismatch between donor and recipient and expression of the relevant 
HLA restriction molecule, the percentage of patients that can be treated with such MiHA-
selective cell therapy remains low10. Considering the complex gene expression profiles in 
hematopoietic cells11 and the enormous number of known allelic polymorphisms12, the 
existence of many more clinically applicable MiHA seems reasonable.
 Several biochemical and molecular methods have successfully led to the 
identification of MiHA including peptide elution from HLA, cDNA library screening, genetic 
linkage analysis, and genome-wide association analysis7;13-16. These methods identified 
MiHA using a forward immunology approach, based on the characterization of epitopes 
recognized by T-cells isolated during a GVL response. 
 The use of soluble fluorescently labeled multimeric peptide-MHC (pMHC) 
complexes has become a widely used approach to detect antigen-specific T-cells in a diverse 
T-cell repertoire17. Furthermore, the development of technology for high-throughput pMHC 
production18;19, makes it possible to also screen for T-cell reactivity against large panels of 
potential antigens  by flow cytometry either by combinatorial encoding20, or by extension 
of the number of fluorescent labels used for pMHC tetramer labeling21;22. 
 In this study we set out to determine whether genome-wide identification of MiHA 
by pMHC-tetramer screening is feasible. In addition, we assessed whether these screens are 
possible in an unbiased approach, in which patient are screened with a fixed set of pMHC 
tetramers. To this purpose, we first predicted a large number of potential MiHA epitopes 
using HLA-peptide binding algorithms, single nucleotide polymorphism (SNP) data and 
gene-expression databases. Subsequently, flow cytometry-based high-throughput analysis 
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of antigen-specific T-cell responses, followed by functional testing of identified T-cell clones 
was used to assess the clinical value of predicted MiHA. This unbiased screen resulted in the 
generation of a large number of pMHC tetramer positive T-cell lines. Subsequent functional 
analysis demonstrated the isolation of two high-affinity T-cell populations specific for the 
known HMHA-1 MiHA as well as a previously unknown epitope. However, since this novel 
epitope was not produced to a sufficient level by the endogenous antigen presentation 
machinery, it should not be considered a bona fide MiHA.
 Two major conclusions can be drawn from our study: First, high-throughput 
analysis of antigen-specific T-cell responses in small patient samples is technically feasible 
using the highly sensitive technologies developed here. Second, when such screens are 
performed using unbiased peptide sets that are based on epitope binding, irrespective 
of peptide processing data and SNP status of donor and recipient, the vast majority of 
T-cell responses detected are of insufficient avidity to allow recognition of endogenously 
produced antigen, or are directed against epitopes that are not naturally presented to a 
sufficient extent to allow T-cell recognition.
Results
Identification of genes with a hematopoiesis-restricted expression pattern
In many hematological malignancies it is likely to be essential to therapeutically target not 
only the differentiated leukemic cells, but also the leukemic stem cell fraction, because of 
this, genes that are expressed in hematopoietic precursor cells are of interest as a potential 
source of MiHA, as these genes are likely to be expressed in leukemic precursor cells as 
well. To obtain a better insight into the gene expression profiles of specific hematopoietic 
cell fractions, we performed microarray analyses on hematopoietic stem cells purified 
from bone marrow, G-CSF mobilized peripheral blood and cord blood. Both CD34+/
CD38- and CD34+/CD38+ fractions were analyzed, representing early and more committed 
hematopoietic stem cells, respectively. Subsequently, these data were merged with gene 
expression data for similar and other cell types from the NCBI GEO database23, to identify 
genes expressed in stem cells with a hematological restricted pattern. The robustness of 
the approach was shown by the identification of known hematopoiesis-restricted MiHA 
encoding genes such as HMHA-1 and PTPRC (CD45). In addition, ubiquitous and non-
hematopoiesis tissue specific genes like KLK2 and GAPD, were also found to have the 
expected expression profiles, demonstrating that this combined database was sufficiently 
robust to identify genes with a hematopoiesis-restricted expression pattern (e.g. ITGB2 
and FLT3 (Fig. S1A-F). The combined database was subsequently used to identify 79 non-
Y-chromosomal genes that are relatively specifically expressed in hematopoiesis-restricted 
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SNP identification in selected genes
The molecular basis for the immunogenicity of most MiHA is formed by amino acid 
changes in MHC-restricted epitopes that occur as a consequence of single nucleotide 
polymorphisms. Identification of such SNPs within our 79 hematopoiesis-restricted genes 
using the NCBI’s dbSNP polymorphism database24 revealed 315 SNPs, of which the majority 
was nonsynonymous. In addition, as MiHA have been reported to also be encoded by 
alternative reading frames5;6 (ARF) we also included synonymous SNPs to ensure no MiHA 
encoded by ARF were left out. At the time of this SNP selection (dbSNP build 126), allele 
frequencies were unknown for many of these SNPs, and SNPs with an unknown allele 
frequency were included.
Prediction of MiHA epitope candidates
To predict potential MiHA epitopes encoded by this set of SNPs, we generated peptide 
sequences in silico, based on the nucleotide sequences of both allelic variants of the SNP. 
Peptide sequences were generated both from the canonical and from the two alternative 
forward reading frames, using gene segment encoding ten amino acids N-terminal and 
C-terminal of the SNP-containing codon. This peptide sequence set was then used to 
predict 9-, 10- and 11-mer polymorphic HLA-A2 binding peptides using three different HLA-
peptide binding algorithms, Syfpeithi25, Bimas26 and netMHC27. Predicted HLA-A2 binding 
peptides were selected for further testing when at least passing the threshold for one of 
the three algorithms. Peptides predicted from an ARF were only selected if an upstream 
alternative start site was detected. In total, 973 unique peptides were selected with a 
predicted HLA-A2 binding affinity (Table SII). The successful prediction of known MiHA such 
as HMHA-1, indicated that the quality of the gene-expression and SNP databases combined 
with HLA-peptide binding algorithms was sufficient to predict putative MiHA (Fig. S1G,H).
Assessing the HLA-A2 binding affinity of predicted MiHA epitopes
To evaluate the HLA-A2 affinity of these predicted MiHA, the set of 973 peptides was 
synthesized and analyzed using two different MHC binding assays (“MHC ELISA” and  “MHC 
bead assay”) that are both based on UV-induced conditional ligand cleavage, followed 
by peptide affinity dependent rescue of the MHC complex18;28,29 (Fig. 1). To set selection 
thresholds for both binding assays, a number of control peptides with high, intermediate 
or low HLA-A2 affinity were included. Peptide-MHC rescue scores (RS) were determined 
in both assays and normalized to the high affinity CMV-pp65NLV peptide
30. Results of both 
assays showed a clear correlation and all control peptides demonstrated the expected 
HLA-A2 affinity. Based on this analysis, 333 peptides with RS≥57 (MHC-ELISA) or RS≥60 
(MHC-bead assay) were selected (Table SIII).
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Analysis of efficiency and sensitivity for pull down of MiHA specific T-cell 
populations
Antigen specific T-cells can be present at very low frequencies. MiHA specific T-cell responses 
may therefore go undetected, especially when analyzed directly ex vivo in clinical specimens 
that often contain only a few million cells and that are generally not obtained during the 
peak GVL response. To allow high-throughput screening with a very large unbiased set of 
pMHC tetramers in PBMC samples with low cell numbers, we first developed an approach 
to simultaneously isolate T-cells reactive with any of the pMHC tetramers, and then expand 
these T-cells in vitro, prior to flow cytometric analysis. To address the sensitivity of this 
approach, we attempted the detection of a MiHA specific T-cell population in an allo-SCT 
patient PBMC sample obtained at 15 months after DLI, and in which HMHA-1 specific T-cells 
were barely detectable (~0.01% of CD8+ T-cells) ex vivo. After magnetic pull down with the 
entire PE-labeled 333 pMHC tetramer set and subsequent expansion of the cells, HMHA-1 
reactive T-cells were clearly detectable at a frequency of 2.56% of total CD8+ T-cells (Fig. 
S2). Thus, magnetic pull down with large collections of pMHC tetramers can be used to 





















Figure 1. HLA-A2 affinity of predicted peptides measured in parallel by two different assays. HLA-A2 
affinity of 973 predicted MiHA peptides was measured in parallel by two different binding assays. Each dot 
(black) represents a pMHC complex rescued by a tested peptide after UV induced cleavage of a conditional 
ligand. On the y-axis rescue score (RS) are shown for MHC-ELISA assay. On the x-axis RS are shown for MHC-
bead assay. RS are normalized to the HLA-A2 high affinity CMV-pp65NLV peptide and CMV-pp65NLV peptide 
RS set to 100 for both assays. Selection threshold: RS≥57 (MHC-ELISA) and RS≥60 (MHC-bead assay). High 
affinity peptide controls: CMV-NLVPMVATV (green), FLU-GILGFVFTL (pink), EBV-GLCTLVAML (orange) and 
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Identification of MiHA specific T-cell populations
Having successfully established the feasibility of our pull down and in vitro expansion 
method for the detection of MiHA specific T-cells in small PBMC samples, we subsequently 
utilized the entire set of 333 PE-labeled pMHC tetramers to pull down MiHA specific T-cells 
from 20 HLA-A2 positive allo-SCT patients with various hematologic malignancies. Selected 
patients all demonstrated a clear graft versus leukemia response after DLI, and samples 
were obtained at the memory phase of the GVL response, when MiHA specific T-cells are 
expected to be present but at low frequencies. Following magnetic isolation, isolated cells 
were expanded in vitro until cell numbers allowed the detection of MiHA-reactive T-cell 
populations by MHC tetramer combinatorial encoding19;20;28;31. For this purpose, a set of 
fluorescently labeled pMHC tetramers was generated in which each specific pMHC complex 
was encoded by a unique combination of fluorochromes20, to screen for recognition of all 
333 selected epitopes in a limited number of stainings. The total set of selected epitopes 
was hierarchically clustered to 16 groups of up to 25 unique pMHC complexes according to 
the order of priority, i.e. SNP frequencies and HLA-A2 affinity (Table SIII). 
 After pull down and an average of two weeks of expansion, flow cytometric 
analysis of these samples revealed 71 different pMHC tetramer-reactive T-cell populations, 
specific for 47 unique pMHC complexes (Table SIV). In most cases, T-cell frequencies varied 
between 0.02% and 4.9% of total CD8+ T-cells. A representative example of a full panel 
with 25 different 2-color coded pMHC complexes is shown in Fig. 2A, in which 3 potential 
MiHA-tetramer reactive T-cell populations were observed for the predicted MiHA peptides 
89 (0.11%),104 (0.22%) and 109 (0.17%). In one patient we detected a T-cell population 
specific for the previously identified HMHA-1H epitope.
 To assess the peptide specificity and functional activity of these T-cell populations 
we selected the 21 most interesting MiHA specific T-cell populations for the generation 
of cell lines by pMHC tetramer based cell sorting (Fig. 2B-E). We based our selection on 
favorable SNP allele frequencies according to the dbSNP database and focused on T-cell 
populations that only showed reactivity with one of the allelic counterparts of a specific 
peptide. The purity of cell lines generated in this manner was verified by pMHC tetramer 
staining and 2 representative examples are shown in Fig. S2C,D. We were able to generate 
cell lines with sufficient purity for subsequent functional assessment for 17 out of 21 
selected T-cell populations.
Assessing the functionality of isolated T-cell lines by peptide stimulation
To analyze the functional activity of the isolated pMHC tetramer specific T-cells, we measured 
IFN γ production upon incubation with peptide-loaded HLA-A2+ target cells. As our T-cell 
isolations were solely based on pMHC tetramer reactivity and not on functional activity, we 
also measured the overall IFN γ secretion capacity of these cells, by nonspecific stimulation 
with αCD3/CD28 stimulation beads (Fig. 3A). Although IFN γ production capacity varied, 
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Figure 2. Detection of potential MiHA specific T-cell populations by pMHC tetramer staining. These 
FACS analyses show the detection of MiHA specific T-cell populations through dual-encoding after pMHC 
tetramer pull down and in vitro expansion. Shown are total CD8+ T-cells. All dot plots are shown with bi-
exponential axes and display fluorescence intensity for the indicated fluorochromes at the top and right of 
the plot matrix. Non-pMHC tetramer specific CD8+ T-cells are indicated black. Dot plots of pMHC tetramer 
positive T-cell populations are shown by staining one expanded cell culture with 16 separate panels of up 
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peptide specific IFN γ production could be demonstrated for 10 out of 17 pMHC tetramer 
positive cell lines, including 9 cell lines directed against potential MiHA and one directed 
against the known HMHA-1 epitope. Six cultures only demonstrated IFN γ production when 
stimulated with stimulation beads, indicating that these cell lines were not functionally 
reactive to peptide antigen. In addition, pMHC-tetramer positive cell line P235 PRKCB1RIG 
totally lacked IFN γ production capacity. Peptide-specificity of the 10 T-cell lines that 
produced IFN-γ upon peptide stimulation was confirmed by assessing TCR internalization 
upon stimulation with peptide-loaded target cells (Fig. 3B). TCR downregulation clearly 
correlated with IFN γ production and was observed for all cell lines that demonstrated 
peptide specific IFN γ production. Minimal downregulation was observed for the four 
tested cell lines that lacked peptide specific IFN γ production, as well as the cell line that 
showed no overall IFN γ producing capacity. Hence, these data indicate that 10 out of 17 
tested cell lines are reactive against their specific peptide when added exogenously. 
Wide range of peptide affinity observed for pMHC tetramer positive T-cell 
populations 
To examine the ligand sensitivity of the generated peptide specific cell lines, INF-γ 
production was measured after stimulation with T2 cells that were loaded with a range 
of peptide concentrations (Fig. 4). In this assay (performed for 8 representative cell lines), 
peptide concentrations required for T-cell recognition were compared to those required 
for a previously identified T-cell clone that is specific for the HMHA-1H epitope. This T-cell 
clone has been demonstrated to be present in a GVL response and was obtained during 
the subsequent memory phase. The 8 cell lines tested showed a wide range of peptide 
sensitivity. Specifically, the cell lines specific for P218 MAP4K1IMA and P46 HMHA1VLH were 
capable of target recognition at low picomolar peptide concentrations, similar to the 
peptide concentration required for the HMHA-1-specific control T-cell clone. Cell lines 
specific for P91 FLT3KVL, P309 HSPA6SMC and P188 FLT3ALA required low nanomolar peptide 
concentrations and those specific for P37 DOCK2SIQ, P203 ATP2A3KMN and P104 ZFP36L2RLL 
only showed target recognition at high nanomolar peptide concentrations (IC50: ±50pM, 
±5nM and ±500nM respectively for the three groups of cell lines). Comparison of the 
peptide concentration required for T-cell activation and the MHC binding affinity of the 
different peptides indicated that a requirement for high peptide concentrations to obtain 
patient BDY3356. Detection of three dual-labeled potential MiHA specific T-cell populations: P89 ITGAMRLQ 
(red), P104 ZFP36L2RLL (blue) and P109 FMNL1SLW (green). Frequencies indicate MiHA specific T-cells of 
total CD8+ cells. A selection of 21 potential MiHA specific T-cell populations was made with the highest 
clinical potential. Selected T-cell populations were derived from allo-SCT patient: OBB1465 (B), JMO2750 
(C), BDY3356 (D) and APM4461 (E). Dot plots shown are representative for all detected dual-positive CD8+ 
T-cell populations (red). 
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Figure 3. Peptide stimulation leads to IFN γ production and TCR downregulation for 10 out of 17 pMHC 
tetramer positive cell lines. Isolated pMHC tetramer positive cell lines were stimulated with peptide-
loaded HLA-A2+ T2 target cells for 18 hours. Data is shown for 17 cell lines that were successfully generated 
by flowcytometry based cell sorting. Tested cell lines were derived from four different allo-SCT patients as 
indicated at the top of the graph. As a control an alloreactive CTL clone specific for a HLA-A2 epitope was 
used (Allo-A2). (A) Antigen specificity and functionality was analyzed by cytokine secretion in a standard 
IFN γ ELISA. Cell lines were stimulated with non-peptide loaded T2 cells (dark grey), [1 ug/ml] peptide-
loaded T2 cells (black) and αCD3/CD28 stimulation beads (light grey). Data are presented as cytokine 
concentration. (B) Antigen specificity and functionality was analyzed by TCR internalization upon peptide 
stimulation. Cell lines shown were stimulated with [1 ug/ml] peptide-loaded T2 cells (black) and αCD3/
CD28 stimulation beads (light grey). TCR downregulation was normalized to stimulation with non-peptide 
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T-cell activation was not simply due to a lower pMHC affinity. As an example, the peptides 
recognized by cell-lines P91 FLT3KVL and P203 ATP2A3KMN displayed a comparably high MHC 
affinity (as measured in Fig. 1) as those of the two highly sensitive cell lines P218 MAP4K1IMA 
and P46 HMHA1VLH. Thus, the low peptide sensitivity of many of the isolated T-cell lines 
formed a direct reflection of a low affinity TCR-pMHC interaction.
Isolated T-cell populations are not involved in the clinical response 
To determine whether the observed T-cell reactivities could be involved in the clinical 
response observed after DLI in these patients, we screened the high- and intermediate-
avidity T-cell lines for differential recognition of patient- and donor-derived EBV-LCLs 
and T-cell-blasts. Results are shown for 5 representative T-cell lines isolated from patient 
BDY3356 and JMO2750 (Fig. 5A,B). Peptide loaded target cells of both donor and recipient 
origin were recognized by all cell lines. In contrast, all cell lines were unable to recognize 
recipient target cells, indicating that these cells were not likely to be involved in the GVL 
response observed in these patients. As a control, all hematopoietic target cells were 
recognized by an HLA-A2 alloreactive CTL control clone, indicating that HLA-A2 expression 
was sufficient to allow target-cell recognition. Notably, recognition of recipient cells was 
also not observed for the HMHA-1 specific cell-line.
 To test whether the lack of reactivity that was observed could be explained by 
absence of the immunogenic MiHA allele variants, we next screened the SNP haplotypes 
for selected donor-recipient pairs (Table I). For 15 out of the 17 functionally tested cell 


























Figure 4. Analysis of peptide affinity of pMHC tetramer positive cell lines. MHC tetramer positive T-cell 
lines demonstrated a wide range of peptide sensitivity. HLA A2+ T2 cells were pulsed with specific MiHA 
peptide. Peptide concentrations were titrated in 10-fold dilution steps starting from 10ug/ml. T-cell reactivity 
was analyzed by cytokine secretion in a standard IFN γ ELISA. Data are presented as cytokine concentration. 
Shown are eight representative generated T-cell lines and a high affinity control clone specific for HMHA-1H 
(open square). Cell lines APM4461 derived P37 DOCK2SIQ and JMO2750 P185 HSPA6FMT were not tested due 
to technical limitations.
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Figure 5. No recognition of hematopoietic donor and recipient target cells by MiHA specific T-cells. 
Isolated IFN γ producing cell lines were stimulated with HLA-A2+ donor and patient derived hematopoietic 
target cells for 18 hours. T-cell reactivity was measured in a standard IFN γ ELISA. Data are presented as 
cytokine concentration. Cell lines shown are representative for all cell lines. As a control for T-cell reactivity 
an alloreactive HLA-A2 specific CTL clone was used (black). (A) BDY3356 derived cell lines P37 DOCK2SIQ 
(white), P203 ATP2A3KMN (dark grey) and P218 MAP4K1IMA (light grey) stimulation with donor and recipient 
T-cell blasts and EBV-LCLs loaded with (+) or without (-) specific peptide [1 ug/ml]. (B) JMO2750 derived cell 
lines P104 ZFP36L2RLL (dark grey) and P188 FLT3ALA (light grey) stimulation with donor and recipient T-cell 
and EBV blasts loaded with (+) or without (-) specific peptide [1 ug/ml].
addition, only 7 out of 15 tested cell lines recognized “non-self” antigen variants (i.e. the 
variant not encoded by the donor genome), whereas 8 cell lines recognized “self” antigen 
variants. Interestingly, both high-avidity T-cell populations that were isolated (specific for 
P218 MAP4K1IMA and P46 HMHA1VLH) recognized “non-self” antigen variants, whereas 
all cell lines that recognized “self” antigen variants were of intermediate or low-avidity. 
These results suggest a possible role for clonal deletion of high-avidity T-cells specific for 
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hypothesized that the low or intermediate avidity of most MiHA specific cell lines that 
we generated could explain the inability of these cell lines to recognize endogenously 
processed antigen. The only two cell lines that were derived from a transplantation setting 
in which there was a relevant SNP mismatch between the donor and recipient were specific 
for P23 CD79bLLL and P109 FMNL1SLW. Although these cell lines could theoretically recognize 
the immunogenic MiHA allele variant of the patient, both cell lines demonstrated no 
recognition of endogenously processed antigen in the prior functional analyses.
Assessing the MiHA recognition potential of isolated T-cell populations 
The above data indicate that unbiased MHC tetramer-based enrichment often results in 
the isolation of T-cell populations that do not play a role in GVL, as based on the lack of 
the relevant mismatch. However, this does not exclude that such cell populations could 
recognize target cells that do express the relevant MiHA allele. To investigate the potential 
capacity of these MiHA specific T-cell populations to recognize MiHA allele -positive 
target cells, the cell lines were tested against a panel of SNP-genotyped HLA-A2+ EBV-
LCLs. Interestingly, the HMHA-1 specific T-cell population, isolated from a transplantation 
setting in which both donor and recipient were homozygous negative for the immunogenic 
allele variant of the MiHA, recognized target cells in accordance with their SNP haplotype. 
Specifically, this tested cell line strongly recognized non-peptide loaded homozygote 
positive and heterozygote EBV-LCLs, whereas homozygote negative EBV-LCLs were not 













P4 PLCB2 R I L V G R L R A A A AG AA no self
P23 CD79b L L L S A E V Q Q H L A GG AG yes non-self
P37 (BDY) DOCK2 S I Q N Y H P F A A AA AA no self
P37 (APM DOCK2 S I Q N Y H P F A A AA AA no self
P46 HMHA1 V L H D D L L E A A GG GG no non-self
P89 ITGAM R L Q V P V E A V G GG GG no self
P91 FLT3 K V L H E L F G M D I A AA AA no self
P104 ZFP36L2 R L L P L W A A L P L G GG GG no self
P109 FMNL1 S L W Q L G A A V M L G CC CG yes non-self
P153 DOCK2 K L L Q I Q L R A G GG GG no self
P203 ATP2A3 K M N V F D T N L A GG GG no non-self
P218 MAP4K1 I M A I E L A E L A GG GG no non-self
P235 (APM) PRKCB1 R I G Q R Q E T V G AA AA no non-self
P235 (JMO) PRKCB1 R I G Q R Q E T V G AA AA no non-self
P309 HSPA6 S M C R F S P L TL A AG AG no self
Table I.    MiHA haplotype disparities in selected donor and recipient pairs 
α
Polymorphic residue in red α
β
β Disparities are indicated in respect to the donor haplotype
Table I. MiHA haplotype disparities in selected donor and recipient pairs
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as the intermediate avidity cell lines were unable to recognize any target in the SNP-typed 
EBV-LCL panel. 
Lack of target cell recognition by high-avidity T-cells is caused by inappropriate 
processing and surface presentation of predicted epitope
The P218 MAP4K1IMA specific T-cell population demonstrated efficient recognition of target 
cells loaded with picomolar concentrations of peptide, whereas no reactivity was observed 
in accordance with the SNP haplotype of tested targets. To determine whether the inability 
of this high avidity T-cell line to recognize endogenously processed antigen was due to 
the inability of the target cells to process and present the MAP4K1IMA epitope, a retroviral 
minigene vector was constructed that encoded the minimal MAP4K1IMA peptide sequence 
directly attached to an ER-signal sequence32. In this design, delivery of the potential 
T-cell epitope to the ER occurs co-translationally, and hence independent of proteasomal 
processing and TAP transport. As a positive control, a similar minigene was created for 
the HMHA-1H epitope. HLA-A2+ JY cells that are homozygous negative for both the P218 
MAP4K1IMA and the HMHA-1H allele were transduced with the two minigene constructs, 
and demonstrated to be recognized by the HMHA-1 T-cell line as well as by the MAP4K1IMA 
specific T-cell line (Fig. 6). These results indicate that when endogenous presentation of 

















P218 MAP4K1IMAP46 HMHA1VLH HMHA-1 memory 
Figure 6. Recognition of EBV target cells by high-avidity MiHA T-cells after minigene transduction.
High-avidity cell lines P46 HMHA1VLH (white) and P218 MAP4K1IMA (grey) were stimulated with HLA-A2
+ EBV-
LCL JY transduced with minigene constructs (MG) encoding minimal peptide sequence directly attached to 
an ER-signal sequence. T-cell reactivity was measured after 18 hours in a standard IFN γ ELISA. Data are 
presented as cytokine concentration. The MOCK transduced cells only encoded an ER-signal sequence. As 
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This study demonstrates the feasibility and limitations of using a reverse immunology 
approach for the identification of potential MiHA. We combined large scale prediction 
of HLA-restricted MiHA with functional assessments of these polymorphic epitopes by 
identifying MiHA specific T-cell populations in a high-throughput unbiased fashion. In this 
study we used a reverse immunology approach, based on UV-induced peptide exchange 
technology, in which the predicted MiHA epitopes were the starting point for identification 
of new MiHA specific T-cell responses. By investigating MiHA source proteins with a 
hematopoietic tissue restricted expression pattern, we aimed to identify potential CTL 
epitopes that would selectively target recipient hematopoiesis. 
 The combined use of three prediction programs resulted in the generation of a 
synthetic peptide library of 973 experimental peptides encoded by hematopoietic stem 
cells. The MHC binding capacity of these peptides was verified by UV-induced MHC-peptide 
exchange. Based on the binding capacity of well studied natural ligands, we estimate 
that one third of the predicted peptide set could be defined as high affinity, one third as 
intermediate affinity and one third as low affinity HLA-A2.
 To assess the ability of these epitopes to serve as TCR ligands we monitored T-cell 
responses in a high throughput unbiased fashion using multiplexed fluorescently labeled 
sets of pMHC complexes. We were able to detect epitope specific T-cell recognition for 71 
of the 333 screened pMHC complexes of which 24 epitopes were recognized in multiple 
and 47 epitopes were recognized in single individuals. Taken into account that these T-cells 
were isolated from small cell size PBMC samples of allo-SCT patients with only partially 
reconstituted TCR repertoires, this data highlights both the immense capacity of the TCR 
repertoire to recognize random HLA-ligands and the high-sensitivity of our enrichment 
protocol. Unfortunately, most isolated pMHC tetramer positive T-cells appeared to be of 
low or intermediate avidity. Two cell lines recognized their respective peptide with high 
avidity. In the case of MAP4K1IMA, no reactivity against endogenously processed antigen was 
observed, but cells expressing a minigene encoding this epitope were efficiently recognized, 
suggesting that inappropriate processing explains the lack of recognition of epitope derived 
from the parental protein. The second high avidity T-cell population recognized the HMHA-
1H epitope, and target cell recognition by the T-cell line fully matched HMHA-1 status. 
 As the identification of the HMHA-1 and MAP4K1IMA specific T-cell responses in 
our experiments occurred in a fully unbiased screen, this forms evidence that the type of 
genome-wide screen developed here can be successful. Nevertheless, the fact that only 
the HMHA-1 specific T-cell population showed recognition of endogenously produced 
antigen shows that this discovery process is still highly suboptimal, and we see 3 major 
areas for improvement for this. 
 First, the capacity of a specific T-cell to bind to a pMHC tetramer does not necessarily 
reflect its capacity to elicit potent T-cell reactivity when stimulated with a relevant pMHC 
complex. In this study only 2 out of the 16 T-cell populations that produced IFN γ upon 
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nonspecific stimulation also demonstrated IFN γ production (and TCR internalization) at 
picomolar range peptide concentrations. Importantly, these high-avidity T-cell populations 
do not necessarily demonstrate a more intense pMHC tetramer staining intensity as 
compared to low and intermediate avidity T-cell populations, making it difficult to weed 
out less interesting T-cell populations on the basis of MHC tetramer staining intensity. Thus, 
alternative strategies are required to obtain a rough estimate of T-cell sensitivity early in 
the screening process. 
 Second, in this screen, T-cell populations were isolated using the full set of pMHC 
tetramer complexes for each sample, irrespective of SNP status of donor and recipient. 
The frequent encounter of low avidity pMHC tetramer positive T-cells from donors for 
which this epitope forms a “self” antigen could therefore reflect clonal deletion of high 
avidity T-cells, due to presentation of the predicted epitopes in the donor thymus. In 
future screens it seems useful to apply stringent epitope selection criteria to restrict high-
throughput analysis to those epitopes that can be considered neo-antigens in a given 
transplant combination, something that can readily be done by evaluation of  donor (and 
recipient) SNP status.
 Third, of the two high avidity T-cell populations isolated, only one could recognize 
epitopes derived from the endogenous antigen. In this project ligand prediction focused 
solely on the HLA affinity of predicted peptides and disregarded other aspects of the HLA 
processing and presentation pathway. As a consequence, many of the predicted epitopes 
used here may not be part of the natural peptidome and thereby lack biological relevance. 
In future work, this issue may to some extent be addressed by the use of antigen processing 
algorithms that predict proteosomal cleavage and TAP-dependent peptide transport33;34. 
As a second, and in our view even more attractive option, the peptide set used for high-
throughput screening could be derived from a database of HLA eluted peptides, thereby 
guaranteeing presentation of the epitopes concerned.
 In conclusion, our isolation and detailed analysis of potential MiHA candidates in 
a high-throughput fashion has revealed the technical feasibility of this reverse immunology 
approach. We have demonstrated that TCR repertoires against very large sets of antigens 
can rapidly be screened. However, the productive use of such high-throughput screening 
technology will require further improvements. In particular, stringent epitope selection 
criteria including the availability of high quality databases of MHC ligands and SNP 
genotypes are likely to be of value to increase the percentage of isolated T-cell populations 
that is not only pMHC tetramer reactive but also biologically relevant.
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Materials and methods
PBMC samples and T-cell staining. After study approval of the Leiden University Medical Center 
institutional review board, PBMC samples were obtained from allo-SCT patients during the memory 
phase of a graft versus leukemia response after DLI as determined by mixed hematopoietic chimerism 
and/or quantitative BCR-ABL analysis after approval of the Leiden University Medical Center 
institutional review board and informed consent according to the Declaration of Helsinki. Informed 
consent form all participants involved in this study were written for samples obtained since 2003 and 
verbal for older samples when guidelines provided no written consent. PBMC were isolated by Ficoll 
gradient centrifugation, and frozen in liquid nitrogen. For T-cell staining of approximately 1x106 PBMC 
a final concentration of 2μg/mL per pMHC tetramer was added and incubated for 15 min at 37ºC. 
Next, antibody-mix consisting of CD8-Alexa700 (Caltag) and CD4-, CD14-, CD16-, CD19- and CD40-
FITC (BD) was added and cells were incubated for 30 min at 4ºC. Prior to flow cytometry, cells were 
washed twice and Propidium lodide (PI) was added to allow dead cell exclusion. Dual-encoding pMHC 
tetramer analysis was performed as previously described20. 
Gene expression of hematopoietic cell fractions by microarray analysis. Hematopoietic precursor 
CD34+ cells were isolated by MACS (Miltenyi) from bone marrow; G-CSF mobilized peripheral blood 
and cord blood PBMC according to manufacturer’s protocol. Total RNA was isolated using Trizol 
(Invitrogen) and transcribed into cDNA by reverse transcriptase (Invitrogen) using oligo-dT primers 
(Roche Diagnostics). Microarray analysis of gene expression profiles in CD34+/CD38- and CD34+/CD38+ 
fractions was performed by Affymetrix U133 array according to the manufacturer’s instructions. 
Additional gene expression information was retrieved from the NCBI Gene Expression Omnibus 
database23.
Prediction of HLA-A2+ MiHA ligands. The following prediction algorithms were applied to the peptide 
candidates: Syfpeithi25, Bimas26 and netMHC27. Peptides with a score of ≥19 (Syfpeithi), ≥1 (Bimas) 
and ≤875 (netMHC) were considered to have potential HLA-A2+ binding capacities. SNP data was 
retrieved from NCBI’s dbSNP polymorphism database24. Amino acid sequences were obtained from 
NCBI Entrez engine.
Generation of peptide-MHC complexes. All peptides were synthesized in-house using standard 
Fmoc chemisty or purchased from Pepscan (Pepscan Presto). The UV-sensitive building block J was 
synthesized as described18. Recombinant HLA-A2 heavy chain and human β2m light chain were in-
house produced in Escherichia coli. MHC class I refolding was performed as previously described with 
minor modifications20. MHC class I complexes were purified by gel-filtration HPLC in PBS. Peptide-
MHC complexes were generated by MHC-peptide exchange. Prefolded UV-liable pMHC complexes 
(100μg/ml) were subjected to 366nm UV light (Camag) for 1 h in presence of the specific peptide 
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(200μM)19;28. After exchange, samples were spun at 16,000g for 5 min and supernatants were used 
for pMHC tetramer formation. The peptide HLA-A2+ binding affinity was assessed using two different 
HLA-binding assays in parallel; MHC-ELISA and MHC bead as previously described18;29. For generation 
of pMHC tetramers, 8 different fluorochrome-streptavidin (SA) conjugates were used as previously 
descibed20. Phycoerythrin (PE), allophycocyanin (APC) and the quantum dots (QD); QD565, QD585, 
QD605, QD655, QD705 and QD800 were used (Invitrogen). Complexes were stored at 4ºC and prior 
to use pMHC tetramers were spun at 17.000g for 2 min. 
Isolation of MiHA specific T-cells by pMHC tetramer pull down. Prior to isolation of peptide-specific 
T-cells, pMHC tetramers were made coupled to SA-PE. PBMC were stained with pMHC tetramers 
for 1 hour at 4ºC. Subsequently, cells were washed and incubated with anti-PE Ab coated magnetic 
beads (Miltenyi). Cells were than isolated by MACS (Miltenyi), using an LS column, following the 
manufacturers protocol. Eluted cells were washed and cultured in Iscove Modified Dulbecco Medium 
(IMDM; Lonza BioWhittaker) supplemented with 5% human serum, 5% fetal calf serum (FCS; 
Cambrex), 100 IU/mL IL-2 (Chiron), 10ng/mL IL-15 (Peprotech). Eluted cells were cultured per 5000 
cells with 2x104 irradiated autologous feeder cells and 5000 anti-CD3/CD28 Dynabeads (Invitrogen) 
in 96-well plates. Cultures were split at least twice a week. After 2-3 weeks, cell cultures were 
analyzed for peptide-specific T-cell populations by pMHC tetramer flow cytometry. Subsequently 
pMHC tetramer reactive T-cell populations were sorted on a FACSAria (Becton Dickinson) into 96 well 
plates containing 1x105 irradiated feeder cells supplemented with 0.5μg/mL phytohaemagglutinin 
(PHA; Biochrom AG) as previously described35. 
Flow cytometry. Data acquisition was performed on an LSR-II flow cytometer (Becton Dickinson) with 
FacsDiva software using the following 11-color instrument settings: 488nm laser: PI: 685LP, 695/40; 
PE: 550LP, 575/26; FITC: 505LP, 530/30; SSC: 488/10. 633nm laser: Alexa700: 685LP, 730/45; APC: 
660/20. 405nm laser: QD800: 770LP, 800/30; QD705: 680LP, 710/50; QD655: 635LP, 660/40; QD605: 
595LP, 650/12. 355nm laser: QD585: 575LP, 585/15; QD565: 545LP: 560/20. Approximately 200,000 
lymphocytes were recorded for each analysis. To identify antigen-specific T-cells we followed the 
gating strategy as described in Fig. S2.
IFN γ release assay. MiHA specific T-cell lines (1x104) were stimulated with HLA-A2+ T2 cells, EBV-LCLs 
or T-cell blasts (2,5x104) in 96 well plates for 18h at 37ºC and 5% CO2. Peptide pulsing was performed 
by incubating stimulator cells for 1 h with synthetic peptides (1 μg/ml) in IMDM containing 2% FCS 
and cells were washed twice before use. Cytokine release was measured by IFN γ ELISA (Sanquin) 
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Supplementary information
Figure S1. Gene expression profiles and MiHA prediction of hematopoiesis-restricted genes obtained 
with microarray analysis. Gene expression profiles of CD34+/CD38- and CD34+/CD38+ hematopoietic 
precursor cell populations. On the x-axis 100 different tissues or cell material are shown, clustered by 
organ system. On the y-axis the mRNA expression of the gene is shown. SC: stem cells, BM: bone marrow, 
PB: peripheral blood, Imm: immunological tissues, Apc: antigen presenting cells, Mal: hematological 
malignancies, CNS: central nervous system. Repr: reproductive organs, Gla: endocrine glands: Conn: 
connective tissues, Li: liver, Lu: lung, Dig: digestive tracts, Hea: heart, SK: skin, EC: endothelial cells. (A,B) 
HMHA-1 and PTPRC (CD45) have a clear hematopoiesis-restricted gene expression pattern. (C) Prostate 
kallikrein 2 (KLK2) demonstrate a tissue-specific gene expression pattern. (D) glyceraldehyde-3-phosphate 
dehydrogenase (GAPD) is ubiquitously expressed. (E,F) Integrin beta 2 (ITGB2) and FMS-like tyrosine 
kinase 3 (FLT3) were identified as genes (2 out of 78) with a hematopoiesis-restriced gene expression 
pattern by data-mining the combined microarray database. MiHA prediction based on peptide sequences 
representing the nucleotide sequences of both allelic variants of a SNP using three HLA-peptide binding 
algorithms. Polymorphic residue encoding triplet is highlighted (grey) and start-codon is underlined. ARF: 
alternative reading frame, NRF: normal reading frame S: Syfpeithi25, B: Bimas26, N: netMHC27. (*): Only N was 
used to predict 11-mers HLA-binding. Selection threshold S: binding score (BS) ≥ 19, B: BS≥1, N: BS≤500. 
(G) Prediction of MHMA-1 epitopes for RH139 polymorphism. Described immunogenic MiHA epitope; 










































































a   HMHA-1 b   PTPRC
c   KLK2
e   ITGB2
d   GAPD
f   FLT3
BM         PB   Imm Apc Mal                   CNS                 Repr Conn           Li  Ki Lu Dig Hea Sk EC      
BM         PB   Imm Apc Mal                   CNS                 Repr Conn           Li  Ki Lu Dig Hea Sk EC      
BM         PB   Imm Apc Mal                   CNS                 Repr Conn           Li  Ki Lu Dig Hea Sk EC      
BM         PB   Imm Apc Mal                   CNS                 Repr Conn           Li  Ki Lu Dig Hea Sk EC      
BM         PB   Imm Apc Mal                   CNS                 Repr Conn           Li  Ki Lu Dig Hea Sk EC      
BM         PB   Imm Apc Mal                   CNS                 Repr Conn           Li  Ki Lu Dig Hea Sk EC      
P AL RA V C C V T T S L R A R GN L R S
A RL EG C V L R D D L L E R P RK L K E
G PP *G V C V A * R P P * P P AE T * G
P AL RA V C C M T T S L R A R GN L R S
A RL EG C V L H D D L L E R P RK L K E
G PP *G V C V A * R P P * P P AE T * G
Gene: HMHA1  RefSeq mRNA seq: NM_012292.2
SNP:  RH139  dbSNP ID:        rs_1801284
5’gagggccttgagaaacttaaggagtgtgtgttgcgtgacgacctccttgaggcccgccgcccgcgggcc 3’
5’gagggccttgagaaacttaaggagtgtgtgttgcatgacgacctccttgaggcccgccgcccgcgggcc 3’
R AP VH P A P S A * S S K P L GA S T S
K GP CS S C A E C L K F E P F GG K Y I
K GT LL L L R R V P E V R P L WW Q V H
R AP VH P A P S A * S S K P L GA S T S
K GP CS S C A K C L K F E P F GG K Y I
K GT LL L L R Q V P E V R P L WW Q V H
Gene: ITGB2  RefSeq mRNA seq: NM_000211.3
SNP:  KE630  dbSNP ID:        rs_2230531
5’ccctcaccctgtggcaagtacatctcctgcgccgagtgcctgaagttcgaaaagggcccctttgggaag 3’
5’ccctcaccctgtggcaagtacatctcctgcgccaagtgcctgaagttcgaaaagggcccctttgggaag 3’
H L L R R V P E V      29  20      29
H L L R Q V P E V      29  20      31
V H L L R R V P E V    20
V H L L R Q V P E V    20
W Q V H L L R R V          15
W Q V H L L R Q V          15
H L L R Q V P E V R K   *   *  62
T L W Q V H L L R R V   *   *  57  70
T L W Q V H L L R Q V   *   *  55  70
ITGB2           S   B   R   N
V P E V   29 0   29
V P E V   29 0   31
V   * 57 70
V   * 55 70
S   B R N
g   Prediction of HMHA-1 epitopes
h   Prediction of ITGB2 epitopes
HMHA1 (HA-1)    S   B   R   N
V L R D D L L E A 23   6       71
V L H D D L L E A 23  80       15
S V C C V T T S L 20   2     1613
S V C C M T T S L 20   2     1450
S   B R N
23   6  71
23  80   15
20   2  1613
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Figure S2. Flowcytometric analysis of pMHC tetramer specific cell lines. Flowcytometric analysis of 
HMHA-1 specific T-cells in an allo-SCT patient sample obtained 15 months after DLI, during the memory 
phase of the GVL response. (a) Life gating strategy to reduce background pMHC tetramer staining. FSC and 
SSC width and height channels were used to reduce background staining. Propidium iodide (PI) was used as 
a death cell marker. In all plots total lymphocytes are grey, total CD8+ T-cells are black and pMHC tetramer 
positive T-cells are highlighted red.  Dot plots are shown with bi-exponential axes and display fluorescence 
intensity for the indicated fluorochromes. (b) Flowcytometric analysis of HMHA-1 specific T-cells after pull 
down and in vitro expansion. pMHC tetramer positive T-cell frequencies are expressed as total CD8+ T-cells. 
(c,d) Flowcytometric purity analysis of pMHC tetramer specific cell lines. Dot plots show total lymphocytes 
(black). Dot plots are shown with bi-exponential axes and display fluorescence intensity for the specific 
pMHC tetramer complexes on the x-axis and CD8 expression on the Y-axis. Shown frequencies indicate 
pMHC tetramer positive T-cells out of total lymphocytes. (c) BDY3356 derived CD8+ cell line: P37 DOCK2SIQ. 
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Supplementary Table I.          Identified genes with a hematopoiesis-resricted expression pattern
Gene symbol Official full name mRNA accession Protein accession
AIF1 Allograft inflammatory factor 1   NM_001623.3   NP_001614.3
AREG Amphiregulin   NM_001657.2   NP_001648.1
ARHGAP4 Rho GTPase activating protein 4   NM_001164741.1   NP_001158213.1
ARHGAP15 Rho GTPase activating protein 15   NM_018460.3   NP_060930.3
ARHGAP25 Rho GTPase activating protein 25   NM_001007231.1   NP_001007232.1
ATP2A3 Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 isoform a   NM_005173.2   NP_005164.2
BTK Bruton agammaglobulinemia tyrosine kinase   NM_000061.2   NP_000052.1
CBFA2T3 Protein CBFA2T3 isoform MTG16b   NM_005187.4   NP_005178.4 
CCL3 Chemokine (C-C motif) ligand 3   NM_002983.2   NP_002974.1
CD37 CD37 molecule   NM_001774.2   NP_001765.1
CD48 CD48 molecule   NM_001778.2   NP_001769.2
CD52 CD52 molecule   NM_001803.2   NP_001794.2
CD69 CD69 molecule   NM_001781.2   NP_001772.1
CD79b CD79b molecule, immunoglobulin-associated beta   NM_000626.2   NP_000617.1
CD83 CD83 molecule   NM_001040280.1   NP_001035370.1 
CENTB1 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1   NM_014716.3   NP_055531.1
CG018 NEDD4 binding protein 2-like 1   NM_001079691.1   NP_001073159.1 
CORO1A Coronin, actin binding protein, 1A   NM_001193333.2   NP_001180262.1 
CPVL Carboxypeptidase, vitellogenic-like   NM_019029.2   NP_061902.2 
CRHBP Corticotropin releasing hormone binding protein   NM_001882.3   NP_001873.2 
CSF3R Colony stimulating factor 3 receptor   NM_000760.3   NP_000751.1
CXorf9 SAM and SH3 domain containing 3   NM_018990.3   NP_061863.1
DOCK2 Dedicator of cytokinesis 2   NM_004946.2   NP_004937.1 
DOK2 Docking protein 2   NM_003974.2   NP_003965.2 
DUSP22 Dual specificity phosphatase 22   NM_020185.3   NP_064570.1 
EVI2B Ecotropic viral integration site 2B   NM_006495.3   NP_006486.3
FCER1A Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide   NM_002001.2   NP_001992.1
FLT3 Fms-related tyrosine kinase 3   NM_004119.2   NP_004110.2
FMNL1 Formin-like 1   NM_005892.3   NP_005883.2 
FNBP1 Formin binding protein 1   NM_015033.2   NP_055848.1
FOSB FBJ murine osteosarcoma viral oncogene homolog B   NM_001114171.1   NP_001107643.1
GATA2 GATA binding protein 2   NM_001145661.1   NP_001139133.1 
GMFG Glia maturation factor, gamma   NM_004877.2   NP_004868.1
GNA15 Guanine nucleotide binding protein, alpha 15   NM_002068.2   NP_002059.2 
HMHA-1 Histocompatibility minor HA-1   NM_012292.2   NP_036424.2
HOXA9 Homeobox A9   NM_152739.3   NP_689952.1
HSPA6 Heat shock 70kDa protein 6   NM_002155.3   NP_002146.2 
ICAM3 Intercellular adhesion molecule 3   NM_002162.3   NP_002153.2 
IL2RG Interleukin 2 receptor, gamma   NM_000206.2   NP_000197.1  
IQGAP2 IQ motif containing GTPase activating protein 2   NM_006633.2   NP_006624.2  
ISG20 Interferon stimulated exonuclease gene 20kDa   NM_002201.4   NP_002192.2 
ITGAL Integrin, alpha L   NM_001114380.1   NP_001107852.1
ITGAM Integrin, alpha M   NM_000632.3   NP_000623.2 
ITGB2 Integrin, beta 2   NM_000211.3   NP_000202.2
KCNAB2 Voltage-gated potassium channel subunit beta-2 isoform 1   NM_003636.2   NP_003627.1
LAT2 Linker for activation of T-cells family member 2   NM_014146.3   NP_054865.2 
LCP2 Lymphocyte cytosolic protein 2   NM_005565.3   NP_005556.1 
LOC81691 Putative RNA exonuclease NEF-sp isoform 2   NM_001144924.1   NP_001138396.1 
LRMP Lymphoid-restricted membrane protein   NM_006152.2   NP_006143.2 
LTB Lymphotoxin-beta isoform a   NM_002341.1   NP_002332.1  
LYN Tyrosine-protein kinase Lyn isoform B   NM_001111097.1   NP_001104567.1  
MAP4K1 Mitogen-activated protein kinase kinase kinase kinase 1 isoform 1   NM_001042600.1   NP_001036065.1 
MCM5 DNA replication licensing factor MCM5   NM_006739.3   NP_006730.2 
MPL Thrombopoietin receptor precursor   NM_005373.2   NP_005364.1 
NCF4 Neutrophil cytosol factor 4 isoform 1   NM_000631.4   NP_000622.2  
NUP210 Nuclear pore membrane glycoprotein 210 precursor   NM_024923.2   NP_079199.2  
PIK3CD Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform   NM_005026.3   NP_005017.3 
PIM2 Serine/threonine-protein kinase pim-2   NM_006875.3   NP_006866.2 
PLCB2 1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-2   NM_004573.2   NP_004564.2
PLEK Pleckstrin   NM_002664.2   NP_002655.2 
PRKCB1 Protein kinase C beta type isoform 2   NM_002738.6   NP_002729.2 
PSD4 PH and SEC7 domain-containing protein 4   NM_012455.2   NP_036587.2 
PSMB10 Proteasome subunit beta type-10 proprotein   NM_002801.2   NP_002792.1 
PSMB8 Proteasome subunit beta type-8 isoform E1 proprotein   NM_004159.4   NP_004150.1  
PTPN22 Tyrosine-protein phosphatase non-receptor type 22 isoform 3   NM_001193431.1   NP_001180360.1  
PTPN6 Tyrosine-protein phosphatase non-receptor type 6 isoform 1   NM_002831.5   NP_002822.2  
PTPRC Receptor-type tyrosine-protein phosphatase C isoform 1 precursor   NM_002838.3   NP_002829.2 
PTPRCAP Protein tyrosine phosphatase receptor type C-associated protein   NM_005608.2   NP_005599.1 
RASGRP2 RAS guanyl-releasing protein 2   NM_153819.1   NP_722541.1 
RGS1 Regulator of G-protein signaling 1   NM_002922.3   NP_002913.3 
SELL L-selectin precursor   NM_000655.4   NP_000646.2 
SELPLG P-selectin glycoprotein ligand 1   NM_003006.3   NP_002997.1 
SEPT6 Septin-6 isoform B   NM_015129.5   NP_055944.2 
SF1 Splicing factor 1 isoform 6   NM_001178030.1   NP_001171501.1 
SOCS2 Suppressor of cytokine signaling 2   NM_003877.3   NP_003868.1 
SP110 Sp110 nuclear body protein isoform d   NM_001185015.1   NP_001171944.1 
SYNGR1 Synaptogyrin-1 isoform 1a   NM_004711.4   NP_004702.2 
TNRC5 Protein canopy homolog 3 precursor   NM_006586.3   NP_006577.2
ZFP36L2 Zinc finger protein 36, C3H1 type-like 2   NM_006887.4   NP_008818.3
Table SI. Identified genes with a hematopoiesis-associated expression pattern
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Supplementary Table II.          Total MiHA epitopes predicted by HLA-peptide binding algorithm
Gene symbol Residue Change RefSNP accession dbSNP AH Minor Frequency Reading Frame Length Peptide Sequence
AIF RG 14 rs2736182 0,22 0,01 NRF 10 D L Q G G K A F G L
AIF RG 14 rs2736182 0,22 0,01 NRF 10 D L Q G G K A F R L
AIF RG 14 rs2736182 0,22 0,01 NRF 11 G L L K A Q Q E E R L
AIF RG 14 rs2736182 0,22 0,01 NRF 9 L Q G G K A F G L
AIF RG 14 rs2736182 0,22 0,01 NRF 9 L Q G G K A F R L
AIF RG 14 rs2736182 0,22 0,01 NRF 11 R L L K A Q Q E E R L
AREG PP 10 rs1615111 0,18 0,02 ARF 9 A G A G G A V A L
AREG PP 10 rs1615111 0,18 0,02 ARF 9 A G A S G A V A L
AREG PP 10 rs1615111 0,18 0,02 ARF 9 A T A G A G G A V
AREG PP 10 rs1615111 0,18 0,02 ARF 9 A T A G A S G A V
AREG PP 10 rs1615111 0,18 0,02 ARF 11 A T A G A S G A V A L
AREG PT 76 rs7656521 0,09 0,01 NRF 10 A A H P P G L H S L
AREG PT 76 rs7656521 0,09 0,01 NRF 10 A A H T P G L H S L
AREG PT 76 rs7656521 0,09 0,01 NRF 9 A H P P G L H S L
AREG PT 76 rs7656521 0,09 0,01 NRF 9 A H T P G L H S L
AREG FF 177 rs2291715 0,22 N.D ARF 9 I L V N G V G K S 
AREG FF 177 rs2291715 0,22 N.D ARF 11 N V S K N I L V N G V
AREG FF 177 rs2291715 0,22 N.D ARF 11 N V S K N I S V N G V
AREG FF 177 rs2291715 0,22 N.D ARF 9 S K N I L V N G V
AREG FF 177 rs2291715 0,22 N.D ARF 9 S K N I S V N G V
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 9 L L S P L H C W A
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 10 L L S P L H C W A V
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 11 L L S P L H C W A V L
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 9 L L S P L H C W V
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 10 L L S P L H C W V V
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 11 L L S P L H C W V V L
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 9 L S P L H C W A V
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 9 P L H C W A V L L
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 9 P L H C W V V L L
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 10 S L L S P L H C W A 
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 11 S L L S P L H C W A V
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 10 S L L S P L H C W V 
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 11 S L L S P L H C W V V
ARHGAP4 VA 104 rs5987182 0,14 0,00 NRF 10 S P L H C W V V L L
ARHGAP4 VV 523 rs2070098 N.D. 0,00 ARF 9 A C A P G G G E L
ARHGAP4 VV 523 rs2070098 N.D. 0,00 ARF 9 A C A P G R G E L
ARHGAP4 VV 523 rs2070098 N.D. 0,00 ARF 10 A P G G G E L H S L
ARHGAP4 VV 523 rs2070098 N.D. 0,00 ARF 10 A P G R G E L H S L 
ARHGAP4 VV 523 rs2070098 N.D. 0,00 ARF 10 S L C P W S W R A A
ARHGAP4 VV 523 rs2070098 N.D. 0,00 ARF 10 S L C P W W W R A A
ARHGAP15 LF 438 rs11538443 N.D. 0,00 NRF 11 F L R A E N E T G N M 
ARHGAP15 LF 438 rs11538443 N.D. 0,00 NRF 9 G I V F G P T F L
ARHGAP15 LF 438 rs11538443 N.D. 0,00 NRF 9 G I V F G P T L L
ARHGAP15 LF 438 rs11538443 N.D. 0,00 NRF 10 I V F G P T F L R A
ARHGAP15 LF 438 rs11538443 N.D. 0,00 NRF 10 I V F G P T L L R A
ARHGAP15 LF 438 rs11538443 N.D. 0,00 ARF 10 K L G D C I W T Y L
ARHGAP15 LF 438 rs11538443 N.D. 0,00 ARF 11 K L G D C I W T Y L S
ARHGAP15 LF 438 rs11538443 N.D. 0,00 ARF 11 K L G D C I W T Y P S
ARHGAP15 LF 438 rs11538443 N.D. 0,00 NRF 11 L L R A E N E T G N M
ARHGAP15 LF 438 rs11538443 N.D. 0,00 NRF 10 S L G I V F G P T L 
ARHGAP15 LF 438 rs11538443 N.D. 0,00 NRF 9 T L L R A E N E T
ARHGAP15 LF 438 rs11538443 N.D. 0,00 NRF 11 T L L R A E N E T G N
ARHGAP25 AA 384 rs17604346 0,01 0,02 ARF 9 M L L K T S E F L
ARHGAP25 AA 384 rs17604346 0,01 0,02 ARF 11 M L L K T S E F L G Q
ARHGAP25 RS 555 rs4241344 0,43 0,27 NRF 10 K L I L C R V W S K
ARHGAP25 RS 555/MT 556 Combination 0,43/0,44 0,27/N.D. NRF 9 S L Q S T V Q E L
ARHGAP25 RS 555 rs4241344 0,43 0,27 NRF 9 S L Q R M V Q E L
ARHGAP25 RS 555 rs4241344 0,43 0,27 NRF 9 S L Q S M V Q E L
ARHGAP25 RS 555 rs4241344 0,43 0,27 NRF 11 S L Q S M V Q E L R K
ARHGAP25 RS 555 rs4241344 0,43 0,27 NRF 10 S M V Q E L R K E I
ARHGAP25 MT 556 rs10177248 0,44 N.D. NRF 9 M V Q E L R K E I
ARHGAP25 MT 556 rs10177248 0,44 N.D. NRF 10 R M V Q E L R K E I
ARHGAP25 MT 556 rs10177248 0,44 N.D. NRF 9 S L Q R T V Q E L
ARHGAP25 MT 556 rs10177248 0,44 N.D. NRF 9 T V Q E L R K E I
ATP2A3 W*stop 77 rs17846878 N.D. 0,00 NRF 9 A L V S F V L A W
ATP2A3 W*stop 77 rs17846878 N.D. 0,00 ARF 9 L L C P G L I R G
ATP2A3 W*stop 77 rs17846878 N.D. 0,00 ARF 10 L L C P G L I R G G
ATP2A3 W*stop 77 rs17846878 N.D. 0,00 ARF 9 L L C P G L V R G
ATP2A3 W*stop 77 rs17846878 N.D. 0,00 ARF 10 L L C P G L V R G G
ATP2A3 LL 302 rs9915542 N.D. 0,00 ARF 10 C L L L Q D R R G L
ATP2A3 LL 302 rs9915542 N.D. 0,00 ARF 9 L L L Q D R R G L
ATP2A3 AA 424 rs1800911 N.D. 0,44 ARF 10 R L W T T T R P R V
ATP2A3 ND 458 rs9913158 N.D. 0,00 NRF 9 K M N V F D T D L
ATP2A3 ND 458 rs9913158 N.D. 0,00 NRF 9 K M N V F D T N L
ATP2A3 ND 458 rs9913158 N.D. 0,00 NRF 9 N V F D T D L Q A 
ATP2A3 ND 458 rs9913158 N.D. 0,00 NRF 10 N V F D T D L Q A L
ATP2A3 ND 458 rs9913158 N.D. 0,00 NRF 9 N V F D T N L Q A  
ATP2A3 ND 458 rs9913158 N.D. 0,00 NRF 10 N V F D T N L Q A L 
ATP2A3 ND 458 rs9913158 N.D. 0,00 NRF 9 T N L Q A L S R V 
ATP2A3 DE 519 rs12946879 N.D. 0,00 NRF 11 K M F V K G A P D S V 
ATP2A3 DE 519 rs12946879 N.D. 0,00 NRF 11 K M F V K G A P E S V 
ATP2A3 DE 519 rs12946879 N.D. 0,00 NRF 11 M F V K G A P E S V I
ATP2A3 CR 674 rs9895012 N.D. 0,07 ARF 10 L L L R P R G A R T
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     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
      
     
     
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     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
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      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
      
     
     
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     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
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     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
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     
     
     
     
     
     
     
     
     
     
     
     
     
     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
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     
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     
     
     
     
     
     
     
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     
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Table SIV. Total pMHC tetramer-reactive T-cell populations revealed after pull down and two weeks of 
expansion
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3     The low frequency of antigen-specific naïve T-cells has challenged numerous laboratories to develop various 
techniques to study the naïve T-cell repertoire. Here we combine 
the generation of naïve repertoire-derived antigen-specific 
T-cell lines based on MHC-tetramer staining and magnetic-
bead enrichment with in-depth functional assessment of the 
isolated T-cells. Cytomegalovirus (CMV) specific T-cell lines 
were generated from seronegative individuals. Generated T-cell 
lines consisted of a variety of immunodominant CMV-epitope 
specific oligoclonal T-cell populations restricted to various HLA-
molecules (HLA-A1, A2, B7, B8 and B40), and the functional 
and structural avidity of the CMV-specific T-cells was studied. 
Although all CMV-specific T-cells were isolated based on their 
reactivity towards a specific peptide-MHC complex, we observed 
a large variation in the functional avidity of the MHC-tetramer 
positive T-cell populations, which correlated with the structural 
avidity measured by the recently developed Streptamer koff-rate 
assay. Our data demonstrate that MHC-tetramer staining is not 
always predictive for the sensitivity of specific T-cell reactivity, 
and challenge the sole use of MHC-tetramers as an indication 
of the peripheral T-cell repertoire, independent of the analysis 
of functional activity or structural avidity parameters.
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Introduction
The almost unlimited size of the T-cell repertoire enables the adaptive immune system to 
protect the individual against a wide range of pathogens. T-cells can recognize pathogen 
derived antigens when presented on the cell membrane by the major histocompatibility 
antigen complex (MHC) via their unique T-cell receptor. An adequate T-cell receptor 
repertoire size is crucial for the immune system to continuously respond to new threats. The 
immense size of the T-cell receptor repertoire is accomplished by somatic recombination 
of the genes encoding the two different T-cell receptor heterodimer chains and is shaped 
by central tolerance to an estimated range of 106 to 107 unique T-cell receptors1. After 
exposure to novel pathogen, immune surveying naïve T-cells that encounter their cognate 
antigen become activated, initiate a robust immune response and differentiate into memory 
T-cells. Precursor frequencies of antigen specific naïve T-cells are reported to influence 
both primary and memory T-cell responses to infection2-4.
 The frequencies of distinct naïve T-cell clones are extremely low and these 
low numbers have complicated the possibilities to study the naïve T-cell repertoire5;6. 
Quantification of preexisting antigen-specific T-cell numbers have been established by 
several functional assays such as limiting dilution analysis and repeated in vitro stimulations 
with antigen-loaded dendritic cells7-11. In addition, MHC-class-I tetramers have been used 
to identify antigen-specific CD8+ T-cells in the memory and naïve repertoire12-15. However, 
the fact that functional CD8+ T-cells responding to infection can generally be identified 
by MHC-tetramer staining within the memory T-cell repertoire does not imply that T-cells 
identified in the naïve repertoire by MHC-tetramer staining are also generally antigen 
responsive. As we previously reported that MHC-tetramer positive T-cells within in vitro 
generated primary immune responses could demonstrate impaired T-cell reactivity16;17, we 
aim to address this issue. Our observations may put the MHC-tetramer based quantification 
of naïve antigen specific T-cells into a different perspective. Functional characterization of 
antigen-specific naïve T-cells may provide insight into the natural avidity range of T-cells 
present within a MHC-tetramer positive T-cell repertoire in the absence of in vivo antigen 
exposure and subsequent selection of high-avidity T-cell clones. In addition it may help to 
understand intrinsic differences observed between T-cells derived from the memory or the 
naïve compartment18;19. 
 In this report we present a method for the generation of naïve repertoire 
derived antigen-specific T-cell lines based on the combined use of MHC-tetramer staining 
and magnetic-bead enrichment. This method was used for the generation of functional 
CMV-specific T-cell lines from seronegative individuals within four weeks. We studied the 
functional characteristics of MHC-tetramer positive CMV-specific T-cells derived from the 
naïve compartment. Although the enriched T-cells were isolated based on their reactivity 
towards specific MHC-tetramers, we observed a large avidity variation within the isolated 
oligoclonal naïve T-cell populations. Part of the CMV-specific T-cells derived from the naïve 
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repertoire exhibited equal antigen-specific functionality as well as high MHC-tetramer 
staining as their memory response derived counterparts. However MHC-tetramer staining 
was not always predictive for antigen reactivity of isolated T-cells, since also functional 
non-reacting T-cells appeared MHC-tetramer positive. Our data indicate that when MHC-
tetramers are used to isolate antigen-specific T-cells in an unbiased T-cell repertoire, both 
high and low-avidity T-cells may be isolated including T-cells that react to peptide in the 
context of MHC-tetramers but are functional non-reacting. 
Results
Isolation of CMV-specific T-cells by MHC-tetramer pull down from seronegative 
individuals
Primary CMV-specific T-cell lines were generated from peripheral blood mononuclear cells 
(PBMCs) of CMV-unexposed healthy donors as defined by CMV serology and confirmed 
by absence of MHC-tetramer positive T-cells. Four CMV-unexposed donors were selected 
for in duplicate generation of primary CMV-specific T-cell lines, by incubating 100*106 
PBMCS with a set of CMV-specific MHC-tetramers, followed by enrichment of MHC-
tetramer positive cells on a magnetic column. The set of MHC-tetramers covered 10 
immunodominant CMV epitopes distributed over 5 HLA alleles that are most common 
among Dutch populations (HLA-A*0101, A*0201, B*0702, B*0801 and B*4001). The set 
of MHC-tetramers used for pull down was adjusted to the HLA-typing of each donor. After 
isolation of the MHC-tetramer enriched fraction, T-cells were expanded using anti-CD3/
CD28 beads in the presence of irradiated autologous feeder cells, IL-2 and IL-15 for 14 
days, and analyzed by multiparametric flow cytometry21. 
 After MHC-tetramer enrichment and subsequent expansion of all in duplicate 
generated T-cell lines, we were able to detect MHC-tetramer positive CD8+ T-cells specific 
for 8 out of 10 CMV-epitopes in one or more of the CMV-unexposed individuals covering 
all 5 selected HLA alleles (Table I). In all cases MHC-tetramer positive T-cell frequencies 
were low and varied between 0.01% and 2.3% of total CD8+ T-cells. A representative flow 
cytometric analysis of one T-cell line with the full panel of 11 different 2-color coded MHC-
tetramers is shown in Fig. 1, in which 5 CMV-specific populations of the 8 CMV MHC-
tetramer populations searched for were observed. In addition, a positive control HBV-
specific T-cell population was detected.
 After two weeks of expansion, additional MHC-tetramer isolations were performed 
to increase the frequencies of MHC-tetramer positive T-cells. For each donor, with the 
exception of donor B, the cell line with the most abundant MHC-tetramer positive T-cell 
populations was selected for a second pull down. For all donors, repeated pull down using 
the identical set of MHC-tetramers as was used for the initial isolation, resulted in increased 
frequencies of MHC-tetramer positive T-cells (Table I). CMV-specific MHC-tetramer positive 
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T-cell frequencies increased to 9.74%, 21.9%, 44.0% and 51.4% of total CD8+ T-cells for 
donor A, B, C and D, respectively. Testing with individual MHC-tetramers revealed that 10 
of 14 previously detected populations were increased in frequency after an extra round 
of MHC-tetramer pull down. The frequency of 1 population remained similar (Donor D; 
B7-pp65-TPR), and 3 populations decreased or became undetectable (Donor B, C and 
D; A2-pp65-NLV). Four MHC-tetramer positive populations were newly discovered after 
the second pull down (Donor A; A1-p50-VTE, Donor B; A1-pp50-VTE and B8-IE1-ELR and 
Donor D; B7-pp65-RPH). Although the prevalence of some populations remained low after 
repeated MHC-tetramer isolation, most frequencies allowed functional assessment.
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Figure 1. Dual color MHC-tetramer analysis of generated cell lines. CMV-specific T-cells were detected 
by dual-color MHC-tetramer screening after pull down and in vitro expansion. All dot plots are shown with 
bi-exponential axes and display fluorescence intensity for the indicated fluorochromes at the top and side 
of the plot matrix. Non MHC-tetramer specific CD8+ T-cells are indicated in black. (A) Schematic overview of 
dual-color MHC-tetramer screen covering 11 different CMV and HBV epitopes. Each peptide-MHC complex 
was encoded by a unique combination of fluorochromes, to screen for recognition of all epitopes in a 
single staining. (B) Representative example of MHC-tetramer screen of the pull down S1 derived T-cell line 
from donor B with a panel of 11 different dual-color MHC-tetramer combinations. Shown are total CD8+ 
T-cells. Specific MHC-tetramer positive T-cells will appear double positive for the respective peptide-HLA-
fluorochrome combination. To determine the efficiency of the pull down protocol, we included in some 
experiments a human hepatitis B virus (HBV)-derived epitope. Detected are 6 dual-labeled CMV- and HBV-
specific T-cell populations: IE1-QIK (red), IE1-ELR (pink), pp50-VTE (dark blue), pp65-YSE (green), pp65-
NLV (blue) and HBV-FLP (orange). Indicated percentages are frequencies of gated double MHC-tetramer 
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Precursor frequencies of MHC-tetramer positive T-cells affect the enriched 
T-cell line composition
Although the composition of the in duplicate generated T-cell lines was relatively similar 
for each CMV-unexposed donor, the absence of MHC-tetramer positive T-cells specific for 
some well-described immunodominant epitopes was remarkable. To investigate whether 
the composition of the generated cell lines was affected by differences in precursor 
frequencies of antigen-specific T-cells, unavailable donor TCR repertoire or reflected low 
reproducibility of the MHC-tetramer pull down method we performed a comparative 
analysis of 10 pull down experiments, all starting with 100*106 PBMCS from another CMV-
unexposed donor (donor E). Consistent with the previous results, MHC-tetramer positive 
T-cell populations were detected in each of the 10 generated cell lines (Table II). A1-pp65-
YSE MHC-tetramer positive T-cells were detected in each cell line, whereas, A1-pp50-VTE, 
A2-pp65-NLV or A2-IE1-VLE MHC-tetramer positive T-cells were detected in 1 or 2 of the 10 
T-cell lines. Importantly, the composition of the T-cell lines cannot be considered as direct 
calculations of antigen-specific precursor frequencies as they are analyzed after in vitro 
expansion and its accuracy may be affected by selective expansion of specific T-cell clones. 
However, for A1-pp65-YSE specific T-cells a minimal number of 1 cell per 100*106 PBMCS, 
corresponding with 14*106 CD8+ T-cells stained positive with the specific MHC-tetramer. 
Table II. CMV-specific CD8+ T-cells frequencies after 10 parallel MHC-tetramer pull down experiments
























E A*01 A*02 B*51 B*57 S1 0.48 0.16 0 0
S2 0.72 0 0 0
S3 0.27 0 0 0
S4 0.26 0 0 0
  S5 0.33 0 0 0
S6 0.62 0 0 0.04
S7 0.53 0 0 0
S8 0.37 0 0 0
S9 0.36 0 0.01 0
  S10 0.36 0.17 0 0.01
Frequencies indicate percentage of total CD8+ T-cells
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The precursor frequencies of T-cells specific for any of the other 3 CMV epitopes tested in 
donor E may be estimated to be at least 5-fold lower. Based on these data we speculate 
that, the composition of the T-cell lines, enriched from a fixed PBMCS number, is affected 
by variable precursor frequencies.
T-cell lines show CMV-specific IFN-γ production, but MHC-tetramer positive 
T-cells respond different
To assess the functionality of the enriched MHC-tetramer positive T-cell populations we 
stimulated the T-cell lines from the 4 donors with peptide loaded target cells and measured 
overnight IFN-γ production. As may be expected from the low frequencies of MHC-tetramer 
positive T-cells in the cell lines generated after one round of pull down, no or only marginal 
IFN-γ production was observed when these cell lines were stimulated with the different 
peptides for donor A, B and C (Fig. 2A-C). Only the enriched S1 T-cell line derived from 
donor D demonstrates a low IFN-γ response directed against the A1-pp65-YSE peptide 


















































































































































































































































































































Figure 2. Stimulation assay MHC-tetramer enriched T-cell lines. Enriched CMV-specific T-cell lines derived 
from (A) donor A, (B) donor B, (C) donor C and (D) donor D were stimulated with single HLA-molecule 
transduced K562 target cells loaded with specific peptide after one and two rounds of MHC-tetramer pull 
down. T-cell reactivity was analyzed by measuring the secreted IFN-γ concentration in a standard ELISA. 
Data are shown as mean/median + SD/SEM of 3 replicates and are from one experiment representative of 
2 performed.  
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(Fig. 2D). Increase in the frequency of the MHC-tetramer positive T-cell populations by a 
second pull down did result in a peptide-specific IFN-γ production for 3 of the 4 tested cell 
lines derived from donor A, C and D. However, not all T-cell populations present in these 
T-cell lines demonstrated to produce IFN-γ upon peptide-specific stimulation. The T-cell 
line derived from donor A, C and D that were enriched by second pull down harboring 4, 
1 and 7 different CMV-specific T-cell populations, appeared only reactive to one peptide: 
A1-pp65-YSE, B40-pp65-HER and A1-pp65-YSE, respectively. Although for donor A and C 
the observed single peptide reactivity could be explained by the absence of other high 
frequent MHC-tetramer positive T-cell populations, donor D obtained 4 populations with 
frequencies above 2% of total CD8+ T-cells but appeared only reactive to A1-pp65-YSE 
stimulation. In addition both the high frequent A1-pp65-YSE (10,4%) and B8-IE1-QIK (11%) 
specific T-cell populations in donor B appeared unable to produce IFN-γ upon specific 
peptide stimulation.
 To investigate whether the lack of IFN-γ production by some of the MHC-tetramer 
positive T-cell populations was due to their low frequencies or whether these T-cells were 
incapable to produce IFN-γ upon peptide-specific stimulation, we generated single MHC-
tetramer specific T-cell lines. For this purpose, different donor E-derived T-cell lines were 
used for a second enrichment with single MHC-tetramers. This resulted in the generation 
of 7 T-cell lines specific for 3 CMV-epitopes with frequencies varying from 5.1% to 24.6% 
of total MHC-tetramer positive T-cells. T-cells specific for the A2-IE1-VLE epitope were lost 
after isolation. Subsequently, the single MHC-tetramer enriched T-cell lines were tested 
in a peptide titration assay to assess their peptide specificity and avidity (Fig. 3A). Four 
of the 7 enriched T-cell lines demonstrated a clear sigmoid shape antigen-dose response 
with variable half-maximum response (EC50). The enriched T-cell lines S10 A1-pp50-VTE 
(13.2%) and S1 A1-pp65-YSE (16.1%) demonstrated EC50 values between 1 and 5ng/ml, 
comparable with those of 3 high-avidity memory control clones, T-cell lines S8 A1-pp65-YSE 
(18.5%) and S1 A1-pp50-VTE (24.6%) demonstrated EC50 values of approximately 300 ng/
ml. No peptide-specific IFN-γ production was observed for S6 A1-pp65-YSE (14.0%), S6 A2-
pp65-NLV (5.2%) and S10 A2-pp65-NLV (5.1%) even when these T-cell lines were exposed 
to very high peptide concentrations. Stimulation with a panel of CMV-protein transduced 
target cells demonstrated that all T-cell lines that demonstrated peptide induced IFN-γ 
production were capable of recognizing endogenously presented peptide, irrespective 
of variable EC50 values (Fig. 3B-D). In addition, we screened the reactive and functional 
non-reactive MHC-tetramer positive T-cell lines for their capacity to produce 17 other 
cytokines, chemokines and growth factors besides IFN-γ upon activation (data not shown). 
Unlike the reactive T-cell lines the functional non-reactive T-cell lines were not capable of 
producing other cytokines. These data indicate that functional heterogeneity exists among 
the different MHC-tetramer positive T-cell lines generated from an identical donor, and that 
this did not correlate with the frequencies of the specific T-cell populations.
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Figure 3. Avidity analysis of MHC-tetramer positive T-cell lines. Single MHC-tetramer positive T-cell lines 
demonstrated a wide range of peptide sensitivity. Single MHC-tetramer positive T-cell lines were generated 
from donor E and stimulated with (A) peptide-pulsed or (B) pp50, (C,D) pp65 CMV protein-transduced 
(TD) HLA-A*0101+ and HLA-A*0201+ EBV-LCL cells. Specific CMV-peptide was titrated in 3-fold dilution 
steps starting from 10 µg/ml. T-cell reactivity was analyzed by measuring the overnight IFN-γ secretion 
in a standard ELISA. For each epitope a control clone derived from the memory compartment of a CMV 
experienced donor was used.  Data are shown from one experiment.
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 To assess whether all MHC-tetramer positive T-cells within a single T-cell line 
contributed equally to the CMV-specific response, the T-cell lines were antigen specifically 
activated and the individual T-cells within the T-cell lines were screened for CMV-specific 
T-cell activation by measuring the efficiency of TCR internalization and induction of the 
activation marker CD137. The results shown in Fig. 4 demonstrate that variable parts of 
the total MHC-tetramer positive T-cell population revealed activation induced expression 
of CD137 and decreased MHC-tetramer staining intensity. For the S1 A1-pp65-YSE T-cell 
line containing 18.2% MHC-tetramer positive T-cells only 7.0% and 9.2% of CD8+ T-cells, 
corresponding with 38% to 51% of total MHC-tetramer positive cells,  demonstrated 
activation induced CD137 expression when stimulated with peptide loaded or CMV-protein 
transduced target cells, respectively, and clearly downregulated their TCR as measured by 
decreased MHC-tetramer staining intensity. Comparable results were obtained with the 
S1 A1-pp50-VTE T-cell line containing 44.4% MHC-tetramer positive T cells as 15.9% and 
36.5% of CD8+ T-cells, corresponding with 36% to 82% of total MHC-tetramer positive cells, 
demonstrated activation induced CD137 expression when stimulated with either peptide 
loaded or CMV-protein transduced stimulator cells, respectively. Furthermore, for the S6 
A2-pp65-NLV T-cell line that previously showed no peptide-specific IFN-γ production, only 
marginal T-cell activation could be observed when stimulated with CMV-specific antigen. 
Irrespective of their specificity, all tested T-cell lines demonstrated strong activation by 
αCD3/28 beads, indicating their intrinsic capacity to become activated via TCR-mediated 
stimulation. Activated T-cells demonstrated a clear downregulation of MHC-tetramer 
staining after overnight stimulation. These data indicate that a substantial part of the MHC-
tetramer positive T-cells fail to respond to specific antigen stimulation.
Functional heterogeneity by variable TCR-ligand koff rate of MHC-tetramer 
reactivity T-cell clones
To study the functional heterogeneity observed among the isolate MHC-tetramer positive 
T-cells we analyzed the TCR Vβ-usage of the MHC-tetramer positive T-cell lines derived 
from donor E by staining the cells with MHC-tetramer in combination with a Vβ-antibody 
kit. At least 6 different TCR’s could be identified within the 3 enriched A1-pp65-YSE MHC-
tetramer positive T-cell lines S1, S6 and S8. For A1-pp50-VTE and A2-pp65-NLV MHC-
tetramer positive T-cells, 3 and 2 different TCR Vβ-usage were detected, respectively. T-cell 
clones representing the oligoclonal TCR spectrum were generated by single cell sorting 
and analyzed for their MHC-tetramer specificity. For the 6 A1-pp65-YSE specific T-cell 
clones variable MHC-tetramer reactivity was demonstrated when stained with a fixed 
MHC-tetramer concentration (Fig. 5A). The reactivity range varied between the S1.5.Y TCR 
VβND T-cell clone demonstrating high MHC-tetramer staining relatively similar to that of 
the YSE-memory control clone, and S6.12.Y TCR Vβ22 T-cell clone demonstrating a 2.5 fold 
lower MHC-tetramer reactivity. As a control for nonspecific MHC-tetramer staining a VTE-
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memory control clone was stained with the A1-pp65-YSE specific MHC-tetramer.
 Subsequently, expanding T-cell clones were analyzed for antigen reactivity by 
stimulating the clones with titrated concentration of peptide. For the A1-pp65-YSE specific 
T-cell clones a wide avidity range was demonstrated. Two representative T-cell clones 
expressing 2 different TCRs (S1.11.Y TCR Vβ4 and S1.5.Y TCR VβND) exhibited a high avidity 
recognition pattern similar to that of the memory control clone, 1 T-cell clone (S6.4.Y 
TCR Vβ17) demonstrated only marginal IFN-γ production when stimulated with very high 
peptide concentrations and 3 T-cell clones (S6.25.Y TCR VβND, S6.6.Y TCR Vβ2 and S6.12.Y 
TCR Vβ22) demonstrated no peptide recognition (Fig. 5B). No different cytokine profiles 
were observed when these T-cell clones were screened for their capacity to produce other 
cytokines besides IFN-γ (data not shown). All the high avidity T-cell clones were capable 
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pp50-VTE specific T-cell clones expressing different TCRs as 2 out of 3 clones demonstrated 
high avidity peptide recognition and 1 clone demonstrated no peptide reactivity. No IFN-γ 
production was observed for T-cell clones specific for A2-pp65-NLV (data not shown).
 To analyze whether the observed MHC-tetramer reactivity correlated with the 
detected T-cell avidity we compared the results of both assays obtained for various A1-
pp65-YSE specific T-cell clones expressing different TCRs (Fig. 5C). Although the high avidity 
TCR VβND expressing specific T-cell clones demonstrated relatively similar MHC-tetramer 
reactivity compared to YSE memory control clone, the high avidity TCR Vβ4 expressing 
T-cell clones demonstrated a significant 2-fold lower MHC-tetramer reactivity (YSE M: 
P = 0.003, VβND: P = 0.004, as determined by the unpaired t-test; P<0.05). The MHC-
tetramer reactivity of the TCR Vβ4 expressing T-cell clones was relatively similar to that of 
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Figure 4. Flow cytometric analysis of stimulated CMV-
specific T-cell lines. To demonstrate antigen specificity 
and functionality of the donor E-derived MHC-tetramer 
positive T-cell lines the cell lines were co-cultured with 
peptide pulsed (1 µg/ml), CMV-protein transduced 
(TD) HLA-A*0101+  and HLA-A*0201+  EBV-LCL or 
αCD3/28 stimulation beads. TCR internalization and 
activation induced CD137 expression was analyzed by 
flow cytometry after 18 hours. Data are shown for the 
representative cell lines S1-A1-pp50-VTE, S1-A1-pp65-
YSE and S6-A2-pp65-NLV. All dot plots are shown with 
bi-exponential axes and display fluorescence intensity 
for the indicated MHC-tetramer or cell markers. Most 
EBV-LCLs are deleted by CD19+ back-gating. However 
some EBV-LCL contamination remains and is indicated 
as CD8- black dots. Non MHC-tetramer positive CD8+ 
T-cells are indicated black. T-cells expressing CD137 
expression after stimulation are indicated blue. MHC-
tetramer positive T-cells that do not express CD137 
are indicated in red. Frequencies of MHC-tetramer+ 
or CD137+ T-cells are indicated and are percentages of 
total CD8+ T-cells.  Data shown are representative of 3 
experiments performed.
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Figure 5. MHC-tetramer reactivity and structural TCR binding avidity of A1-PP65-YSE specific T cell clones 
Figure 5. MHC-tetramer reactivity and structural TCR binding avidity of A1-PP65-YSE specific T-cell 
clones. Clonally expanded donor E-derived A1-pp65-YSE specific T-cell clones were compared with a 
memory control clone and demonstrated a wide range of functional heterogeneity. (A) Flow cytometric 
analysis of 6 representative A1-pp65-YSE specific T-cell clones expressing different TCRs is shown. For flow 
cytometry T-cell clones were mixed 1:5 with CD4+ T-cells prior to incubation with PE-coupled MHC-tetramer 
to prevent aggregate formation. Included are a high-avidity A1-pp65-YSE memory and a non-specific A1-
pp50-VTE memory control clone. The MFI of the CD4-MHC-tetramer+ population is indicated in the upper 
right quadrant. (B) A1-pp65-YSE specific T-cell clones were stimulated with HLA-A*0101 and HLA-A*0201 
positive EBV-LCLs pulsed with a titrated concentration of A1-pp65-YSE peptide starting with a concentration 
of 3 µM. As a control for high avidity recognition of endogenously presented peptide, T-cells were stimulated 
with pp65 protein transduced target cells. T-cell reactivity was analyzed by measuring the IFN-γ production 
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Figure 5. MHC-tetramer reactivity and structural TCR binding avidity of A1-PP65-YSE specific T cell clones 
after overnight stimulation in a standard ELISA. Data are shown as mean + SD/SEM of 3 replicates and are 
from one experiment representative of 2 performed. (C)  Relationship between MHC-tetramer reactivity 
and T-cell avidity. High avidity T-cell clones were defined by their capacity to recognize endogenously 
presented peptide. Low avidity T-cell clones were defined by their capacity only to respond to high peptide 
concentrations and non functional T-cell clones demonstrated no IFN-γ production when stimulated with 
specific peptide. Data shown are from one representative experiment out of two experiments performed. 
(D) koff rate assay of 5 representative T-cell clones. The t1/2 of 12 to 24 single cells of each T-cell clone 
stained with the HLA*0101/PP65-YSE Streptamer is shown. The values above symbols indicate the mean 
t1/2 with standard deviation (± SD) for each measurement. The MFI of the tetramer staining of these T-cell 
clones was S1.4: MFI 27.500, S1.15: MFI 31.200, S6.20: MFI 13.000, S6.30: MFI 24.060, and S6.42: MFI 
32.450.  Data shown are from one experiment.
88
3     
significant lower than that of the low avidity TCR Vβ17 expressing T-cell clone (P = 0.008), 
demonstrating that functionality of T-cells does not correlate with the intensity of MHC-
tetramer staining.
 To prove that the observed functional heterogeneity was not due to intrinsic 
differences between the TCR-bearing T-cells such as their naïve or memory phenotype, or 
coreceptor and adhesion molecule expression differences, we performed a Streptamer-




































































































































Figure 6. Stimulation assay TCR transduced T-cell clones. After clonal expansion a high-affinity pp65-
NLV specific TCR was introduced in (A) low avidity T-cell clone YSE-Vβ22 and (B) high avidity clone VTE-
Vβ17. TCR-transduced T-cell clones were stimulated with CMV PP50 or PP65 transduced (TD) HLA-A1 and 
–A2 positive EBV-LCL or peptide pulsed (1 µg/ml) K562 transduced with HLA-A1 and –A2 for 18 hours. 
Endogenous and introduced TCR-reactivity was analyzed by cytokine secretion in a standard IFN-γ ELISA. As 
a control for overall IFN-γ production, T-cells were nonspecifically stimulated with αCD3/28 beads. Data are 
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from different T-cell clones was measured21 (Fig. 5D). Representative nonfunctional T-cell 
clones (S6.30.Y VβND, S6.42.Y VβND, and S6.20.Y Vβ22) exhibited very fast t1/2 values, 
whereas the functional T-cells clones S1.4.Y VβND and S1.15.Y VβND bound the peptide-
MHC complex for longer periods. Although all these T-cell clones exhibited positive MHC 
tetramer reactivity (S6.30: MFI 24.060, S6.42: 32.450, S6.20: MFI 13.000, S1.4: MFI 27.500, 
S1.15: MFI 31.200), they demonstrated differential functional avidity that correlated with 
the koff rates of monomeric peptide-MHC complexes as a readout for structural TCR binding 
strength.
 In addition, to confirm that the incapacity of T-cells to functionally react to cell-
surface presented peptide-MHC complexes despite their ability to bind to MHC-tetramer 
and capacity to produce IFN-γ upon non-specific αCD3/28 is due to a low-affinity TCR and not 
caused by a different differentiation state of the tested T-cells, we introduced a high-affinity 
pp65-NLV specific TCR into the non-responsive A1-pp65-YSE specific Vβ22 expressing T-cell 
clone by retroviral transduction22. Upon specific stimulation of the introduced TCR with 
peptide pulsed and CMV-protein transduced target cells, the TCR transduced T-cells were 
able to produce significant amounts of IFN-γ, which was not observed by stimulating the 
endogenous A1-pp65-YSE TCR (Fig. 6A). Introduction of the high affinity pp65-NLV specific 
TCR into the functional A1-pp50-VTE specific TCR Vβ17 expressing T-cell clone, resulted 
in IFN-γ production after stimulation of both the introduced and endogenous TCR (Fig. 
6B). These results indicate that these functionally non-responsive T-cells are intrinsically 
capable of reacting to peptide-MHC-complexes when a high-affinity TCR is introduced.
Discussion
In this study CMV specific T-cells were isolated from 5 healthy CMV unexposed individuals. 
High-avidity CMV-specific T-cell reactivity was observed for T-cell lines generated from 4 out 
of 5 individuals when stimulated with endogenous antigen. Based on specific TCR Vβ-chain 
expression MHC-tetramer positive T-cell clones representing the oligoclonal TCR spectrum 
were generated by single cell sorting. The clonally expanded T-cell clones demonstrated a 
wide avidity range for their specific antigens. As the selected PBMCS donors were CMV-
unexposed no previous clonal selection has taken place among T-cell clones competing for 
cognate antigen, narrowing the range CMV specific T-cells towards a few immunodominant 
clones that can efficiently clear infection23. The in vitro generated T-cell lines were solely 
selected based on TCR-MHC-tetramer with no subsequent selection for CMV reactivity. As 
the TCR diversity in the naïve repertoire has been reported to be at least 100-fold higher 
compared to the memory T-cell repertoire and high avidity T-cells are selectively enriched 
in the memory subset a substantial part of the isolated T-cells will be of low-avidity5;11. The 
composition of the generated T-cell lines most likely reflected the broad MHC-tetramer 
positive T-cell repertoire before antigen driven T-cell selection.
 It has been reported that frequencies of antigen specific naïve T-cells affect the 
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response kinetics to primary infection and regulate immunodominance2;24-27. Although we 
assessed T-cell precursor frequencies by indirect quantification, we demonstrate that the 
number of isolated MHC-tetramer positive T-cells was not predictive for the number of 
functional CMV specific T-cells. The isolation of high avidity T-cells was not restricted to 
the most frequently detected A1-pp65-YSE specific T-cells, and a substantial part of the 
less frequently detected A1-pp50-VTE specific T-cells demonstrated high CMV functional 
reactivity. The precursor frequency of A2-pp65-NLV specific naïve T-cells have been 
described by direct MHC-tetramer analysis to be 1 in 600 thousand (0.6*10-6) CD8+ T-cells 
and conserved among individuals14. We estimated the precursor frequency even 55-fold 
lower to be 1 in 33 million CD8+ T-cells and we only isolated non-functional T-cells. Our 
data indicate that irrespective to quantitative measurements we need to assess the quality 
of MHC-tetramer positive T-cells to be able to predict response kinetics of the naïve T-cell 
repertoire to primary infections.
 To study the impact of variable precursor frequencies of CMV-specific naïve T-cells 
on the shaping of a protective memory repertoire we analyzed 40 seropositive donors by 
MHC-tetramer staining for the prevalence of CMV-specific T-cells (Table III). The frequent 
detection of A1-pp65-YSE specific memory T-cells in 14 of the 17 individuals was in line 
with the frequent detection of high-avidity T-cells specific for this epitope in seronegative 
donors. In contrast, no correlation was observed for the detection of T-cells specific for 
A2-pp65-NLV as a memory response specific for this epitope was frequently observed in 
20 of the 24 individuals but no functional T-cells were isolated from seronegative donors. 
Apparently high avidity T-cells restricted to these immunodominant epitopes are available 
in the majority of individual T-cell repertoires. However, the success rate for finding these 
T-cells in the naïve repertoire may be affected by their low precursor frequencies. The 
incapacity to isolate functional A2-pp65-NLV from the naïve repertoire was also reported 
by Hanley et al28. These data indicate that the observed precursor frequencies of high-
avidity CD8+ T-cells within an unprimed naïve repertoire may not directly reflect the shape 
of the late-phase memory repertoire after in vivo antigen exposure. In vivo priming by 
antigen presenting cells and subsequent cytokine-driven expansion of specific T-cell clones 
may result in uneven clonal expansion of different T-cell clones. 
 The frequent isolation of low avidity T-cells with high MHC-tetramer staining 
addresses the question whether a correlation between TCR-MHC-tetramer reactivity and 
the avidity of a specific T-cell exists and whether MHC-tetramer staining can function as a 
predictive value for T-cell functionality. Although MHC-tetramer reactivity of a given TCR 
may be predictive for its functionality when memory T-cells are compared, the observation 
that A1-pp65-YSE and A1-pp50-VTE specific T-cell clones demonstrated no strict correlation 
between MHC-tetramer reactivity and T-cell avidity suggest that this may be different for 
an unbiased CMV-inexperienced T-cell repertoire. We demonstrated that high avidity CMV-
specific T-cells derived from the naïve T-cell repertoire showed relatively similar MHC-
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Table III. Direct MHC-tetramer analysis of CMV-specific CD8+ T-cells in 40 seropositive donors
 Donor HLA            














































1 + - - - 0.14 0 - - - - - -
2 - + + - - - 0.01 0 0.06 0.02 - -
3 + - - + 0.15 0.14 - - - - 0.07 0
4 - + - - - - 0.09 0.02 - - - -
5 - + + - - - 0.49 0 0 0.01 - -
6 + - - + 0.9 0.03 - - - - 2.5 0
7 + + - + 0.6 0.05 0.06 0 - - 0.1 0
8 - - + - - - - 0.13 0.74 - - -
9 + - - + 0.11 0.07 - - - - 0 0.64
10 + - - + 0.02 0.04 - - - - 0 0.64
11 - + - - - - 0.76 0.3 - - - -
12 - + - - - - 0.1 0 - - - -
13 - + - + - - 0.65 0 - - 0 0
14 - + + - - - 0.9 0 0.06 0.3 - -
15 + + - + 1.2 0.01 0.36 0 - - 0.3 2.1
16 - - + - - - - - 0.16 0.07 - -
17 + + + + 0.58 0.02 0 0 0.5 0.27 0 0
18 + + + + 0.54 0 0.03 0 0.51 0.02 0.02 0
19 - - + - - - - - 0.81 0.06 - -
20 + - - + 0 0.06 - - - - 0.01 0
21 - + + - - - 0.06 0 0 0.06 - -
22 - + + - - - 0.11 0 0.35 0.11 - -
23 - + - + - - 0.3 0 - - 0.2 0
24 - - + - - - - - 0.05 0.01 - -
25 + + - + 0.01 0 0 0 - - 0.01 0
26 - - + - - - - - 0.36 0.56 - -
27 - + - + - - 0.46 0 - - 0.03 0.54
28 + + - + 0.05 0.02 0.22 0 - - 0.01 0
29 + - - + 0.35 0.02 - - - - 0.02 0
30 - + - - - - 0.12 0.07 - - - -
31 + + - + 0.13 0.02 0.19 0 - - 1.3 0
32 - + - - - - 0.15 0 - - - -
33 - - + - - - - - 0.07 0.03 - -
34 + - - + 0.42 0.06 - - - - 0.22 0.24
35 - + + - - - 0 0 0.15 0.7 - -
36 - + + - - - 0 0.06 0.36 0.68 - -
37 - - + - - - - - 0 0.1 - -
38 + - - - 0.13 0.03 - - - - - -
39 - + - + - - 0.68 0 - - 0.9 0
40 + + - + 0.05 0.02 0.12 0 - - 0.33 0
MHC-tetramer positive 16/17 14/17 20/24 4/24 13/16 16/16 15/19 5/19
Average frequency   0.32 0.04 0.26 0.14 0.29 0.27 0.27 0.88
Frequencies indicate percentage of total CD8+ T-cells
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tetramer reactivity as high avidity T-cells obtained from a memory response. In addition, 
low or nonfunctional T-cell clones could demonstrate comparable or even increased MHC-
tetramer staining when compared to high-avidity T-cell clones with the same specificity 
and obtained from the same individual. Non-responsiveness of MHC-tetramer positive 
T-cell clones has also been reported by others for tetramer positive T-cell-derived from 
the naïve repertoire24;29. The discrepancy between MHC-tetramer reactivity and T-cell 
functionality may be explained by the staining with multimerized MHC-peptide complexes. 
Multimerization of MHC-peptide complexes alter the TCR-MHC-peptide dissociation on- 
and off-rate kinetics and may result in increased binding avidity of the multimerized MHC-
peptide complex to surface TCR30. By measuring the TCR binding strength to monomeric 
peptide-MHC complexes we demonstrated that the dissociation kinetics correlated with 
the observed functional avidity of the different T-cell clones, and that this was independent 
of the intensity of MHC-tetramer reactivity. 
 In conclusion, the method described in this study may find application in studying 
the naïve T-cell repertoire before antigen driven T-cell selection. Our data put a critical note 
to the direct monitoring of the shape of the peripheral naïve T-cell repertoire independent 
of the analysis of functional activity or structural avidity parameters.
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Materials and methods
Culture conditions and cells. Peripheral blood was obtained from different individuals with informed 
consent (Sanquin Reagents, Amsterdam, The Netherlands). All experiments were approved by 
the local medical ethics committees. Blood samples were HLA-typed by high-resolution genomic 
DNA-typing and serological immunoassay was performed using the AxSYM microparticle enzyme 
immunoassay (Abbott, Abbott Park, IL) for the detection of anti-CMV IgG/IgM antibodies. Peripheral 
blood mononuclear cells (PBMCS) were isolated by Ficoll gradient separation and cryopreserved 
for further use. Donor samples were included when CMV serology was negative and when the 
frequencies of MHC-tetramer positive T-cells appeared less than 0.01% of total CD8+ T-cells. T-cells 
were cultured in Iscove’s Modified Dulbecco’s Media (IMDM: Lonza, Basel, Switzerland) containing 
5% human serum, 5% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/
ml streptomycin (Invitrogen, Carlsbad, CA) supplemented with 100 IU/ml IL-2 (Proleukin; Chiron, 
Amsterdam, The Netherlands). Feeder fractions were irradiated with 50 Gy. Stable Epstein-Barr 
virus-transformed lymphoblastoid B-cell lines (EBV-LCL) and phytohemagglutinine (PHA) blasts were 
generated using standard procedures.
Generation of peptide-MHC complexes. All peptides were synthesized in-house using standard 
Fmoc chemisty. Recombinant HLA-A*0201 heavy chain and human β2m light chain were in-house 
produced in Escherichia coli. MHC class I refolding was performed as previously described with minor 
modifications31. MHC class I complexes were purified by gel-filtration HPLC in PBS and stored at 4⁰C.
Isolation of CMV-specific T-cells by MHC-tetramer pull down. Prior to isolation PBMCS samples 
were stained with PE-coupled MHC-tetramers for 1 hour at 4ºC. Subsequently, cells were washed 
and incubated with anti-PE antibody coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany). Cells were than isolated by magnetic activated cell sorting (MACS) using an LS column, 
following the manufacturers protocol (Miltenyi). Eluted cells were cultured per 5000 cells with 5x104 
irradiated (50 Gy) autologous feeder cells in presence of 100 IU/ml IL-2, 5ng/ml IL-15 (Biosource) and 
11.000 anti-CD3/CD28 Dynabeads (Invitrogen) for polyclonal stimulation in 96-well plates. Cultures 
were refreshed at least twice a week. After 2 weeks, cell cultures were analyzed for peptide-specific 
T-cell populations by MHC-tetramer flow cytometry. Subsequently MHC-tetramer pull down and 
expansion procedure was repeated or MHC-tetramer positive T-cell populations were sorted on a 
FACSAria (BD Biosciences, San Diego, USA) into 96 well plates containing 1*105 irradiated feeder cells 
supplemented with 0.5 μg/mL PHA.
Flow cytometry and T-cell staining. Data acquisition was performed on an LSR-II flow cytometer 
(BD) with FacsDiva software using the following 11-color instrument settings: 488 nm laser: PI: 685LP, 
695/40; PE: 550LP, 575/26; FITC: 505LP, 530/30; SSC: 488/10. 633 nm laser: Alexa700: 685LP, 730/45; 
APC: 660/20. 405 nm laser: QD800: 770LP, 800/30; QD705: 680LP, 710/50; QD655: 635LP, 660/40; 
QD605: 595LP, 650/12. 355 nm laser: QD585: 575LP, 585/15; QD565: 545LP: 560/20. Approximately 
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1*106 PBMCS were stained for each analysis with a final concentration of 2 µg/mL per MHC-tetramer 
in 100 µl Phosphate buffered saline (PBS) with 5% (v/v) pasteurized plasma protein solution (GPO). 
Next, antibody-mixtures consisting of CD8-Alexa700 (Caltag-Medsystems, Buckingham, UK), CD4-, 
CD14-, CD19-FITC or CD137-allophycocyanin (BD) were added and cells were incubated for 30 min 
at 4°C. Prior to flow cytometry, cells were washed twice. For dual-encoding MHC-tetramer staining 
a set of fluorescently labeled MHC-tetramers was generated in which each specific peptide-MHC 
complex was encoded by a unique combination of two fluorochromes, to screen for recognition of 
all CMV-epitopes in a single sample. For assessment of TCR-Vβ-chain usage the TCR-Vβ repertoire kit 
was used (Beckman Coulter, Takeley, UK) according to the manufactory protocol.
Functional analysis. For analysis of IFN-γ production, 5000 T-cells were cocultured with 25.000 target 
cells loaded with different concentrations of CMV, control peptides or with artificial Ag-presenting 
beads. To test the functional activity of the T-cells against target cells presenting endogenously 
processed antigen, we used K562 transduced with single HLA molecules or EBV-LCL transduced with a 
retroviral vector containing a CMV-pp65/ -pp50 or –IE1 expression construct as target cells32. Peptide 
loading was performed by incubating target cells for 1 hour in 96 well plates at 37ºC and 5% CO2 in 
IMDM containing 2% FBS and cells were washed twice before use. After 24 h, supernatants were 
harvested, and the concentration of IFN-γ was measured by an enzyme-linked immunosorbent assay 
(Sanquin Reagents). For FACS analysis of activation induced TCR internalization 10.000 effector cells 
were incubated with 50.000 target cells. 
TCR gene transfer. The construction of the retroviral vector encoding the TCR chains of the CMV-pp65 
specific T-cell clone have been described earlier33. The high-affinity CMV-TCR-AV18 T-cell receptor 
was transduced in the selected T-cell clones two days after stimulation as previously described. 
Marker gene eGFP and NGF-R double positive T-cells were subsequently sorted34.
koff-rate assays. The dissociation kinetics of monomeric pMHC molecules bound to cell surface 
expressed TCRs was determined using the Streptamer-based koff rate assay that was recently 
described21. In short, T-cell clones were incubated with Strep-Tactin Allophycocyanin (APC) and 
HLA*0101/PP65-YSE Atto565 double labeled Streptamers for 45 min on ice. To prevent internalization 
of MHC molecules, Streptamer-stained cells were constitutively kept at 4oC. Fluorescence images 
were taken on a Leica SP5 confocal laser scanning microscope before and every 10 seconds after the 
addition of D-biotin until complete dissociation of the MHCs. 
95
M
ixed functional characteristics of the naive T-cell repertoire
3     
References
1.  Davis,M.M. and Bjorkman,P.J., T-cell antigen receptor genes and T-cell recognition. Nature 
1988. 334: 395-402.
2.  Obar,J.J., Khanna,K.M., and Lefrancois,L., Endogenous naive CD8+ T cell precursor frequency 
regulates primary and memory responses to infection. Immunity. 2008. 28: 859-869.
3.  La Gruta,N.L., Rothwell,W.T., Cukalac,T., Swan,N.G., Valkenburg,S.A., Kedzierska,K., 
Thomas,P.G., et al., Primary CTL response magnitude in mice is determined by the extent of 
naive T cell recruitment and subsequent clonal expansion. J Clin.Invest 2010. 120: 1885-1894.
4.  Kwok,W.W., Tan,V., Gillette,L., Littell,C.T., Soltis,M.A., LaFond,R.B., Yang,J., et al., Frequency 
of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human 
memory repertoire. J Immunol 2012. 188: 2537-2544.
5.  Arstila,T.P., Casrouge,A., Baron,V., Even,J., Kanellopoulos,J., and Kourilsky,P., A direct estimate 
of the human alphabeta T cell receptor diversity. Science 1999. 286: 958-961.
6.  Goldrath,A.W. and Bevan,M.J., Selecting and maintaining a diverse T-cell repertoire. Nature 
1999. 402: 255-262.
7.  Peterson,D.A., DiPaolo,R.J., Kanagawa,O., and Unanue,E.R., Quantitative analysis of the T cell 
repertoire that escapes negative selection. Immunity. 1999. 11: 453-462.
8.  Teh,H.S., Harley,E., Phillips,R.A., and Miller,R.G., Quantitative studies on the precursors of 
cytotoxic lymphocytes. I. Characterization of a clonal assay and determination of the size of 
clones derived from single precursors. J.Immunol. 1977. 118: 1049-1056.
9.  Blattman,J.N., Antia,R., Sourdive,D.J., Wang,X., Kaech,S.M., Murali-Krishna,K., Altman,J.D.,  et 
al., Estimating the precursor frequency of naive antigen-specific CD8 T cells. J.Exp.Med. 2002. 
195: 657-664.
10.  Ho,W.Y., Nguyen,H.N., Wolfl,M., Kuball,J., and Greenberg,P.D., In vitro methods for generating 
CD8+ T-cell clones for immunotherapy from the naive repertoire. J.Immunol.Methods 2006. 
310: 40-52.
11.  Geiger,R., Duhen,T., Lanzavecchia,A., and Sallusto,F., Human naive and memory CD4+ T cell 
repertoires specific for naturally processed antigens analyzed using libraries of amplified T 
cells. J.Exp.Med. 2009. 206: 1525-1534.
12.  Altman,J.D., Moss,P.A., Goulder,P.J., Barouch,D.H., McHeyzer-Williams,M.G., Bell,J.I., 
McMichael,A.J., et al., Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 
274: 94-96. J.Immunol. 2011. 187: 7-9.
13.  Hataye,J., Moon,J.J., Khoruts,A., Reilly,C., and Jenkins,M.K., Naive and Memory CD4+ T Cell 
Survival Controlled by Clonal Abundance. Science 2006. 312: 114-116.
14.  Alanio,C., Lemaitre,F., Law,H.K., Hasan,M., and Albert,M.L., Enumeration of human antigen-
specific naive CD8+ T cells reveals conserved precursor frequencies. Blood 2010. 115: 3718-
3725.
15.  Seah,S.G., Sutherland,R.M., La Gruta,N.L., Brown,L.E., Carrington,E.M., Belz,G.T., Brady,J.L., et 
al., The linear range for accurately quantifying antigen-specific T-cell frequencies by tetramer 
staining during natural immune responses. Eur.J Immunol 2011. 41: 1499-1500.
16.  Hombrink,P., Hadrup,S.R., Bakker,A.H, Kester,M.G.D., Falkenburg,J.H.F., von dem Borne,P.A., 
Schumacher,T.N.M., et al., High-Throughput Identification of Potential Minor Histocompatibility 
Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations. PLoS ONE 2011. 6: 
e22523.
17.  Amir,A.L., van der Steen,D.M., van Loenen,M.M., Hagedoorn,R.S., de Boer,R., Kester,M.D., de 
Ru,A.H., et al., PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity 
96
3     
useful for therapeutic T-cell receptor gene transfer. Clin.Cancer Res. 2011. 17: 5615-5625.
18.  Hinrichs,C.S., Borman,Z.A., Cassard,L., Gattinoni,L., Spolski,R., Yu,Z., Sanchez-Perez,L., et al., 
Adoptively transferred effector cells derived from naive rather than central memory CD8+ 
T cells mediate superior antitumor immunity. Proc.Natl.Acad.Sci.U.S.A 2009. 106: 17469-
17474.
19.  Berard,M. and Tough,D.F., Qualitative differences between naive and memory T cells. 
Immunology 2002. 106: 127-138.
20.  Hadrup,S.R., Bakker,A.H., Shu,C.J., Andersen,R.S., van Veluw,J., Hombrink,P., Castermans,E., 
et al., Parallel detection of antigen-specific T-cell responses by multidimensional encoding of 
MHC multimers. Nat.Methods 2009. 6: 520-526.
21.  Nauerth,M., Weißbrich B, and Knall,B., TCR-ligand koff-rate predicts protective capacity of 
antigen-specific CD8+ T cells for adoptive transfer. Sci Transl Med 2013. 5: 192ra87.
22.  Heemskerk,M.H.M., Hoogeboom,M., Hagedoorn,R., Kester,M.G.D., Willemze,R., and 
Falkenburg,J.H.F., Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells 
Using T Cell Receptor Gene Transfer. The Journal of Experimental Medicine 2004. 199: 885-
894.
23.  Busch,D.H. and Pamer,E.G., T cell affinity maturation by selective expansion during infection. 
J.Exp.Med. 1999. 189: 701-710.
24.  Ford,M.L., Koehn,B.H., Wagener,M.E., Jiang,W., Gangappa,S., Pearson,T.C., and Larsen,C.P., 
Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and 
requirement for costimulation. J.Exp.Med. 2007. 204: 299-309.
25.  Moon,J.J., Chu,H.H., Pepper,M., McSorley,S.J., Jameson,S.C., Kedl,R.M., and Jenkins,M.K., 
Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity 
and response magnitude. Immunity. 2007. 27: 203-213.
26.  Tan,A.C., La Gruta,N.L., Zeng,W., and Jackson,D.C., Precursor frequency and competition 
dictate the HLA-A2-restricted CD8+ T cell responses to influenza A infection and vaccination 
in HLA-A2.1 transgenic mice. J Immunol 2011. 187: 1895-1902.
27.  Day,E.B., Charlton,K.L., La Gruta,N.L., Doherty,P.C., and Turner,S.J., Effect of MHC class I 
diversification on influenza epitope-specific CD8+ T cell precursor frequency and subsequent 
effector function. J Immunol 2011. 186: 6319-6328.
28.  Hanley,P.J., Cruz,C.R., Savoldo,B., Leen,A.M., Stanojevic,M., Khalil,M., Decker,W., et al., 
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be 
expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. 
Blood 2009. 114: 1958-1967.
29.  Derby,M.A., Wang,J., Margulies,D.H., and Berzofsky,J.A., Two intermediate-avidity cytotoxic 
T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. 
Int.Immunol 2001. 13: 817-824.
30.  Knabel,M., Franz,T.J., Schiemann,M., Wulf,A., Villmow,B., Schmidt,B., Bernhard,H., et al., 
Reversible MHC multimer staining for functional isolation of T-cell populations and effective 
adoptive transfer. Nat.Med. 2002. 8: 631-637.
31.  Burrows,S.R., Kienzle,N., Winterhalter,A., Bharadwaj,M., Altman,J.D., and Brooks,A., Peptide-
MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol 2000. 165: 
6229-6234.
32.  Amir,A.L., D’Orsogna,L.J., Roelen,D.L., van Loenen,M.M., Hagedoorn,R.S., de Boer,R., van 
der Hoorn,M.A., et al., Allo-HLA reactivity of virus-specific memory T cells is common. Blood 
2010. 115: 3146-3157.
33.  Heemskerk,M.H., Hoogeboom,M., de Paus,R.A., Kester,M.G., van der Hoorn,M.A., Goulmy,E., 
97
M
ixed functional characteristics of the naive T-cell repertoire
3     
Willemze,R., et al., Redirection of antileukemic reactivity of peripheral T lymphocytes using 
gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes 
expressing a conserved alpha joining region. Blood 2003. 102: 3530-3540.
34.  Kuball,J., Dossett,M.L., Wolfl,M., Ho,W.Y., Voss,R.H., Fowler,C., and Greenberg,P.D., Facilitating 
matched pairing and expression of TCR chains introduced into human T cells. Blood 2007. 
109: 2331-2338.

D I S C O V E R Y  O F  T - C E L L  E P I T O P E S 
I M P L E M E N T I N G  H L A - P E P T I D O M I C S  I N T O 
A  R E V E R S E  I M M U N O L O G Y  A P P R O A C H
Journal of Immunology 2013
Pleun Hombrink1, Chopie Hassan2, Michel G.D. Kester1, Arnoud 
H. de Ru2, Cornelis A.M. van Bergen1, Harm Nijveen3, Jan W. 
Drijfhout2, J.H. Frederik Falkenburg1, Mirjam H.M. Heemskerk1,$ 
and Peter A. van Veelen2,$
4
1 Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands; 
2 Department of Immunohematology and Blood Transfusion, Leiden University Medical 
Center, Leiden, The Netherlands; 
3 The Laboratory of Bioinformatics, Wageningen University, Wageningen, The Netherlands
$ Shared Senior Authorship
100
4     T-cell recognition of minor histocompatibility antigens (MiHA) plays an important role in the graft-versus-tumor 
(GVT) effect of allogeneic stem cell transplantation (allo-
SCT). Selective infusion of T-cells reactive for hematopoiesis-
restricted MiHA presented in the context of HLA class I or II 
molecules may help to separate the GVT effects from graft-
versus-host disease (GVHD) effects after allo-SCT. Over the 
years, increasing numbers of MiHA have been identified by 
forward immunology approaches that are characterized by 
the isolation of T-cells with antigen specificities which are not 
predefined. As the tissue distribution of MiHA affects the clinical 
outcome of T-cell responses against these antigens it would 
be beneficial to identify predefined MiHA that are exclusively 
expressed on malignant cells. Therefore, several reverse 
immunology approaches have been explored for the prediction 
of MiHA. Thus far, these approaches frequently resulted in the 
identification of T-cells directed against epitopes that are not 
naturally processed and presented. In this study we established 
a method for the identification of biologically relevant MiHA 
implementing mass spectrometry based HLA-peptidomics into 
a reverse immunology approach. For this purpose HLA class I 
binding peptides were eluted from transformed B-cells, analyzed 
by mass spectrometry and matched with a database dedicated 
to identify polymorphic peptides. This resulted in a set of 40 
MiHA candidates that was evaluated in multiple selection steps. 
The identification of LB-NISCH-1A demonstrated the technical 
feasibility of our approach. Based on these results we present 
an approach that can be of value for the efficient identification 
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Introduction
Over the past decades, allogeneic stem cell transplantation (allo-SCT) and subsequent 
donor lymphocyte infusion (DLI) has proven to be a valuable therapeutic regimen to treat 
hematological malignancies1;2. Eradication of tumor burden and long-term remission in 
patients with hematological malignancies including leukemia has been attributed to the 
recognition of malignant cells by donor T-cells. Detailed analyses of T-cell immune responses 
in patients responding to DLI have demonstrated that the donor T-cells recognize minor 
histocompatibility antigens (MiHA) presented in the context of HLA molecules on malignant 
cells. These MiHA are peptides derived from polymorphic proteins that differ between 
donor and recipient due to single nucleotide polymorphisms (SNP) 3-5. Whether donor 
T-cells mediate beneficial graft-versus-leukemia (GVL) responses or harmful graft-versus-
host-disease (GVHD) is likely to depend on the tissue distribution of the target antigen. If 
the donor T-cell response is directed against MiHA that are ubiquitously expressed it may 
mediate GVHD6, a major cause of transplant-related morbidity and mortality7;8, whereas 
selective infusion of T-cells reactive with MiHA exclusively expressed on hematopoietic 
cells is considered an attractive therapy to establish a GVL response in absence of GVHD9.
 Over the years, increasing numbers of MiHA have been identified by cDNA library 
screening10-12, genetic linkage analysis13-15, peptide elution from HLA16-18 and genome-wide 
association analysis19-21. Collectively, these methods use a forward immunology approach 
characterized by the isolation of activated T-cells from patients demonstrating a clinical 
response to DLI after allo-SCT and subsequent elucidation of the antigens recognized. 
The intrinsic property of these methods is isolation of T-cells with antigen specificities 
which are not predefined. As a consequence, many MiHA specific T-cells were isolated 
that recognized at least some non-hematopoietic cells, marking them inappropriate for 
adoptive transfer as they may mediate GVHD toxicity.
 To increase the efficiency of characterizing MiHA with therapeutic potential, we 
and others have used an alternative approach called reverse immunology in which peptide 
predictions are the starting point and peptide candidates are subsequently screened for 
their capacity to induce a T-cell specific response22-24. This approach has the advantage 
to specifically screen for T-cells recognizing MiHA that are exclusively expressed by 
hematopoietic cells. However, we and others have previously reported that when such 
peptide predictions are solely based on computer algorithms that predict peptide-HLA 
binding affinity and proteolytic cleavage, the vast majority of T-cell responses detected 
is directed against epitopes that are not naturally processed and presented and as a 
consequence will not kill their target cells25;26. The identification of the HLA-associated 
peptidome of hematopoietic cells by mass spectrometric analysis evades this peptide 
selection problem. The implementation of HLA-peptidomics into a reverse immunology 
approach guarantees HLA-restricted processing and presentation of eluted peptide 
candidates27-29.
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 In this study we investigated whether the identification of biologically relevant 
MiHA is feasible by merging HLA-peptidomics, single nucleotide polymorphism (SNP) 
databases, MHC-tetramer technology and multi-parametric flow-cytometric analysis 
into an efficient selection algorithm. For this purpose peptide elution experiments were 
performed resulting in the generation of a large set of eluted peptides. Subsequently, 
this library was screened for potential MiHA using a database dedicated to identify 
polymorphic peptides30. A set of 40 MiHA candidates was synthesized and subsequently 
evaluated by mass spectrometric analysis, SNP validation and peptide-HLA binding assays. 
After evaluation, 12 polymorphic peptides were selected for MHC-tetramer production31-33. 
Subsequently, MHC-tetramer positive T-cells lines were generated from healthy peripheral 
blood mononuclear cells (PBMC) donors by magnetic activated cell sorting (MACS). 
Flow cytometry-based analysis of antigen-specific T-cells, followed by functional testing 
of identified T-cell clones demonstrated the immunogenic potential of eluted MiHA and 
resulted in the isolation of high avidity T-cell clones specific for a novel MiHA.
 The identification of the LB-NISCH-1A MiHA demonstrated the technical feasibility 
of our HLA-peptidomics based reverse immunology approach. In addition, by establishing 
strict selection criteria we could create an algorithm that can be exploited to selectively 
target T-cells specific for MiHA with a defined tissue distribution.
Results
Selection of MiHA candidates from eluted peptide set
To establish a database of eluted peptides 4 EBV-LCL cell lines were expanded and lysed 
prior to use. Subsequently, HLA-A*0201 molecules were isolated by BB7.2 monoclonal 
antibody covalently linked to protein A beads and ligands were eluted by acid treatment34. 
The complex ligand pool was fractionated by C18 reverse-phase HPLC and subsequently 
analyzed by on-line tandem mass spectrometry for sequencing. Tandem mass spectra were 
matched to the Human Short Peptide Variation Database (HSPVdb) for polymorphic peptide 
identification using the Mascot search engine30;40. Peptide sequences encoded by both the 
normal and alternative reading frames were identified with a length of 7 to 14 amino acids 
allowing methionine oxidation, a minimal Best Mascot Ion score (BMI) of 20 and a mass 
accuracy of 10 parts per million (ppm). The HSPVdb database is specifically designed to 
address all peptide variations and only contains mRNA sequence fragments covering each 
polymorphism. As a consequence non-polymorphic mRNA regions are not included. This 
may result in false positive assignment of eluted non-polymorphic peptides to polymorphic 
mRNA regions. Therefore, as a first check, the tandem mass spectra were matched against 
both the HSPVdb and the regular IPIhuman database36. Polymorphic peptide assignments 
were only allowed if the HSPVdb peptide identification confidence score was greater than 
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human genome we further screened the MiHA candidates for sequence alignment with 
homologous genes and selected for those peptides that were uniquely encoded by a single 
gene of the human genome. In addition, MiHA candidates were only allowed to contain one 
polymorphism and as a consequence most peptides encoded by very polymorphic genes 
such as HLA, taste and olfactory receptor genes were excluded. The top 40 of identified 
MiHA candidates was selected and synthesized by standard Fmoc chemistry (Table SI)41.
Validation of eluted MiHA candidates
For final confirmation of the identity of the MiHA candidates the tandem mass spectra of 
the eluted peptides were compared with their synthetic counterparts. For 23 peptides, 
representing 58% of the MiHA candidates a perfect match confirmed the identification of 
the eluted peptides (Table I). For 10 peptides, representing 25% of the MiHA candidates, 
the tandem mass spectra did clearly differ, indicating that the peptide assignment was 
wrong. The assignment of 7 candidates MiHA could not be confirmed due to poor spectral 
quality. These candidates remained in the study until subsequent selection steps proved 
otherwise.
    To confirm whether the SNP haplotype of the elution target cells corresponded 
with the allelic variant of the eluted peptides, we screened the 4 EBV-LCL cell lines for 
the respective set of polymorphisms using an Illumina Human1M-duo array supplemented 
with KASPar SNP genotyping assays. No SNP haplotype disparities were revealed for all the 
30 remaining MiHA candidates. In addition a panel of 100 Dutch individuals was analyzed 
to evaluate the SNP allele frequencies of the remaining MiHA candidates (Table I). Although 
their existence was suggested by the NCBI dbSNP database42, we could not verify the SNP 
for 7 candidates and these non-polymorphic peptides were excluded from the potential 
MiHA list.
Assessment of the HLA-A*0201 affinity of eluted MiHA candidates
Although low affinity polymorphic peptides may be eluted from the HLA-peptidome these 
can not be validated as MiHA due to the necessity to isolate T-cells reactive to these 
peptides via MHC-tetramer isolation. Therefore in our MiHA identification method we 
analyzed the remaining MiHA candidates for their HLA-A*0201 affinity using a binding 
assay that is based on UV-induced conditional ligand cleavage32;39. In this assay recombinant 
HLA-monomers that are prefolded around a UV-liable ligand, are subsequently exposed to 
UV in the presence of one of the MiHA candidate peptides. The UV-induced degradation 
of the conditional ligand will result in rapid disintegration of the HLA-monomer, a process 
that may be prevented by the affinity dependent binding of the presented MiHA candidate 
peptide into the empty binding-groove of the HLA-molecule (Fig. 1). After UV-exchange 
HLA-monomer rescue scores (R) were normalized to the high HLA-A*0201 affinity CMV-
PP65-NLV peptide. A selection threshold was set based on the 40% HLA-rescue score that 
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Figure 1. HLA-A*0201 binding affinity of eluted MiHA candidates. (A) HLA-A*0201 binding affinity of 23 
confirmed MiHA candidates was measured by a binding assay that is based on UV-exchange monomer 
technology. After UV-exchange the HLA-monomer rescue score was normalized to the high affinity CMV 
PP65-NLV (NLVPMVATV) peptide which was set to 100%. Selection threshold was set to 40% HLA recovery 
based on the low affinity MART-1-WT-AAG (AAGIGILTV) peptide. As negative control no rescue peptide 
was added. Experiment was performed in triplicate, data are mean ± SD. (B) The HLA-A*0201 recovery 
of 2 high- and 2 low-affinity eluted peptides was normalized to the input of total HLA heavy chain and 
β2M complex after conventional HLA-refolding. (C) HLA-A*0201 binding affinity of 9 predicted allelic MiHA 
variants (CP) was measured by the UV-exchange monomer based binding assay. 
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was demonstrated by the low HLA-A*0201 affinity MART-1-WT-AAG peptide as only a 
modified MART-1-ELA peptide analog can be used for successful MHC-tetramer formation. 
For 13 out of the residual 23 MiHA candidates rescue scores above 40% were obtained. 
Thus, although eluted from HLA-A*0201, a substantial number of 10 validated peptides 
demonstrated rescue scores beneath the MART-1-WT-EAA based selection threshold, 
corresponding with low HLA-A*0201 binding affinity.
 Next, we analyzed whether these low affinity peptides could be used for MHC-
tetramer formation by conventional HLA-refolding. In this assay we tested a representative 
high-, intermediate and two low-affinity MiHA candidate peptides for their capacity 
to support stable refolding of the heavy chain and β2m recombinant subunits of a 
HLA-A*0201 complex. HLA-recovery levels of 23.5%, 49.0%, 4.5% and 6% were obtained 
for P15 HIVEP-1S, P18 NISCH-1A, P39 USP31-1S and P40 ZNF610-1V respectively. For the 
control peptides CMV-PP65-NLV and MART-1-WT-AAG, HLA-recovery levels of 58.8% and 
5.4% were obtained (Fig. 1B). These results indicate that for the high- and intermediate 
affinity peptides, MHC-tetramer formation can be achieved using both the conventional 
and conditional HLA-monomer formation methods. However, as the two tested low-affinity 
peptides demonstrated low HLA-recovery scores comparable to the negative control 
MART-1-WT-AAG peptide, no peptide-HLA-monomer complex remains for MHC-tetramer 
formation. As a consequence, the low-affinity peptides were removed from the MiHA 
candidate list and 13 MiHA candidates remained for further validation.
Isolation of peripheral blood derived MiHA-specific T-cells by MHC-tetramer 
pull down
For the two MiHA candidates encoded by the APOBEC3F and NISCH gene, see Table I, 
peptides expressing both allelic variants of the SNP were eluted. As bi-directional T-cell 
recognition of both allelic MiHA variants has been reported43;44, we hypothesized that the 
prediction of the allelic variants of the remaining high affinity eluted MiHA candidates could 
be a valuable contribution to our candidate list. We therefore synthesized the predicted 
allelic MiHA variants of the remaining MiHA candidates and tested them for HLA-A*0201 
affinity. With the exception of the allelic CHRNA9-1L variant, demonstrating low peptide-
HLA affinity, all predicted allelic MiHA variants demonstrated similar affinity as their eluted 
counterpart (Fig. 1C). Subsequently, with the exception of both TRIM9 variants, MHC-
tetramers were successfully generated for all peptides and bringing the total number of 
MHC-tetramers up to 19, specific for 12 eluted and 7 predicted allelic MiHA variants.
 Next, MiHA-specific T-cell lines were generated by incubating 100*106 PBMC from 
14 healthy donors with a specific set of MHC-tetramers, followed by enrichment of MHC-
tetramer positive cells on a magnetic column. To increase the isolation frequency of high-
affinity T-cell populations, the set of MHC-tetramers was specifically adjusted to each PBMC 
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Table II. MHC-tetramer pull down scheme.
negative in the respective donor (Table II). Due to unfavorable allele frequencies of some 
SNP encoding MiHA, no homozygous negative individuals were available for the CMPK1-1S, 
HIVEP1-1N, NISCH-1V, TYK2-1V and UCRC-1I MiHA candidates. After 14 days of expansion 
either one or more MHC-tetramer positive T-cell populations were detected in 7 of 
the generated T-cell lines by flow cytromety (FACS). In total 11 different MHC-tetramer 
positive T-cell populations were detected specific for the eluted HIVEP1-1S and NISCH-
1A and predicted PARP10-1P and UCRC-1V allelic MiHA variants. Overall MHC-tetramer 
positive T-cell frequencies varied between 0.01% and 1.19% of total CD8+ T-cells (Table II). 
Representative examples for each of these MiHA candidates are shown in Fig. 2A. For each 
MHC-tetramer positive T-cell population a purified T-cell line was generated by FACS cell 
sorting (from now on referred to as “purified T-cell lines”). Purity varied between 95% and 
100% of total T-cells.
MHC-tetramer positive T-cell lines demonstrate MiHA-specific IFN-γ production
To assess the reactivity of the purified MHC-tetramer positive T-cell lines we stimulated 
them with T2 target cells loaded with either one of the allelic MiHA variants separately in 
a titration assay and measured overnight IFN-γ production. For each MiHA candidate the 
T-cell line demonstrating the highest avidity for the specific peptide that was used for MHC-
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tetramer isolation is shown in Fig. 2B. Tested T-cell lines demonstrated variable peptide 
avidity and a half maximum response (IC50) of ±3 nM was obtained for the high-avidity 
DHA PARP10-1P and DGT UCRC-1V T-cell lines. The DGT HIVEP1-1S and DBS NISCH-1A T-cell 
lines demonstrated an approximately 10-fold lower peptide sensitivity of ±30 nM. As the 
MiHA candidates where eluted from HLA they are expected to be of biological relevance. 
As a consequence, high-avidity T-cells reactive to one allelic variant of the candidate 
MiHA are not expected to recognize the other allelic variant due to clonal deletion of high 
avidity T-cells directed towards potential self antigens. When stimulated with both allelic 
variants of the MiHA candidates, the DGT HIVEP1-1S and DBS NISCH-1A T-cell lines did not 
demonstrate any recognition of their allelic MiHA variants; however the DHA PARP10-1P 
T-cell line demonstrated low avidity recognition of the PARP10-1L variant and the DGT 
UCRC-1V T-cell line demonstrated equally high avidity peptide recognition of both allelic 
MiHA variants. Apparently the valine (V) to isoleucine (I) substitution at position 6 in the 
UCRC decamer peptide did not affect recognition by the UCRC-1V specific MHC-tetramer 
positive T-cells. These data indicate, that either the allelic UCRC-1I variant is not processed 
Figure 2. Purified MHC-tetramer positive 
T-cell lines demonstrate MiHA specific 
IFN-γ production after peptide stimulation. 
(A) Detection of MiHA specific T-cell 
populations by FACS analysis after MHC- 
tetramer pull down and in vitro expansion 
for 14 days. Representative examples are 
shown of MHC-tetramer positive T-cell 
populations detected in the indicated T-cell 
lines and specific for 4 unique MiHA of which 
two were eluted (upper part) and two were 
predicted allelic variants (lower part). All 
dot plots display fluorescence intensity for 
CD8 and specific MHC-tetramer staining. 
MHC-tetramer positive T-cells are indicated 
gray, total lymphocytes are indicated black. 
Frequencies indicate MiHA specific T-cells of 
total CD8+ cells. (B) Purified MHC-tetramer 
positive T-cell lines were generated by 
FACS sort and stimulated with HLA-A*0201 
positive T2 target cells loaded with titrated 
concentrations of peptides for 18 hours 
[E:T] 5000:25000. For each specificity the 
purified MHC-tetramer positive T-cell line 
is shown that demonstrated the highest 
avidity when tested against their specific 
(black) or allelic MiHA variant peptide 
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Figure 3. High avidity MHC-tetramer positive T-cell clone demonstrates MiHA positive target cell 
recognition. (A) Donor DNJ7281 derived NISCH-1A purified MHC-tetramer positive T-cell line and generated 
Vβ8 and VβND restricted T-cell clones were stimulated with peptide-loaded HLA-A*0201 positive T2 target 
cells for 18 hours [E:T] 5000:25000. Peptide concentrations were titrated in 3-fold dilution steps starting 
from 1 μM. MiHA specificity and peptide reactivity was analyzed by cytokine secretion in a standard 
IFN-γ ELISA. (B) Donor DNJ7281 derived NISCH-1A purified MHC-tetramer positive T-cell line (black) and 
generated Vβ8 and VβND restricted T-cell clones (light and dark grey) were stimulated with a panel of 10 
HLA-A*0201 positive and SNP genotyped EBV-LCL target cells positive (+) or negative (-) for the indicated 
MiHA for 18 hours. T-cell reactivity was measured by standard IFN-γ ELISA. As a control for MiHA specific 
T-cell reactivity a high avidity HA-1 specific T-cell clone was used (white). 
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and presented in the context of HLA to allow clonal deletion, or that the identity of the 
UCRC-1V is wrongly assessed by MS analysis and therefore lacks biological relevance.
 Next, the purified T-cell lines were stimulation with a panel of 10 SNP genotyped 
and HLA-A*0201 positive EBV-LCL target cells to screen for MiHA specific reactivity 
against endogenously presented peptide. Although IFN-γ production was observed after 
stimulation with some MiHA positive target cells, no MHC-tetramer positive T-cell lines 
demonstrated recognition of each MiHA positive target cell throughout the whole EBV-LCL 
panel (Fig. S1).
Detection of high-avidity MiHA specific T-cell clones among the total MHC-
tetramer positive T-cell population
To investigate whether the lack of endogenously presented peptide recognition by the 
purified MHC-tetramer positive T-cell lines was due to an overall low-avidity of the isolated 
MHC-tetramer specific T-cells or could be the result of the presence of low frequent high 
avidity T-cells within the T-cell lines, we studied the clonal composition of the generated 
T-cell lines with a TCR Vβ-usage antibody kit. Although the applied kit only covered up to 
60% of all known Vβ-chains, we were able to demonstrate the oligoclonal composition 
of all the purified MHC-tetramer positive T-cell lines. For the DNJ NISCH-1A T-cell line a 
minimum number of 3 different clones was identified. For T-cells within this particular T-cell 
line; 88.8% used TCR Vβ14, 0.6% used TCR Vβ8 and 10.6% used an unknown TCR Vβ-chain. 
With the exception of TCR Vβ14, single T-cell clones were successfully generated for the 
other two clones by FACS sorting. Subsequently, generated T-cell clones were stimulated 
with peptide-loaded T2 cells in a titration assay and their avidity was compared to that 
of the oligoclonal T-cell line and a HA-1 control clone obtained from a memory response 
after allo-SCT (Fig. 3A). The NISCH-1A TCR Vβ8 and HA-1 control T-cell clone demonstrated 
high avidity peptide recognition with IC50 ±100 pM and ±1 nM respectively, approximately 
100-fold higher than that of the oligocloal T-cell line. In contrast, the T-cell clone with an 
unknown TCR Vβ-chain did not demonstrate any peptide recognition. 
 Next, the generated DNJ NISCH-1A specific T-cell clones were stimulated with a 
panel of SNP genotyped EBV-LCL, as previously described, for recognition of endogenously 
presented peptide. Upon stimulation and according to the peptide-avidity recognition 
patterns, only the DNJ NISCH-1A derived TCR Vβ8 positive T-cell clone, representing 0.6% 
of the total cell line, demonstrated high IFN-γ production when stimulated with target cells 
positively expressing the NISCH-1A MiHA (Fig. 3B). Apparently, the majority of T-cells within 
this MHC-tetramer positive T-cell line were of insufficient avidity to recognize endogenously 
presented peptide. Also for the other specificities T-cell clones were generated, however no 
other T-cell clone was able to recognize endogenously presented peptide. The identification 
of a MiHA-specific high-avidity T-cell clone demonstrated that this reverse immunology 
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Discussion
The aim of this study was the development of an efficient algorithm for the identification of 
MiHA. To establish this algorithm we applied broad selection thresholds in each selection 
step of our pipeline approach starting from epitope selection to the identification of 
antigen-specific T-cells. We started our approach by selecting the top 40 eluted MiHA 
candidates and ended with the identification of LB-NISCH-1A (Fig. 4). Although this yield 
is encouraging when compared to some previous reverse immunology based studies25;26, 
the majority of MiHA candidates were lost during the first three selection steps as a 
Figure 4. MiHA selection strategy by numbers of eluted peptide candidates. This figure describes the MiHA 
selection strategy as applied in this study. By setting broad selection thresholds the figure demonstrates 
the countdown of MiHA candidates following 7 selection steps. The number of residual MiHA candidate 
that remained in list after each selection step is indicated at the left. Percentages indicate the residual 
peptides as part of the initial set of 40 eluted MiHA candidates (right). Selection steps (from left to right): 
First, Mass spectrometry (MS) based validation of eluted peptides. Second, analysis of SNP encoded MiHA 
allele frequencies in a panel of 100 Dutch individuals. Third, analysis of the HLA-A*0201 affinity of eluted 
peptides. Fourth, generation of MHC-tetramers. Fifth, selection of donors that are homozygous negative 
(-/-) for the SNP encoding MiHA and could be used for MHC-tetramer pull down experiments. Sixth, FACS 
analysis of expansion T-cell cultures for the detection of MHC-tetramer positive T-cells. Seventh, generation 
of MHC-tetramer positive T-cell clones and subsequent functional assessment to detect high avidity T-cells.
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consequence of wrongly assigned tandem mass spectrometry, incorrect SNP information in 
dbSNP and the incapacity to generate MHC-tetramers for some eluted peptides. By careful 
step-by-step evaluation we can increase the efficiency of our algorithm.
 Initially, peptides were assigned from the tandem mass spectra using a generally 
considered broad criterium of a BMI of >20, and a tight mass accuracy criterium of <10 ppm. 
Validation of the identification of the MiHA candidates by comparison of the tandem mass 
spectra of the eluted peptides with their synthetic counterparts, illustrated that 10 of the 
40 MiHA (25%) appeared to be false positive (Fig. 4). By setting more stringent conditions 
(Table SII), this number could be reduced to 22% (BMI>30) and 18% (mass deviation <2 
ppm). Combination of these conditions can further reduce the false positive identification 
rate to 13% with only 4 of the selected 30 MiHA candidates being false positive. Setting 
Figure 5. Selection algorithm for 
discovery of MiHA implementing 
HLA-peptidomics into a reverse 
immunology approach. By setting 
tight selection criteria for both the 
theoretical and functional evaluation 
of MiHA candidates an efficient 
selection algorithm was established. 
For theoretical evaluation of MiHA 
candidates before peptide synthesis, 
MS based thresholds are set for BMI, 
ppm and peptide length. Tandem 
mass spectra of eluted peptides will 
be matched against both the HSPVdb 
and the regular IPIhuman database. 
Polymorphic peptide assignments will 
only be allowed if the HSPVdb peptide 
identification confidence score is 
greater than the IPIhuman confidence 
score. Selection threshold for SNP 
encoding MiHA allele frequency will 
be set between 0.05% and 0.7% and 
the netMHC algorithm will be used to 
predict peptide-HLA binding affinity. 
For final confirmation of the identity 
of the MiHA candidates the tandem 
mass spectra of the eluted peptides 
will be compared with their synthetic 
counterparts. Subsequently, peptide-
HLA binding affinity will be analyzed 
and high-affinity peptides will be 
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these conditions will increase the MiHA candidate selection efficiency. For peptides 
encoded by alternative reading frames a similar false positive identification rate (29%) was 
obtained as that of peptides encoded by the normal reading frame (21%) (Table SII). These 
results indicate that alternative reading frame peptides may be a valuable contribution to 
the MiHA candidate list when evaluated according to our algorithm.
 To increase the clinical relevance of MiHA candidates, only those SNP could 
be selected with allele frequencies between 0.05% and 0.07% to allow a relative MiHA 
mismatch change of 10% between unrelated donors and recipients. By setting this selection 
threshold, three MiHA candidates for which no homozygous negative donors could be 
found would have been excluded from the candidate list to further increase the efficiency 
of our selection algorithm. 
 The use of HLA-peptidomics as starting point guarantees appropriate processing 
and HLA-dependent presentation of eluted peptides. However 10 out of 23 MS validated 
MiHA candidates demonstrated lower peptide-HLA-complex recovery rates than the 
negative control MART-1-WT-AAG peptide, known for its incapacity to be used for MHC-
tetramer formation45 (Fig. 4). Although the identity of these low-affinity HLA-A*0201 
binding peptides may either be correctly or wrongly assigned by MS analysis, these MiHA 
candidates could not be validated due to the incapacity to generate MHC-tetramers 
needed for isolation of high avidity T-cells directed to these antigens. As MHC-tetramers 
are essential to our approach, these low HLA-affinity peptides should be removed before 
MiHA candidate selection and synthesis. One possible solution may be the incorporation of 
a peptide-HLA binding algorithm such as netMHC. With the exception of peptide 6, none 
of the 10 peptides demonstrating low HLA-recovery were predicted to have HLA-A*0201 
binding motifs (predicted affinity >500 nM) when analyzed using this algorithm (Table I). 
In contrast, HLA-A*0201 binding motifs were confirmed for 10 of the 13 peptides that 
demonstrated high peptide-HLA-complex recovery, including the MiHA candidates for 
which specific T-cell populations were detected, indicating that the use of peptide-HLA 
binding algorithms may be a valuable contribution to the MiHA candidate identification 
efficiency of our algorithm.
 The purified MHC-tetramer positive T-cell lines demonstrated a wide avidity range 
when stimulated with peptide loaded T2 target cells. However, when stimulated with EBV-
LCL target cells, these T-cell lines appeared to be incapable of recognizing endogenously 
presented peptide. Assessment of the TCR Vβ-chain usage demonstrated the oligoclonal 
nature of the MHC-tetramer positive T-cell populations and subsequent functional 
assessment of single T-cell clones demonstrated that the lack of response, observed for 
the MHC-tetramer positive T-cell lines was due to the presence of low frequent high-avidity 
T-cells within the T-cell lines. Only a 0.6% subset of the purified DNJ NISCH-1A specific 
T-cell line appeared reactive to endogenously presented peptide, in contrast to the purified 
MHC-tetramer positive T-cell line that predominantly consisted of low-avidity T-cells.
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 The technical feasibility of our approach was demonstrated by the identification of 
the LB-NISCH-1A MiHA. By introducing several evaluation steps and setting tight selection 
criteria a more efficient MiHA identification algorithm can be achieved for the identification 
of MiHA using a reverse immunology approach (Fig. 5). This new algorithm would allow the 
efficient selection of the most relevant MiHA candidates within a set of eluted peptides 
that fulfill to all criteria. Increased selection efficiency would allow the screening of T-cell 
repertoires for circulating T-cells specific for larger amounts of relevant MiHA candidates. 
In combination with strict gene of interest selection, this algorithm may be of significance 
for future identification of MiHA.
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Materials and Methods
Culture conditions and cells. Peripheral blood was obtained from different individuals after 
informed consent (Sanquin Reagents, Amsterdam, The Netherlands and Leiden University Medical 
Center, Leiden, The Netherlands). All experiments were approved by the local medical ethics 
committees. Blood samples were HLA-typed by high-resolution genomic DNA-typing. Peripheral 
blood mononuclear cells (PBMC) were isolated by Ficoll gradient separation and cryopreserved for 
further use. T-cells were cultured in T-cell medium consisting of Iscove’s Modified Dulbecco’s Media 
(IMDM: Lonza, Basel, Switzerland) supplemented with 5% human serum (HS), 5% fetal bovine serum 
(FBS), 100 IU/ml IL-2 (Proleukin; Chiron, Amsterdam, The Netherlands), 2 mM L-glutamine, 100 U/
ml penicillin, and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA). Epstein-Barr virus-transformed 
lymphoblastoid B-cell lines (EBV-LCL) and phytohemagglutinine (PHA; Murex Diagnostics, Dartford, 
U.K) blasts were generated using standard procedures.
Peptide library of HLA-class I eluted peptides. The peptides used for this study are derived from 
a large peptide library that was recently established. In short: Peptide elution, reverse phase high-
performance liquid chromatography (RP-HPLC), and mass spectrometry (MS) were carried out as 
previously described16;18. Briefly, 60 x 109 HLA-A*0201 and HLA-B*0702 positive EBV-LCL were washed 
with ice cold PBS and stored at -80°C until use. After freeze drying, peptide-HLA-class I complexes 
were purified by affinity chromatography. Subsequently, peptides were eluted from HLA-molecules, 
and separated from the HLA heavy chain fragments and β2-microglobulin by size filtration. The 
peptide mixture was subjected to 3 rounds of fractionation and after the third fractionation, the 
peptide masses present in the fractions were determined and sequenced by tandem MS. The tandem 
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3.87, using the mascot search engine version 2.2.04 (Matrix Science, London, UK), with a precursor 
mass tolerance of 2 ppm and a product ion tolerance of 0.8 Da. For finding polymorphic peptides 
the tandem mass spectra were matched against the HSPVdb30, specifically designed for finding 
polymorphic peptides. 
 The dissolved fractions were analyzed by on-line nanao-HPLC mass spectrometry with 
a system, consisting of a conventional Agilent 1100 gradient HPLC system (Agilent, Waldbronn, 
Germany). The mass spectrometer was an LTQ-FT Ultra (Thermo, Bremen, Germany) and was 
operated in datadependent mode, automatically switching between MS and MS/MS acquisition.
SNP genotyping assays. A panel of 100 HLA-A*0201 positive Dutch EBV-LCL was selected for SNP 
screening as previously described36. Briefly, genomic DNA was isolated from 5x106 EBV-LCL cells using 
Gentra Puregene Cell Kit (Qiagen) and PCR-free whole genome amplification (WGA) was performen. 
The DNA samples were subsequently fragmented, purified, and hybridized to Illumina Human1M-
duo arrays containing probes for 1.1 million SNPs (Illumina). After hybridization, the bead arrays 
were stained and fluorescence intensities were quantified on an Illumina Bead Array 500GX Scanning 
Station. Raw data were analyzed using Illumina Genome Studio software, and SNP genotype reports 
were generated using the Plink software (http://pngu.mgh.harvard.edu/~purcell/plink, version 1.03; 
ref. 30). For SNP that were not present on the Illumina Human1M-duo array, a KASPar SNP genotyping 
assay was performed according to the manufacturer’s protocol.
Generation of peptide-MHC complexes. All peptides were synthesized in-house using standard 
Fmoc chemisty. Recombinant HLA-A*0201 heavy chain and human β2m light chain were in-house 
produced in Escherichia coli. MHC class I refolding was performed as previously described with minor 
modifications37. MHC class I complexes were purified by gel-filtration HPLC in PBS and stored at 4ºC.
The peptide HLA-A*0201 binding affinity was assessed by subjecting prefolded UV-sensitive peptide-
MHC complexes (100μg/ml) to 366nm UV light (Camag) for 1 h in presence of the specific peptide 
(200μM)38. As controls the CMV PP65 NLVPMVATV and wild-type MART1 AAGIGILTV peptide were 
used. After exchange, samples were spun at 16,000g for 5 min and supernatants were used to assess 
HLA-monomer rescue using a bead assay as previously described39. 
Isolation of MiHA specific T-cells by MHC-tetramer pull down. Prior to isolation PBMC samples 
were stained with PE-coupled MHC-multimers for 1 hour at 4ºC. Subsequently, cells were washed 
and incubated with anti-PE antibody coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany). PE-positive T-cells were isolated by magnetic activated cell sorting (MACS) using an LS 
column, according to the manufacturer’s protocol (Miltenyi). Isolated PE-positive cells were cultured 
(5000 cells/well) with 5x104 irradiated (50Gy) autologous feeder cells in T-cell medium supplemented 
with 100 IU/ml IL-2, 5ng/ml IL-15 (Biosource) and 11.000 anti-CD3/CD28 Dynabeads (Invitrogen) in 
96-round bottomed well plates. Cultures were refreshed twice a week. After 2 weeks, T-cell cultures 
were analyzed for MHC-multimer positive T-cell population by MHC-multimer combinatorial coding 
flow cytometry. For the second MHC-multimer pull down the procedure was performed using the 
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identical set of PE-coupled MHC-multimers. MHC-multimer positive T-cell populations were single cell 
sorted on a FACSAria (BD Biosciences, San Diego, USA) into 96-round bottomed well plates containing 
100 μl T-cell medium supplemented with 100 IU/ml IL-2, 800 ng/ml PHA and 1*105 irradiated feeder 
cells.
Flow cytometry and T-cell staining. Data acquisition was performed on an LSR-II flow cytometer 
(BD) with FacsDiva software using the following instrument settings: 488nm laser: 685LP, 695/40; 
PE: 550LP, 575/26; FITC: 505LP, 530/30; SSC: 488/10. 633nm laser: Alexa700: 685LP, 730/45; APC: 
660/20. Approximately 1*106 PBMC were stained for each analysis with a final concentration of 2 µg/
mL per MHC-tetramer in 100 µl Phosphate buffered saline (PBS) with 5% (v/v) pasteurized plasma 
protein solution (GPO). Next, antibody-mixtures consisting of CD8-Alexa700 (Caltag-Medsystems, 
Buckingham, UK) and CD4-FITC (BD) were added and cells were incubated for 30 min at 4°C. Prior 
to flow cytometry, cells were washed twice. TCR β chain (TCR-Vβ) usage was investigated by flow 
cytometry using specific monoclonal antibodies as included in the TCR-Vβ repertoire kit (Beckman 
Coulter).
Functional analysis. For analysis of IFN-γ production, 5000 T-cells were cocultured with 25.000 target 
cells loaded with different concentrations of peptides. Peptide loading was performed by incubating 
target cells for 1 hour in 96 well plates at 37ºC and 5% CO2 in IMDM containing 2% FCS and cells were 
washed twice before use. After 18 hours, supernatants were harvested, and the concentration of 
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Table SII. Evaluation peptide selection thresholds
Figure S1. Stimulation assay MHC-tetramer positive T-cell lines. (A) Donor DBS7251, DIA7274, DKI7276 
and DNJ7281 derived NISCH-1A and (B) DGT7271, DHX7272, DNJ7281 and DMI7280 derived HIVEP1-1S 
and (C) DHX7272 and DNJ7281 derived PARP10-1P and (D) DGT7271 derived UCRC-1V purified MHC-
tetramer positive T-cell lines were stimulated with a panel of 10 HLA-A*0201 positive and SNP genotyped 
EBV-LCL target cells positive (+) or negative (-) for the indicated MiHA for 18 hours. T-cell reactivity was 
measured by standard IFN-γ ELISA. As a control for MiHA specific T-cell reactivity a high avidity HA-1 specific 
T-cell clone was used.
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5     T-cell recognition of minor histocompatibility antigens (MiHA) plays an important role in the beneficial graft-versus-
leukemia (GVL) effect of allogeneic stem cell transplantation 
(allo-SCT) but also mediates serious graft versus host disease 
(GVHD) complications associated with allo-SCT. Using a reverse 
immunology approach we aim to develop a method enabling the 
identification of T-cell responses directed against predefined 
antigens, with the goal to select those MiHAs that can be used 
clinically in combination with allo-SCT. In this study, we used a 
recently developed MiHA selection algorithm to select candidate 
MiHAs within the HLA-presented ligandome of transformed 
B-cells. From the HLA-presented ligandome, that predominantly 
consisted of monomorphic peptides, 25 polymorphic peptides 
with a clinically relevant allele frequency were selected. By 
high-throughput screening the availability of high-avidity T-cells 
specific for these MiHA-candidates in different healthy donors 
was analyzed. With the use of MHC-multimer enrichment, 
analyses of expanded T-cells by combinatorial coding MHC-
multimer flow cytometry, and subsequent single cell cloning, 
positive T-cell clones directed to 2 new MiHA: LB-CLYBL-
1Y and LB-TEP1-1S could be demonstrated, indicating the 
immunogenicity of these 2 MiHAs. The biological relevance 
of MiHA LB-CLYBL-1Y was demonstrated by the detection of 
LB-CLYBL-1Y specific T cells in a patient suffering from acute 
myeloid leukemia (AML) that experienced an anti-leukemic 
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Introduction
Allogeneic HLA-matched hematopoietic stem cell transplantation (allo-SCT) and subsequent 
donor lymphocyte infusion (DLI) to eradicate persistent or relapsed malignant cells are 
considered an effective curative treatment for patients with high-risk hematological 
malignancies or patients who fail to respond to chemotherapy1. The curative potential of this 
therapy has been attributed to the recognition of malignant cells by donor T-cells. Detailed 
analyses of T-cell immune responses in patients responding to DLI have demonstrated that 
the donor T-cells recognize minor histocompatibility antigens (MiHA) presented in the 
context of HLA-molecules on malignant cells. MiHA are peptides derived from polymorphic 
proteins that differ between donor and recipient due to single nucleotide polymorphisms 
(SNP)2-5. Previously it has been demonstrated that T-cells directed against MiHA that are 
ubiquitously expressed can mediate life-threatening graft-versus-host-disease (GVHD)6, 
whereas T-cells directed against MiHA with hematopoietic restriction may mediate graft-
versus-leukemia (GVL) response in absence of GVHD7.
 Although the introduction of various molecular and genomic technologies resulted 
in an increased number of HLA-class I restricted MiHA identified by forward immunological 
approaches, the number of MiHA with therapeutic relevance is still limited8,9.  A major 
limitation for clinical implementation of MiHA is the small number of identified MiHA 
derived from genes that are exclusively expressed in hematopoietic cells. To allow the 
selective analysis of hematopoietic restricted MiHA, we and others have used reverse 
immunological approaches in which predicted polymorphic peptides are the starting point 
and peptide candidates are subsequently screened for their capacity to induce a specific 
T-cell response. This approach has the potential to specifically screen for T-cells recognizing 
MiHA that are exclusively expressed by hematopoietic cells. However, it has been reported 
that when such peptide predictions are solely based on computer algorithms that predict 
peptide-HLA binding affinity and proteolytic cleavage, the detected T-cell responses 
are often directed against epitopes that are not naturally processed and presented and 
therefore fail to lyse malignant target cells10-12. To circumvent this peptide selection problem 
we and others previously introduced mass spectrometry (MS) based HLA-ligandomes as a 
reliable source for naturally processed and presented peptides and developed an algorithm 
that can be exploited to identify T-cells specific for potential clinically relevant MiHA13,14. 
  The emerging availability of high quality SNP data in combination with 
the implementation of HLA-ligandomes provides a large supply of MiHA-candidates with 
guaranteed processing and HLA-restricted presentation at the cell surface15. We used our 
recently established algorithm13 to select the top 25 MiHA-candidates from our newly 
established large set of B-lymphocyte derived HLA-class I eluted peptides16. To validate these 
MiHA candidates it is essential to demonstrate their immunogenic potential by isolation 
of high avidity specific T-cells. We therefore screened the TCR repertoire of 16 unrelated 
donors for the presence of T-cells specific for these MiHA-candidates. MHC-multimer 
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positive T-cells lines were generated from peripheral blood mononuclear cells (PBMC) by 
magnetic activated cell sorting (MACS). Flow cytometric analysis of antigen-specific T-cells, 
followed by functional testing of MHC-multimer sorted and expanded T-cell clones using 
both IFN-γ and GM-CSF as readout demonstrated the immunogenic potential of LB-CLYBL-
1Y, LB-TEP1-1S and two previously described MiHA. For one of the newly defined MiHA we 
were able to confirm the biological relevance by demonstrating MHC-multimer positive 
T-cells in a patient suffering from AML after treatment with allo-SCT and subsequent DLI. 
Our data illustrate that with this reverse immunology approach biologically relevant MiHA 
can be identified as well as MiHA that are not frequently induced in vivo but can potentially 
be used for immunotherapeutic strategies.
Results
Selection of high affinity HLA-A*0201 and B*0702 binding MiHA-candidates 
from a set of HLA-class I eluted peptides
We have recently reported a MiHA selection algorithm to be able to select MiHA candidates 
from a library of HLA-class I eluted peptides13. This MiHA selection algorithm comprises 
several evaluation steps that are summarized in the material and methods section. This 
algorithm was used to screen our newly established library of eluted HLA-class I peptides 
derived from multiple HLA-A*0201 and B*0702 positive EBV-LCLs, to select for potential 
MiHA candidates16. To validate this newly established library of approximately 16,000 
eluted HLA class I peptides comprising of mainly monomorphic peptides, we first screened 
for the presence of known MiHA. Peptide sequences or their relevant length variants were 
identified for 10 out of 13 MiHA that were expressed by the EBV-LCLs as revealed by SNP 
genotyping (Table SI)3,8,9, illustrating the high quality of this peptide elution library.
 In the next step we selected a set of 25 MiHA-candidates using the MiHA selection 
algorithm, including 22 novel MiHA-candidates as well as the previously reported LB-NISCH-
1A, LB-ERAP1-1R and LB-GEMIN4-1V MiHA (Table SII). We first analyzed the capacity of the 
25 MiHA-candidates to stabilize a peptide-HLA complex in a HLA-binding assay that is based 
on UV-induced conditional ligand cleavage as described previously10,22,26. After UV-exchange, 
the HLA-binding affinity of the tested peptides was normalized to the high-affinity control 
peptides CMV-PP65-NLV and CMV-PP65-TPR for HLA-A*0201 and B*0702, respectively 
(Fig. S1A,B). MiHA-candidates were selected when their HLA-binding affinity exceeded that 
of the MART1-WT-AAG peptide, which binds with low affinity to HLA-A*0201. HLA-binding 
affinity as measured with HLA-rescue scores exceeded that of the MART1-WT-AAG control 
for 8 HLA-A*0201 and 13 B*0702 binding MiHA-candidates. Peptide sequences and allele 
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Isolation of peripheral blood derived MHC-multimer positive T-cells by MHC-
multimer pull down
To validate the 21 peptides as MiHA with immunogenic potential, we generated MHC-
multimers and analyzed the T-cell repertoire of 16 healthy HLA-A*0201 and B*0702 positive 
donors for MHC-multimer reactive T-cells. MiHA-specific T-cell lines were generated by 
incubating 100*106 peripheral blood mononuclear cells (PBMC) with a specific set of 
MHC-multimers, followed by enrichment of MHC-multimer positive cells on a magnetic 
column. To allow the isolation of high avidity T-cell populations, the set of MHC-multimers 
was specifically adjusted for each PBMC sample to cover only those MiHA for which the 
encoding SNP was screened homozygous negative in the respective donor, since in this 
individual’s T-cell repertoire high avidity MiHA specific T-cells will not have been deleted 
due to negative selection. The set of PBMC donors was specifically adjusted to cover as 
many applicable donors per MiHA candidate. Unfortunately, no homozygous negative 
donors were found for the SCRIB-1L MiHA candidate. The MHC-multimer enriched T-cells 
were expanded for 14 days in presence of αCD3/28 beads, IL-2 and IL-15. To increase the 
frequency of MHC-multimer positive T-cells, a second pull down was performed at day 14 
α SNP underlined 
β Published MiHA epitope or length variant 
Non– and Immunogenic Allele indicated by amino acid code, allele frequencies are calculated by 
quantification in a panel of 100 Dutch individuals using SNP genotyping array. 
Table I. Validated MiHA candidates 
HLA Peptide Sequenceα Gene RS number SNP Allele Frequency 
A*02:01 P1 GLLGQEGLVEI PARP10 rs11136343 L/P 0.66% 
 P2 ALAPAPAEV NISCHβ rs887515 A/V 0.17% 
 P3 AMLERQFTV FAM119A rs2551949 T/I 0.19% 
 P4 FLSSANEHL GLRX3 rs2274217 S/P 0.25% 
 P5 MMYKDILLL HNF4G rs1805098 M/I 0.40% 
 P6 SLAAYIPRL CLYBL rs17577293 Y/D 0.05% 
 P7 SLQEKVAKA HMMR rs299295 V/A 0.20% 
 P8 VLQNVAFSV BCL2A1 rs1138358 N/K 0.69% 
       
B*07:02 P9 APNTGRANQQM BFAR rs11546303 M/R 0.57% 
 P10 LPMEVEKNSTL HDGF rs4399146 L/P 0.40% 
 P11 RPRAPTEELAL C14orf169 rs3813563 A/V 0.40% 
 P12 APDGAKVASL TEP1 rs1760904 S/P 0.49% 
 P13 APAGVREVM AKAP13 rs7162168 M/T 0.37% 
 P14 KPQQKGLRL APOBEC3H rs139298 K/E 0.52% 
 P15 LPQKKSNAL POP1 rs17184326 N/K 0.10% 
 P16 LPQQPPLSL SCRIB rs6558394 L/P 0.64% 
 P17 NPATPASKL C18orf21 rs2276314 A/T 0.21% 
 P18 SPASSRTDL MTRR rs1532268 S/L 0.68% 
 P19 SPSLRILAI LLGL2 rs1671036 R/H 0.50% 
 P20 HPRQEQIAL ERAP1β rs34753 R/P 0.31% 
 P21 FPALRFVEV GEMIN4β rs1045481 V/E 0.20% 
Table I. Validated MiHA candidates.
128
5     
B 
























































































































































0.1%  38.0%  
0.01%  0.02%  
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GEMIN4-1V No combination MTRR-1S 




























































































































































0.1%  38.0%  
0.01%  0.02%  
BFAR-1M HDGF-1L TEP1-1S AKAP13-2M C14orf169-1A 
POP1-1N No combination C18orf21-1A APOBEC3H-1K 
GEMIN4-1V No combination MTRR-1S 
No combination LLGL2-1R 
ERAP1-1R 
Figure 1 
Figure 1. Detection of MiHA-specific T-c lls fter MHC-multimer enrichment and expansion. FACS 
analyses were performed to detect MiHA-specific T-cells through combinatorial coding MHC-multimer 
screening after second pull down and in vitro expansion. Each peptide-MHC complex was encoded by 
a unique combination of fluorochromes. Two HLA-restricted sets of MHC-multimers were used to 
screen for detection of all MiHA-candidates specific T-cells. (A) Representative analysis of the two times 
enriched T-cell line derived from donor OMH with the HLA-B*0702 restricted MHC-multimer set. Total 
CD8+ T-cells are shown and MHC-multimer negative cells or cells staining with more than 2 fluorochromes 
are indicated in black. All dot plots are shown with bi-exponential axes and display fluorescence intensity 
for the fluorochromes indicated on each axis. Frequencies indicate MHC-multimer positive T-cells of total 
CD8+ cells. (B) Total MHC-multimer positive T-cell populations detected in 16 tested PBMC donors after 
second pull down by combinatorial coding MHC-multimer screen. Bars indicate the number of donors 
homozygous negative for the indicated SNP encoding MiHA and applicable for MHC-multimer pull down. 
The number of MHC-multimer positive T-cell populations detected per MiHA candidate is indicated in 
black. No homozygous negative donors were found for SCRIB-1L, and therefore SCRIB-1L is not indicated 
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using the identical initial set of MiHA candidate specific MHC-multimers. After both rounds 
of MHC-multimer enrichment we analyzed the expanding T-cell lines for the presence of 
MHC-multimer positive T-cells by FACS. A representative FACS analysis after two rounds of 
MHC-multimer enrichment is demonstrated in Fig. 1A in which 4 MHC-multimer positive 
T-cell populations specific for HLA-B*0702 binding MiHA-candidates are detected in donor 
OMH. After the first MHC-multimer pull down, MHC-multimer positive T-cell populations 
were detected specific for 11 of the 20 tested MiHA-candidates in one or more T-cell 
cultures. MHC-multimer positive T-cell frequencies varied between 0.01% and 5.0% of 
total CD8+ T-cells (Table SIII). These low frequencies are most likely due to the very low 
frequency of MHC-multimer positive T-cells in the naïve repertoire. After the second MHC-
multimer pull down, MHC-multimer positive T-cell populations were detected specific for 
an increased number of 16 of the 20 tested MiHA-candidates with frequencies up to 85% 
of total CD8+ T-cells (Table SIII). As demonstrated in Figure 1B, T-cells reactive with the 
CLYBL-1Y and LB-GEMIN4-1V MHC-multimer were frequently detected in 8 of the 16 and 
6 of the 9 enriched T-cell lines, respectively. In contrast, T-cells specific for the other MiHA 
appeared more restricted to a few donors.
Detection of high avidity T-cell clones by screening for MiHA-specific IFN-γ and 
GM-CSF production
Next, a total number of 806 MHC-multimer positive T-cell clones representing all detected 
T-cell populations were generated by FACS sorting. To demonstrate recognition of potential 
MiHA-candidates, all 806 T-cell clones were stimulated with specific antigen and cytokine 
production was determined as a measure for antigen specific reactivity. Because the T-cell 
clones were most likely derived from the naïve T-cell repertoire and have presumably not all 
acquired the capacity to produce IFN-γ upon antigen encounter, we first screened all T-cell 
clones for their potential to secrete IFN-γ after αCD3/28 stimulation. As demonstrated in 
Figure 2A, the generated T-cell clones demonstrated a broad range of IFN-γ secretion. To 
investigate whether GM-CSF was of additional value to improve the screening efficiency, the 
GM-CSF production of part of the T-cell clones with variable IFN-γ secretion potential was 
measured after αCD3/28 stimulation. The results demonstrate that a substantial number 
of T-cell clones with poor intrinsic IFN-γ production were able to produce pronounced GM-
CSF levels (Fig. 2B). Therefore by using both IFN-γ and GM-CSF as a readout we could 
increase the number of MHC-multimer positive T-cell clones that could be screened. By 
setting an arbitrary detection limit to 100 pg/ml for both cytokines, 98% of generated T-cell 
clones could subsequently be screened for MiHA specific reactivity.
 To demonstrate the capacity of the isolated MHC-multimer positive T-cell clones 
to recognize specific MiHA peptides we stimulated all T-cell clones with HLA-A*0201 and 
B*0702 positive T2 target cells loaded with titrated concentrations of specific peptide. 
MiHA specific T-cell reactivity was observed for 8 out of 16 tested MiHA-candidates and 
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Figure 2. Isolated T-cell clones vary in 
production of IFN-γ and GM-CSF upon 
αCD3/28 stimulation. (A) Distribution of 
the intrinsic IFN-γ secretion capacity of 806 
MiHA-specific MHC-multimer positive T-cell 
clones stimulated with αCD3/28 beads. 
(B) Production of GM-CSF for 150 selected 
T-cell clones with variable IFN-γ secretion 
capacity. MiHA specific MHC-multimer 
positive T-cell clones were stimulated for 
18 hours in presence of αCD3/28 beads and 
GM-CSF and IFN-γ secretion was measured 
by standard ELISA.
Figure 3. MHC-multimer positive T-cell clones demonstrate 
MiHA specific reactivity. Isolated MHC-multimer positive T-cell 
clones were stimulated with HLA-A*0201 and B*0702 positive T2 
cells loaded with titrated concentrations of peptides for 18 hours 
[E:T] 5,000:25,000. For each donor the MiHA specific T-cell clone 
that demonstrated the highest peptide avidity is shown for the 
respective cytokine. MiHA specific IFN-γ production was observed 
for T-cell clones specific for (A) CLYBL-1Y, (B) ERAP1-1R, (C)GEMIN4-
1V (D) NISCH-1A, HMMR-1V, C18orf21-1A, APOBEC3H-1K, and (E) 
TEP1-1S MiHA-candidates. For the TEP1-1S specific T-cell clone 
K091 derived from donor EPP both the peptide induced IFN-γ 
and GM-CSF secretion are shown. (F,G,H,I,J) To measure the 
reactivity of the MiHA specific T-cell clones against endogenously 
processed and presented antigens, all MiHA specific T-cell clones 
that demonstrated IFN-γ or GM-CSF production in response to 
specific peptide were stimulated with a panel of 10 HLA-A*0201 
and B*0702 positive EBV-LCL target cells positive (+) or negative 
(-) for the indicated MiHA for 18 hours. Cytokine secretion was 
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either IFN-γ or GM-CSF was detected after stimulation with CLYBL-1Y, ERAP1-1R, GEMIN4-
1V, NISCH-1A, HMMR-1V, C18orf21-1A, APOBEC3H-1K and TEP1-1S MiHA peptides. For 
each donor the MiHA specific T-cell clone that demonstrated the highest peptide avidity is 
shown (Fig. 3A-E). MiHA specific T-cell clones demonstrated variable peptide avidity and 
half maximum cytokine production (IC50) varied between an IC50 of ±100 pM for the high 
avidity T-cell clone K156 specific for GEMIN4 (Fig. 3C) and an IC50 of ±62.5 nM for the low 
avidity T-cell clone K337 specific for C18orf21 (Fig. 3E). For the CLYBL-1Y MiHA candidate, 
MHC-multimer positive T-cell clones were successfully isolated from 4 different donors. 
High avidity CLYBL-1Y specific T-cell clones were isolated from donor ABM, whereas only 
low avidity or non-reactive T-cells were isolated from donor UDN, EPP and FHT respectively 
(Fig. 3A). For the previously described MiHA ERAP1-1R, both high and low avidity T-cell 
clones were isolated from the 2 donors that demonstrated MHC-multimer positive T-cell 
populations after pull down. For the previously described MiHA GEMIN4-1V, high avidity 
T-cell clones were only isolated from 4 out of 6 donors that demonstrated MHC-multimer 
positive T-cell populations after pull down (Fig. 3B,C; low-avidity T-cell clones not shown). 
The NISCH-1A, HMMR-1V, C18orf21-1A and APOBEC3H-1K specific T-cell clones were each 
successfully isolated from one donor and exhibited high (HMMR-1V) to low peptide avidity 
(NISCH-1A, C18orf21-1A and APOBEC3H-1K) (Fig. 3D). For the TEP1-1S MiHA candidate 
high avidity T-cell clones were isolated from donor EPP. T-cell clone K091 demonstrated 
high peptide specific GM-CSF production and low IFN-γ production (Fig. 3E). No peptide 
specific T-cell clones specific for the other MiHA-candidates were observed.
 All T-cell clones that demonstrated peptide specific cytokine production were 
stimulated with a panel of 10 SNP genotyped HLA-A*0201 and B*0702 positive EBV-LCL 
target cells to screen for reactivity against endogenously processed and presented peptide. 
As demonstrated in Figure 3F,G,H and J all high avidity T-cell clones specific for CLYBL-
1Y, TEP1-1S, ERAP1-1R and GEMIN4-1V demonstrated recognition of all target cells that 
endogenously process and present their respective MiHA, whereas targets that were 
negative for the MiHA were not recognized. Surprisingly, the high avidity T-cell clone 
K508 specific for HMMR-1V did not show a recognition pattern that correlated with MiHA 
expression. This may be caused by the absence of endogenously presented MiHA peptide 
by some of the SNP positive EBV-LCL or by the recognition of allo-HLA molecules expressed 
by EBV-LCL. No or only marginal target cell recognition was observed for the NISCH-1A, 
C18orf21-1A and APOBEC3H-1K specific T-cell clones (Fig. 3I). These results indicate that 
the MiHA CLYBL-1Y and TEP1-1S represent potentially immunological relevant MiHA-
candidates.
Detection of MiHA specific T-cell responses in patients after allo-SCT
To validate the biological relevance of the MiHA-candidates we analyzed the peripheral 





 discovery by reverse im
m
unology
5     
SCT and DLI and demonstrated a clinical response revealed by declining patient chimerism, 
for the detection of MiHA specific T-cells. Patients were only screened with MiHA-specific 
MHC-multimers when they were positive for the MiHA and received a DLI from a donor who 
was homozygous negative for the SNP encoding MiHA (Table SIII). Tested patient samples 
were obtained during or after the peak response, 5 to 8 weeks after treatment with DLI. 
For the newly identified CLYBL-1Y MiHA, MHC-multimer positive T-cells were detected in 
1 of the 3 screened patients (Fig. 4A) with a frequency of 0.34% of total CD8+ T-cells at 
day 41 after DLI (AML patient MBF, Fig. 4B). For the previously described ERAP1-1R and 
GEMIN4-1V MiHA, MHC-multimer positive T-cells were detected in 1 of the 2 and 1 of the 4 
screened patients (both multiple myeloma (MM) patient CUB at day 86), respectively (Fig. 
4A,B). Detected frequencies of circulating MHC-multimer positive T-cells ranged between 
0.04% and 0.34% of total CD8+ T-cells. For the other 17 MiHA-candidates with validated 
HLA-binding affinity and SNP occurrence, including the newly identified MiHA TEP1-1S, no 
MHC-multimer positive T-cells were detected in the peripheral blood of 1 to 5 screened 
patients (Fig. 4A,B, Table SIII).
 To investigate whether the MHC-multimer enriched T-cell clones exerted 
comparable peptide specific avidity as the in vivo generated patient derived MiHA specific 
T-cells, we generated CLYBL-1Y specific T-cell clones by single cell sorting of CLYBL-1Y MHC-
multimer positive T-cells from patient MBF. After expansion the T-cell clones were stained 
with the MHC-multimer and TCR-Vβ mAbs. The T-cell clone K264, which was generated 
by MHC-multimer enrichment from donor ABM, demonstrated similar MHC-multimer 
staining intensity as the patient derived K2-339 clone (Fig. 5A), but a difference in TCR 
Vβ usage; clones derived from donor ABM expressed TCR Vβ22 and patient MBF derived 
clones were TCR-Vβ1 positive. Clone K264 and K2-339 were stimulated with T2 cells loaded 
with titrated concentrations of either the specific or the allelic variant peptide and IFN-γ 
production was measured (Fig. 5B). Both T-cell clones demonstrated high CLYBL-1Y specific 
peptide reactivity, with IC50 varying between 1-4 pM, whereas the allelic CLYBL-1D variant 
was not or hardly recognized by both T-cell clones, demonstrating that T-cell clones derived 
from an unprimed setting can be equally potent as T-cells derived from an in vivo primed 
setting.
CLYBL-1Y and TEP1-1S specific T-cell recognition of hematopoietic malignant cells
To investigate the expression pattern of the CLYBL and TEP1 genes we performed a 
microarray gene expression array using a panel of primary and cultured malignant (and 
non-malignant) hematopoietic and non-hematopoietic cells (Fig. S1C,D). The data showed 
that the CLYBL gene is broadly expressed in hematopoietic and non-hematopoietic cells. 
Expression of the TEP1 gene was not significantly measured in the majority of the samples. 
To investigate whether the CLYBL-1Y and TEP1-1S specific T-cell clones were able to 
recognize hematopoietic malignant cells they were stimulated with primary CML, AML and 
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ALL cells derived from different MiHA positive and negative patients that were positive for 
the restricting HLA-molecule. As a control, T-cell clones were also tested for recognition 
of EBV-LCL generated from the same individuals. Both the high avidity T-cell clones CLYBL 
K264 and TEP1 K091 demonstrated MiHA specific recognition of primary hematopoietic 
malignant cells (Fig. 6A,C). No reactivity was observed against MiHA negative target 
cells. These data indicate that the tested MiHA can be presented in the context of HLA 
at the surface of leukemic cells and may therefore serve as direct targets of CD8+ T-cells 
involved in a GVL response. In addition, the potential of the MiHA to serve as target in 
GVHD was estimated and the MiHA specific T-cell clones were tested for recognition of 
Figure 4. MHC-multimer positive T-cell populations detected in patients after allo-SCT.
(A) Number of MHC-multimer positive T-cell populations detected by combinatorial coding MHC-multimer 
analysis in peripheral blood samples of 16 patients with various hematologic malignancies that received 
an allo-SCT and demonstrated a clinical response to DLI. Patients were only screened when they were 
positive for the SNP encoding MiHA and received a DLI from a donor that was homozygous negative for 
the SNP encoding MiHA. Bars indicate the number of patients applicable for MiHA-specific MHC-multimer 
screening. The number of MHC-multimer positive T-cell populations detected per MiHA candidate is 
indicated in black. (B) Representative FACS analysis of MHC-multimer positive T-cell populations detected 
in the indicated patients. All dot plots display fluorescence intensity for CD8 and specific MHC-multimer 
staining. Total lymphocytes are shown. Frequencies indicate MiHA specific T-cells of total CD8+ T-cells.
A 












































































































































































 discovery by reverse im
m
unology
5     
non-hematopoietic fibroblasts. To mimic the pro-inflammatory cytokine milieu, early 
after transplant or during potent GVHD responses, fibroblasts were pretreated with IFN-γ. 
Although both the CLYBL K264 and TEP1 K091 T-cell clone poorly recognized non treated 
fibroblasts they clearly recognized those that were IFN-γ pretreated (Fig. 6B,D). These 
data indicate that both CLYBL-1Y and TEP1-1S may be considered as MiHA with potential 
therapeutic value under non-inflammatory conditions, but they may participate in toxic 
GVHD responses in a pro-inflammatory environment.
Discussion 
In this study we demonstrate the identification of two biologically relevant MiHA by a reverse 
immunology approach. We started our approach by selecting MiHA-candidates from our 
recently generated B-lymphocyte derived HLA-class I eluted peptide library(13,16). By 
MiHA candidate specific MHC-multimer enrichments and subsequent single cell sorting 
of MHC-multimer positive T-cells, high avidity MiHA specific T-cell clones directed against 
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Figure 5. Functional avidity of patient and donor derived CLYBL-1Y specific T-cell clones. (A) FACS analysis 
of MHC-multimer positive CLYBL-1Y specific T-cell clones. To prevent doublet formation, CLYBL-1Y specific 
T-cell clones were mixed with CD4 T-cell blasts. Dot plots display fluorescence intensity for MHC-multimer 
staining. Total lymphocytes are shown. (B) CLYBL-1Y specific T-cell clones derived from donor ABM (K264; 
white) or from patient MBF (K2-339; black) were stimulated with HLA-A*0201 positive T2 target cells 
loaded with titrated concentrations of CLYBL-1Y peptide (squares) or allelic variant (triangles) for 18 hours 
[E:T] 5,000:25,000. IFN-γ secretion was measured by standard ELISA.
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malignancies expressing the respective MiHA, indicating the immunogenicity of the two 
MiHA. In addition, we were able to demonstrate an in vivo induced immune response 
against the new CLYBL-1Y MiHA in a patient suffering from AML that experienced an anti-
leukemic response after allo-SCT and subsequent DLI treatment, demonstrating that by 
using this reversed immunology approach, biologically relevant MiHA can be identified. 
For the CLYBL-1Y MiHA, MHC-multimer analysis revealed the presence of T-cells specific for 
this MiHA in one of the 3 patients screened. These in vivo primed T-cells demonstrated to 
be high avidity T-cells specific for the CLYBL-1Y allelic MiHA variant. For the TEP1-1S MiHA 
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Figure 6. MiHA specific T-cell reactivity towards hematopoietic malignancies and fibroblasts. Isolated 
MHC-multimer positive T-cell clones were screened for recognition of various primary hematopoietic 
malignancies and non-hematopoietic fibroblasts isolated from different individuals. As a control for T-cell 
recognition, all T-cell clones were also stimulated with EBV-LCL generated from the same individuals. (A) 
CLYBL-1Y clone K264 and (C) TEP1-1S clone K091 were stimulated with HLA-A*0201 or B*0702 positive 
primary AML, CML and ALL cells either positive (black bars) or negative (gray bars) for the specific MiHA, 
directly after isolation of malignant cells for 18 hours [E:T] 1,000:5,000. To measure the recognition of non-
hematopoietic cells, (B) CLYBL-1Y clone K264 and (D) TEP1-1S clone K091 were stimulated with fibroblasts 
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positive cells. Therefore, the absence of an in vivo induced immune response against TEP1 
-1S could either be due to the low number of patients that could be screened or due to 
subdominance of TEP1 -1S in the immune response. Our reverse immunology approach 
has the advantage to allow identification of subdominant MiHA as the T-cell repertoire of 
patients that are screened in forward immunology approaches is skewed towards highly 
immunodominant MiHA specific responses. Subdominant MiHA, however, may be of 
therapeutic interest as they can be exploited in potential peptide vaccination or adoptive 
T-cell therapies when they demonstrate promising gene expression patterns. 
 A major limitation for the identification of large numbers of MiHA using a reverse 
immunology approach may be the low frequency of high avidity MiHA specific T-cells within 
an individual’s T-cell repertoire. By performing two rounds of MHC-multimer enrichments 
each followed by a 10 days expansion step we increased the number of MHC-multimer 
positive T-cells that was isolated, since we observed that after the second enrichment 
round previously undetected MHC-multimer positive T-cell populations were found. In 
addition, by measuring GM-CSF in addition to IFN-γ as readout for T-cell reactivity, we were 
able to increase the number of MHC-multimer positive T-cell clones that could be screened 
for functional activity. However, the failure to isolate high-avidity T-cells for the previously 
identified LB-NISCH-1A MiHA indicates that isolation of high avidity T-cells may still be a 
matter of chance13. Alternatively, T-cells may be tolerant for some MiHA due to molecular 
mimicry with non-polymorphic epitopes or due to their failure to discriminate between 
both allelic variants of a SNP encoding MiHA27, explaining why not all MiHA-candidates will 
be of clinical relevance. 
 For 8 of the 20 MiHA-candidates MHC-multimer positive T-cell clones were 
isolated that demonstrated MiHA specific peptide reactivity. The different MHC-multimer 
positive T-cell clones however demonstrated functional heterogeneity. We have recently 
demonstrated that CMV-specific MHC-multimer positive T-cells isolated from CMV 
negative individuals by MHC-multimer enrichments also demonstrated a large variation in 
functional avidity28. This heterogeneity in functional activity of the MHC-multimer positive 
T-cell populations may be specific for T-cells isolated from the naïve repertoire as memory 
T-cells are skewed toward a high-avidity range as a result of antigen encounter in vivo. 
Non-responsiveness of MHC-multimer positive T-cell clones has also been reported by 
others for T-cells derived from the naïve repertoire29,30. The discrepancy between MHC-
multimer reactivity and T-cell functionality can most likely be explained by the staining with 
multimerized MHC-peptide complexes. Multimerization of MHC-peptide complexes alters 
the TCR-MHC-peptide dissociation on- and off-rate kinetics and will result in increased 
binding avidity of the multimerized MHC-peptide complex to surface TCR. By measuring 
the strength of TCR binding to monomeric peptide-MHC complexes using the Streptamer 
Koff rate assay, we recently demonstrated that the dissociation kinetics correlated with 
the observed functional avidity of different MHC-multimer positive T-cell clones, and that 
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T-cells demonstrating lower dissociation rates confer significantly better antigen specific 
reactivity than those with fast dissociation rates28,31. 
 For the high throughput isolation of antigen specific T-cells using recombinant 
MHC-peptide complexes the use of MHC-multimer complexes is necessary, since MHC-
monomers do not stably bind to TCRs. However, multimerization of MHC-peptide complexes 
may false positively increase the binding avidity of the multimerized MHC-peptide complex 
to T-cells. The analysis of conventional MHC-multimer based TCR dissociation kinetics is 
complicated by multivalent binding and dissociation rates, even when competitor reagents 
or cold MHC-multimer staining are used32. The controlled disassembly of MHC-multimers 
to monomers directly after MHC-multimer based T-cell isolation and subsequent FACS 
sorting of T-cells expressing a TCR with a low MHC-peptide dissociation rate may further 
increase the efficiency of future reverse immunology approaches33.
 In conclusion, with this reverse immunology approach we have demonstrated the 
immunogenic potential of two newly identified MiHA; LB-CLYBL-1Y and LB-TEP1-1S. The 
biologically relevance of LB-CLYBL-1Y was demonstrated by the detection of MHC-multimer 
positive T-cells with equally high peptide avidity in a patient suffering from AML who 
experienced an anti-leukemic response after treatment with allo-SCT and subsequent DLI. 
The identification of LB-TEP1-1S demonstrated the feasibility of our reverse immunology 
approach to identify MiHA that are not frequently induced in vivo but can potentially be 
used for immunotherapeutic strategies. In addition, these results demonstrate that this 
approach will enable the identification of clinically relevant MiHA when MiHA candidates 
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Material and Methods
Cell collection and culture conditions. Peripheral blood was obtained from different individuals after 
informed consent (Sanquin Reagents, Amsterdam and Leiden University Medical Center, Leiden, The 
Netherlands). All experiments were approved by the local medical ethics committees. Blood samples 
were HLA-typed by high-resolution genomic DNA-typing. Peripheral blood mononuclear cells (PBMC) 
were isolated by ficoll gradient separation and cryopreserved for further use. T-cells were cultured in 
T-cell medium consisting of Iscove’s Modified Dulbecco’s Media (IMDM: Lonza) supplemented with 
5% human serum (HS), 5% fetal bovine serum (FBS), 100 IU/ml IL-2 (Proleukin), 2 mM L-glutamine, 
100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). Epstein-Barr virus-transformed 
lymphoblastoid B-cell lines (EBV-LCL) and phytohemagglutinine (PHA; Murex Diagnostics) blasts 
were generated using standard procedures. The T2 cell line was cultured in IMDM with penicillin/
streptomycin and 5% FCS.
Peptide library of HLA-class I eluted peptides. The peptides used for this study are derived from a 
newly established large peptide library that has been recently described by Hassan et al16. In short: 
Peptide elution, reverse phase high-performance liquid chromatography (RP-HPLC), and tandem mass 
spectrometry (MS/MS) were carried out as previously described17,18. Briefly, 60 x 109 HLA-A*0201 
and HLA-B*0702 positive EBV-LCL were washed with ice cold PBS and pellets were stored at -80°C 
until use. Peptide-HLA-class I complexes were purified from cell lysate by affinity chromatography. 
Subsequently, peptides were eluted from HLA-molecules, and separated from the HLA heavy chain 
fragments and β2-microglobulin by size filtration. The peptide mixture was separated by various first 
dimension separation techniques, after which the peptides were measured by on-line nanoHPLC-MS/
MS.
Selection of MiHA-candidates from a set of eluted peptides. MiHA-candidates were selected based 
on our recently developed MiHA selection algorithm from the recently established peptide elution 
library13. Briefly, the tandem mass spectra of eluted peptides were submitted to the HSPVdb19, a 
database optimized for finding polymorphic peptides. To select for MiHA-candidates within this set 
we evaluated the polymorphic peptides using strict threshold scores for mass spectrometry defined 
sequence reliability (BMI≥30, ppm≤2.0), peptide length (8-11 amino acids), predicted peptide-HLA 
affinity (<500nM), allele frequencies of the SNP encoding polymorphism (0.05-0.7%) and specific 
gene exclusion criteria (no extreme polymorphic genes). After confirming their integrity by comparing 
the tandem mass spectra of the synthetic peptides with that of the eluted counterparts the top 25 
MiHA-candidates, with the highest threshold scores, were selected for further analysis.
Generation of peptide-MHC complexes. All peptides were synthesized in-house using standard 
Fmoc chemisty. Recombinant HLA-A*0201 and HLA-B*0702 heavy chain and β2m were in-house 
produced in Escherichia coli. MHC-class I refolding was performed as previously described with minor 
modifications20. MHC-class I complexes were purified by gel-filtration HPLC in PBS and stored at 4⁰C.
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The peptide HLA-A*0201 or HLA-B*0702 binding affinity was assessed by subjecting prefolded UV-
sensitive peptide-MHC complexes (100μg/ml) to 366nm UV light (Camag) for 1 h in presence of 
the peptide of interest (200μM)21. As controls the CMV PP65 NLVPMVATV, CMV PP65 TPRVTGGAM, 
modified MART1 ELAGIGILTV and wild-type MART1 AAGIGILTV peptide were used. After exchange, 
samples were spun at 16,000g for 5 min and supernatants were used to assess HLA-monomer rescue 
using a bead assay as previously described22.
Isolation of MHC-multimer positive T-cells by MHC-multimer pull down. Prior to isolation PBMC 
samples were stained with PE-coupled MHC-multimers for 1 hour at 4ºC. Subsequently, cells were 
washed and incubated with anti-PE beads (Miltenyi Biotec, Bergisch Gladbach, Germany). PE-positive 
T-cells were isolated by magnetic activated cell sorting (MACS), according to the manufacturer’s 
protocol. Positive fraction was cultured with irradiated autologous feeder cells in T-cell medium 
supplemented with 5ng/ml IL-15 (Biosource) and anti-CD3/CD28 Dynabeads (Invitrogen). After 2 
weeks, T-cell cultures were analyzed by MHC-multimer combinatorial coding flow cytometry. Data 
acquisition was performed on an LSR-II flow cytometer (BD Biosciences, San Diego, USA) and MHC-
multimer positive T-cell populations were single cell sorted on a FACSAria (BD) into 96-round bottomed 
well plates containing 100 μl T-cell medium supplemented with 800 ng/ml PHA and 1*105 irradiated 
feeder cells. T-cell receptor-β variable chain (TCR-Vβ) usage was investigated by flow cytometry using 
specific monoclonal antibodies as included in the TCR-Vβ repertoire kit (Beckman Coulter).
Cytokine secretion assay. For analysis of IFN-γ and GM-CSF production, 5000 T-cells were stimulated 
with 20,000 EBV-LCL or 10,000 fibroblasts loaded with different concentrations of peptides in 
96-round bottomed well plates. Before stimulation, fibroblasts were either pre-treated with IFN-γ 
(100 IU/ml) or not for 5 days. For recognition of primary malignant cells, 1000 T-cells were stimulated 
with 5,000 malignant cells in a 384-well plate. After 18 hours, supernatants were harvested, and 
the concentration of IFN-γ and GM-CSF were measured by an enzyme-linked immunosorbent assay 
(ELISA; Sanquin Reagents). An arbitrary detection limit was set to 100 pg/ml for both cytokines.
SNP genotyping and microarray gene expression analysis. A panel of 100 HLA-typed EBV-LCL was 
selected for SNP screening as previously described9. Briefly, genomic DNA was isolated of 5×106 
EBV-LCL cells using Gentra Puregene Cell Kit (Qiagen) and PCR-free whole genome amplification 
(WGA) was performed. The DNA samples were hybridized to Illumina Human1M-duo arrays. For 
gene expression analysis, total RNA was isolated using small and micro scale RNAqueous isolation 
kits (Ambion), and amplified using the TotalPrep RNA amplification kit (Ambion). After preparation 
using the whole-genome gene expression direct hybridization assay (Illumina), cRNA samples were 
dispensed onto Human HT-12 v3 Expression BeadChips (Illumina) according to the manufacturer’s 
protocol. Sample collection was performed as previously described23-25. Microarray gene expression 
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Supplementary figure 1 
 
The HLA-binding affinity of 25 eluted highly potential MiHA candidates was analyzed by a binding assay that is 
based on HLA-recovery after UV-exchange monomer technology. After UV-exchange the HLA-monomer rescue 
score was normalized to the peptides CMV PP65-NLV and CMV PP65-TPR that exhibit a high binding affinity 
for HLA-A*0201 or B*0702, respectively. Peptides with a higher HLA-recovery score (>40%) compared to the 
low affinity HLA-A*0201 binding MART1-WT-AAG were selected for further analysis. As negative control no 
rescue peptide was added. All control peptides are indicated in grey. The percentage of HLA-recovery as a meas-
ure for HLA-binding affinity for 9 HLA-A*0201 (A) and 16 HLA-B*0702 (B) restricted MiHA candidates was 
shown. MiHA candidates with HLA-recovery score above the selection threshold of 40% are indicated in black. 
MiHA candidates that demonstrated a HLA-recovery below 40% were removed from the study and are indicated 
with stripes. (C,D) Gene expression of CLYBL and TEP1 were analyzed. Normal hematopoietic T-cells, mono-
cytes, B-cells and hematopoietic stem cells (HSC) were isolated from (G-CSF mobilized) peripheral blood and 
bone marrow mononuclear cells (PBMC and BMMC) from donors by flow cytometry cell sorting based on expres-
sion of CD3, CD14, CD19 and CD34, respectively. Skin derived fibroblasts (FB), keratinocytes (KC) and PTEC 
were cultured with and without IFN-γ (100 IU/ml) and hepatocytes were freshly isolated from liver specimen. 
AML, ALL and CML cells were isolated from peripheral blood and bone marrow samples from patients by flow 
cytometry cell sorting based on expression of CD33, CD19 and CD34, respectively. EBV-LCL and PHA blasts 
were generated using standard procedures. Total RNA was isolated and whole-genome gene expression assay was 
performed as previously described26. The probe fluorescence for the indicated genes are shown for each sample, 
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Figure S1. The HLA-binding affinity of 25 eluted highly potential MiHA candidates was analyzed by a 
binding assay that is based on HLA-recovery after UV-exchange monomer technology. After UV-exchange 
the HLA-monomer rescue score was normalized to the peptides CMV PP65-NLV and CMV PP65-TPR that 
exhibit a high binding affinity for HLA-A*0201 or B*0702, respectively. Peptides with a higher HLA-recovery 
score (>40%) compared to the low affinity HLA-A*0201 binding MART1-WT-AAG were selected for further 
analysis. As negative control no rescue peptide was added. All control peptides are indicated in grey. The 
percentage of HLA-recovery as a measure for HLA-binding affinity for 9 HLA-A*0201 (A) and 16 HLA-B*0702 
(B) restricted MiHA candidates was shown. MiHA candidates with HLA-recovery score above the selection 
threshold of 40% are indicated in black. MiHA candidates that demonstrated a HLA-recovery below 40% 
were removed from the study and are indicated with stripes. (C,D) Gene expression of CLYBL nd TEP1 
were analyzed. Normal hematopoietic T-cells, monocytes, B-cells and hematopoietic stem cells (HSC) 
were isolated from (G-CSF mobilized) peripheral blood and bone marrow mononuclear cells (PBMC and 
BMMC) from donors by flow cytometry cell sorting based on expression of CD3, CD14, CD19 and CD34, 
respectively. Skin derived fibroblasts (FB), keratinocytes (KC) and PTEC were cultured with and without 
IFN-γ (100 IU/ml) and hepatocytes were freshly isolated from liver specimen. AML, ALL and CML cells were 
isolated from peripheral blood and bone marrow samples from patients by flow cytometry cell sorting 
based on expression of CD33, CD19 and CD34, respectively. EBV-LCL and PHA blasts were generated using 
standard procedures. Total RNA was isolated and whole-genome gene expression assay was performed as 
previously described26. The probe fluorescence for the indicated genes are shown for each sample, and the 
mean with SD is indicated for each cell type.
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A*02:01  HA-2V YIGEVLVSV JY, ALY, HHC JY, HHC 50.4 
HA-8R RTLDKVLEV JY, ALY JY, ALY 33.8 
LB-SSR1-1S VLFRGGPRGSLAVA HHC HHC 28.6 
LB-PRCP-1D MWDVAEDLKAβ HHC HHC 14.3 
LB-WNK1-1I  TLSPEIITVβ JY, HHC HHC 28.4 
LB-NISCH-1A ALAPAPAEV JY JY 39.0 
SMCY-A2 FIDSYICQV JY NDγ - 
      
B*07:02 LB-EBI3-1I RPRARYYIQV ALY ALY 14.3 
LB-ERAP1-1R  HPRQEQIALβ JY, HHC JY, HHC 36.2 
LB-GEMIN4-1V FPALRFVEV JY JY 42.5 
LB-PDCD11-1F GPDSSKTFLCL ALY, HHC ND - 
SMCY-B7 SPSVDKARAEL JY JY 57.8 
LB-APOBEC3B-1K KPQYHAEMCF ALY, HHC NDγ - 
      
Total detected MiHA        
α Sequence confirmed by matching the MS spectra of synthetic and             
eluted peptide  
β Length variant of published MiHA epitope 
γ Not Detected (ND) 
* Highest detected Best Mascot Ion Score (BMI) 
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# Low HLA-affinity peptides 
α SNP underlined 
β Parts-Per-Million: Difference between observed and exact ion mass 
γ Best-Mascot-Ion-Score: Match between observed MS spectrum and stated peptide 
µ Predicted netMHC affinity (nM), Strong binder ≤50; Weak binder ≤500  
Supplementary Table II. Validation scores MiHA candidates 
HLA Peptide Sequenceα Gene PPMβ BMIγ netMHC
µ 
(nM) 
A*02:01 P1 GLLGQEGLVEI PARP10 0,7 56 96 
 P2 ALAPAPAEV NISCH 0,9 40 12 
 P3 AMLERQFTV FAM119A 0,1 35 3,4 
 P4 FLSSANEHL GLRX3 0,6 36 10,6 
 P5 MMYKDILLL HNF4G 0,1 63 6,9 
 P6 SLAAYIPRL CLYBL 0,8 40 4,1 
 P7 SLQEKVAKA HMMR 0,5 46 356,4 
 P8 VLQNVAFSV BCL2A1 1,1 40 12,7 
 # RLLEAIIRL MYO19 0,1 50 10 
       
B*07:02 P9 APNTGRANQQM BFAR 0,6 44 55,8 
 P10 LPMEVEKNSTL HDGF 0,1 50 49,7 
 P11 RPRAPTEELAL C14orf169 0,1 38 3,3 
 P12 APDGAKVASL TEP1 0,3 45 73,1 
 P13 APAGVREVM AKAP13 0,1 72 20,5 
 P14 KPQQKGLRL APOBEC3H 0,3 36 19,6 
 P15 LPQKKSNAL POP1 0,3 38 6,2 
 P16 LPQQPPLSL SCRIB 0,4 54 14,2 
 P17 NPATPASKL C18orf21 0,1 43 71,6 
 P18 SPASSRTDL MTRR 0,8 45 11,1 
 P19 SPSLRILAI LLGL2 0,1 48 20,4 
 P20 HPRQEQIAL ERAP1 1,3 36 9 
 P21 FPALRFVEV GEMIN4 0,5 43 33 
 # SPRVGFLSSL WDR91 0,6 56 17 
 # LPDGGVRLL TSEN54 0,2 46 135 
 # RPRAPTEEL C14orf169 0,1 36 12 
Table SII. Validation scores MiHA candidates.
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FHT      0,5              0,2 
EPP  0,01    0,2      0,01    0,01   0,01  
UBE      0,2               
AKH                     
JSB                    2,8 
DSP                     
USQ                     
ABM      5,0 0,01            0,01 2,0 
UDN      0,2               
OMH             0,01        
UBF      0,1    0,1  0,1         
OGV      0,01         0,01      
MMY                    0,01 
CLO                     
UHR                     









































































































Supplementary Table III.  
Expanded T-cell lines after first MHC-multimer pull down 
FHT      0,8           0,1   65 
EPP  28 0,3 0,01  8,4      2,0    6,7   3,6  
UBE      0,5               
AKH                     
JSB                    2,8 
DSP                     
USQ                     
ABM      28,3 0,2       0,3     0,2 5,6 
UDN      85               
OMH         0,1    38  0,01 0,02     
UBF      0,1    0,1  0,1   0,01 0,02     
OGV   0,2   54         0,01      
MMY                    0,04 
CLO   0,1                  
UHR                    85 






































































Screening for MHC-tetramer positive T-cell populations in expanded T-cell lines after one or two rounds of 
MHC-multimer pull down. All T-cell populations screened for in PBMC donors homozygous negative for the 
indicated SNP encoding MiHA are indicated in grey. Frequencies indicate MHC-multimer positive T-cells out 




































Expanded T-cell lines after second MHC-multimer pull down 
BWB CML 83                       
AZP CML 62                         
BDV MM 49                        
MDD RCC 67                      
HHC MDS 49                           
CUB MM 86                     0,3 0,04 
MBS CMMOL 54                          
USF PCL 95                          
JBZ CML 59                        
OBB CML 172                         
ASQ AA 35                       
RBH CML 106                       
MBF AML 41      0,34               
YKV CML 50                        
JLW CML 90                       








































































































Circulating MHC-multimer positive T-cell frequencies detected in allo-SCT patients  
Screening for MHC-tetramer positive T-cell populations in 16 MiHA positive patient that received a DLI of a donor that was homozy-
gous negative for the SNP-encoding MiHA. All T-cell populations screened for are indicated in gray 
Frequencies indicate detected MHC-multimer positive T-cells out of total CD8+ T-cells as revealed by FACS analysis 
Table SIII.
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EPP  0,01    0,2      0,01    0,01   0,01  
UBE      0,2               
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Supplementary Table III.  
Expanded T-cell lines after first MHC-multimer pull down 
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Screening for MHC-tetramer positive T-cell populations in expanded T-cell lines after one or two rounds of 
MHC-multimer pull down. All T-cell populations screened for in PBMC donors homozygous negative for the 
indicated SNP encoding MiHA are indicated in grey. Frequencies indicate MHC-multimer positive T-cells out 




































Expanded T-cell lines after second MHC-multimer pull down 
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Circulating MHC-multimer positive T-cell frequencies detected in allo-SCT patients  
Screening for MHC-tetramer positive T-cell populations in 16 MiHA positive patient that received a DLI of a donor that was homozy-
gous negative for the SNP-encoding MiHA. All T-cell populations screened for are indicated in gray 





 discovery by reverse im
m
unology
5     
FHT      0,5              0,2 
EPP  0,01    0,2      0,01    0,01   0,01  
UBE      0,2               
AKH                     
JSB                    2,8 
DSP                     
USQ                     
ABM      5,0 0,01            0,01 2,0 
UDN      0,2               
OMH             0,01        
UBF      0,1    0,1  0,1         
OGV      0,01         0,01      
MMY                    0,01 
CLO                     
UHR                     









































































































Supplementary Table III.  
Expanded T-cell lines after first MHC-multimer pull down 
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Screening for MHC-tetramer positive T-cell populations in expanded T-cell lines after one or two rounds of 
MHC-multimer pull down. All T-cell populations screened for in PBMC donors homozygous negative for the 
indicated SNP encoding MiHA are indicated in grey. Frequencies indicate MHC-multimer positive T-cells out 




































Expanded T-cell lines after second MHC-multimer pull down 
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Circulating MHC-multimer positive T-cell frequencies detected in allo-SCT patients  
Screening for MHC-tetramer positive T-cell populations in 16 MiHA positive patient that received a DLI of a donor that was homozy-
gous negative for the SNP-encoding MiHA. All T-cell populations screened for are indicated in gray 
Frequencies indicate detected MHC-multimer positive T-cells out of total CD8+ T-cells as revealed by FACS analysis 
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Summary
T-cell recognition of MiHA plays an important role in the GVT effect of allo-SCT. Selective 
infusion of T-cells reactive for hematopoiesis-restricted MiHA presented in the context of 
HLA-class I molecules may help to separate the beneficial GVT effects from GVHD after 
allo-SCT. To date, only a few MiHA that form attractive targets for adoptive immunotherapy 
have been characterized and the number of patients that can be treated with such MiHA-
selective cell therapy remains limited. In this thesis we focused on “reverse immunology” 
as an attractive strategy to identify clinically relevant MiHA and other T-cell epitopes. 
In this approach peptide predictions are the starting point and peptide candidates are 
subsequently screened for their capacity to induce a T-cell response. We investigated 
the feasibility of computational genome-wide prediction of hematopoietic MiHA and 
alternatively implemented mass spectrometry based HLA-peptidomics as source for 
candidate peptides. T-cells that reacted with these antigens were collectively isolated 
by MHC-tetramer pull down. Subsequently, the composition of MHC-tetramer positive 
T-cell populations was characterized and tested for reactivity against any of the predicted 
epitopes that was included in the initial MHC-tetramer panel. We generated an algorithm 
that could be exploited to selectively target T-cells specific for clinically relevant MiHA.
 In chapter 2 we demonstrated the technical feasibility of high-throughput 
analysis of antigen-specific T-cell responses in small patient samples. Using three different 
peptide-HLA binding algorithms a set of 973 peptides that contained a SNP and where 
theoretically expressed by hematopoietic stem cells was produced and screened for 
HLA-A*0201 binding. After synthesis all peptides were tested for true peptide-HLA affinity 
in two separate assays resulting in a set of 333 high affinity HLA-A2 peptides that was used 
to generate MHC-tetramers. Subsequently, post-transplantation samples from allo-SCT 
patients were screened for T-cell populations reactive to any of these predicted peptides. 
MiHA-specific T-cell lines were generated by incubating patient PBMC samples, regardless 
of patient SNP status, with the collective set of 333 MHC-tetramers, followed by enrichment 
of MHC-tetramer positive cells on a magnetic column. Isolated T-cells were expanded and 
analyzed for MHC-tetramer reactivity by multi-color flow cytometry. Although a promising 
number of 71 peptide-reactive T-cell populations were generated by FACS sorting of MHC-
tetramer positive cells, with the exception of the defined MiHA HMHA1, none of the other 
T-cell populations that were generated demonstrated recognition of endogenously MiHA 
expressing target cells, even though recognition of peptide-loaded targets was often 
observed. On basis of the result that the high avidity HMHA1 specific T-cell population was 
isolated from a transplantation setting in which both donor and recipient were homozygous 
negative for the MiHA phenotype we assumed that these cells were derived from the naïve 
T-cell repertoire. We concluded that the unbiased screening for T-cell reactivity against large 
sets of predicted MiHA that are solely based on epitope binding, irrespective of peptide 
processing data and SNP status of donor and recipient, did not result in the identification of 
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a novel biological relevant MiHA and we speculated that a more reliable source of naturally 
processed and presented peptide candidates could overcome this problem.
 In chapter 3 we optimized our MHC-tetramer pull down approach to isolate 
antigen-specific T-cells derived from a naïve T-cell repertoire. For this purpose we 
took CMV as a model and aimed to generate functional CMV-specific T-cell lines from 
seronegative individuals within four weeks. Generated T-cell lines consisted of a variety of 
immunodominant CMV-epitope specific oligoclonal T-cell populations restricted to various 
HLA-molecules. Although all CMV-specific T-cells were isolated based on their reactivity 
towards a specific peptide-MHC complex, we observed a large peptide avidity variation 
within the isolated T-cell populations. Specifically, in addition to high-avidity T-cells, clones 
were also present that lacked functional reactivity. In addition, MHC-tetramer staining was 
not always predictive for the observed T-cell reactivity and we demonstrated that this was 
caused by altered MHC-peptide-TCR interaction dynamics due to the multimerized nature of 
MHC-tetramer complexes. Surprisingly, while the frequent isolation of naïve T-cells specific 
for the immunodominant A1-pp65-YSE epitope correlated with the frequent detection of 
a memory T-cell response in seropositive individuals, this correlation was absent for the 
immunodominant A2-pp65-NLV epitope, for which no high avidity T-cells could be isolated 
from any seronegative individuals. Based on the variable functionality of the isolated T-cell 
populations we put a critical note to the direct monitoring of the shape of the peripheral 
T-cell repertoire independent of the analysis of functional activity.
 In chapter 4 we established a method for the identification of naturally 
processed MiHA by implementing mass spectrometry based HLA-peptidomics into a 
reverse immunology approach. For this purpose HLA-class I binding peptides were eluted 
from transformed B-cells, analyzed by mass spectrometry and matched with a database 
dedicated to identify polymorphic peptides. This peptide source guarantees identification 
of naturally processed and presented peptides. MiHA-specific T-cell lines were generated 
by incubating large numbers of PBMC from healthy donors with a specific set of MHC-
tetramers, followed by enrichment of MHC-tetramer positive cells on a magnetic column. 
To increase the isolation frequency of high-affinity T-cell populations, the set of MHC-
tetramers was specifically adjusted to each donor to cover only those MiHA for which the 
encoding SNP was screened homozygous negative in the respective donor. The identification 
of the LB-NISCH-1A MiHA demonstrated the feasibility of this approach. Based on these 
results we generated an algorithm that could be exploited to efficiently identify T-cells 
specific for MiHA and used this in chapter 5 to identify 2 new MiHA: LB-CLYBL-1Y and 
LB-TEP1-1S. Detailed analysis of the cytokine secretion profiles of the isolated T-cells 
demonstrated that these cells were not fully differentiated towards high IFN-γ secreting 
T-cells after several weeks of in vitro culture and that GM-CSF could be used as readout 
for T-cell reactivity to further improve the efficiency of the approach. Although the clinical 
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positive T-cells in a patient with hematologic malignancy after allo-SCT, we underline that 
the identification of LB-TEP1-1S demonstrated the feasibility of our reverse immunology 
approach to identify MiHA that are not frequently induced in vivo. We speculate that these 
so called “subdominant” MiHA can still be of interest for immunotherapeutic strategies.
156






6     
General discussion 
Donor T-cells contribute to the success of allo-SCT and both MiHA specific CD8 and 
CD4 positive T-cells play a crucial role in the eradication of malignant leukemic cells. 
Although preclinical adoptive T-cell approaches directed against single MiHA antigens 
provided promising results1-3, the proof of principle for the effectiveness of MiHA specific 
immunotherapy should be provided by currently ongoing and future clinical studies. 
Although since the first molecular characterization of MiHA, 21 years ago4, 50 MiHA have 
been characterized5, only a few of them demonstrated to be expressed on hematopoietic 
cells, including leukemic stem cells, but not on tissues affected by GvHD. The tissue restricted 
expression of MiHA is crucial to enable the separation of GvL from GvHD upon adoptive 
transfer of T-cells specifically recognizing these MiHA to treat leukemia. Currently, there 
are 15 MiHA identified that are stated to be selectively expressed in hematopoietic cells6;7. 
In reality, this number is lower as T-cells reactive to several of these MiHA, recognized at 
least some non-hematopoietic cells. The low number of validated hematopoietic-restricted 
MiHA limits the broad clinically application of MiHA specific immunotherapy. Due to 
unbalanced population MiHA allele frequencies and HLA-restriction elements, the number 
of patients that could potentially be treated with MiHA based immunotherapy remains low. 
As a consequence the discovery of hematopoietic MiHA remains a high priority.
Future prospects for the identification of clinically relevant MiHA by reverse 
immunology
Although only 3 out of the 50 characterized MiHA were discovered by reverse 
immunology8-10, in theory this is the most efficient methodology towards identification of 
hematopoietic MiHA. Typical for this approach is the screening for T-cells reactive against 
predicted antigens. In theory this approach circumvents the need to screen isolated T-cells 
for unwanted reactivity against non-hematopoietic screening and allows focusing on SNP 
encoding MiHA with a favorable allele frequency and presented in a HLA molecule with 
high population coverage. Unfortunately, the historical low sensitivity and yield of every 
prediction step required a compensatory up-scaling of the initial numbers of candidate 
sequences to be screened. This resulted in a rather complex approach and several attempts 
failed to identify biologically relevant epitopes11-14. The efficacy of reverse immunology 
approaches is dependent on the quality of peptide predictions and the capacity to screen 
for peptide specific T-cell reactivity. As the prediction of MiHA critically relies on the 
identification of polymorphisms, new molecular developments that allow robust gene 
expression profiling and high resolution genome sequencing will help to separate reliable 
polymorphisms from sequence errors and increase the efficacy of valid MiHA candidate 
predictions. In addition, characterization of proteosomal cleavage sites and improvement 
of peptide-HLA binding prediction algorithms enables to better understand the process 
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of antigen processing and presentation. Due to the emerging availability of these 
bioinformatics data an increasing number of MiHA candidates may be predicted. However, 
only when these predictions are linked to high quality gene expression profiling of virtually 
all organs and tissue types to select for MiHA candidates that are exclusively expressed by 
the hematopoietic compartment, MiHA reactive T-cell libraries can be established that may 
broaden the clinically application of MiHA specific immunotherapy. Ultimately this may 
result in “off the shelf” personalized MiHA-based therapies.
 When the predicted MiHA library that was used in chapter 2 was compared with 
the eluted peptide libraries used in chapter 4 and 5 that yield a significant part of the 
B-cell HLA-ligandome, the minimal amount of coverage was striking. Length variants of 
fewer than 5 out of the 1000 predicted peptides were found after sequencing of eluted 
ligands. Although we only used genomic sequence data, gene expression profiling and 
peptide-HLA prediction algorithms for MiHA prediction, no significant improvement was 
observed when we screened a putative MiHA library that included proteosomal cleavage 
and TAP translocation predictions (unpublished data). These low yields indicate that either 
the current knowledge of antigen processing and presentation is insufficient to efficiently 
predict cell-surface presentation of specific peptide-MHC complexes or that the analysis 
of HLA-ligandomes is far from perfect. HLA-ligandome analysis by mass spectrometry may 
be strongly biased towards the most abundantly expressed genes (e.g. over presented 
housekeeping genes) and genes with a lower abundant but favorable gene expression 
profile may be lost in background noise. In addition, the efficiency of HLA-ligandome 
analysis drastically decreases when low numbers of cells, in the range of millions, are used 
as starting material. Ideally, large primary tumor samples should be analyzed and healthy 
tissues of the patient, for example, peripheral blood cells, can serve as a source of reference 
material at least for excluding abundant normal self-peptides from consideration15. 
 Although the identified HLA-eluted peptides may be a fraction of the total 
naturally processed peptide pool, we demonstrate in chapter 4 and 5 that this may serve 
as a reliable source for MiHA identification, when successfully implemented into a reverse 
immunology approach. As the correlation between the transcriptome and HLA peptidome 
has been demonstrated to be low16, it remains questionable how much efficiency gain 
may be expected when new methods to generate genome, gene or transcript sequence 
data are used to predict relevant T-cell epitopes. Although demonstrated to be technically 
feasible, even the state-of-the-art high resolution exome sequencing (only coding regions 
of the genome are sequenced) of patient hematopoietic or malignant cells alone may not 
be sufficient to identify large amounts of clinically relevant T-cell epitopes17-19. Alternatively, 
strategies that focus on ribosome bound mRNA profiling, also called polysome profiling, 
may boost the efficiency of T-cell epitope predictions one step further as it maps the 
translation of proteins and thereby underscoring measurements of mRNA expression 
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unannotated translation products indicating an unanticipated complexity to mammalian 
proteomes22. In yeast, comparing the rate of translation with mRNA abundance from the 
same samples revealed a roughly 100-fold range of translation efficiency (as measured by 
the ratio of ribosome footprints to mRNA reads). In addition, translation was demonstrated 
for approximately 85% of genes for which mRNA abundance was measured suggesting that 
a 15% efficiency gain may be expected when epitope predictions are based on polysome 
profiling compared to total mRNA sequencing. Establishing hematopoietic cell or tumor 
specific polysome profiling sequencing libraries and merge them with a well established 
HLA-peptide affinity prediction algorithm may theoretically boost the efficiency of reverse 
immunology based MiHA prediction.
 Although both exome and polysome sequencing methods, in contrast to HLA 
peptidome analysis have the benefit to be applicable on limited size malignant samples and 
may identify disease related mutations and genomic translocations, the unpredictability 
of post-translational modifications and proteosomal degradation of cellular proteins 
into peptides remain a bottleneck for efficient epitope prediction. As proteasomes are 
responsible for generation of the majority of MHC class I presented T-cell epitopes, the 
development of new prediction algorithms that are more accurate than those currently in 
use will be crucial to boost the efficacy of reverse immunology based epitope predictions23-25. 
In addition, ongoing and future technical developments in the field of mass spectrometry 
that enable more sensitive peptide detection in limited material samples will greatly 
boost the efficiency in which eluted peptide libraries can be used to predict reliable T-cell 
epitopes. Novel developments may also enable a more efficient identification of peptides 
eluted from limited size samples such as specific primary cell subsets or hematopoietic 
malignancies. 
Rationale for the characterization of new MiHA by reverse immunology
Based on the fact that approximately 3 million SNP were identified per individual genome, 
irrespective of MiHA phenotype frequencies, each allo-SCT HLA-matched donor and 
recipient pair is mismatched for thousands of SNP and it is likely that many MiHA have yet 
to be discovered. The recurrent characterization of identical MiHA specific T-cell responses 
in various patients after allo-SCT suggests a strong role for immunodominance26. Dissecting 
the mechanism of immunodominance whereby the donor T-cells responds to only a 
few of the many possible MiHA may become very relevant for future immunotherapy 
as some MiHA specific T-cell responses that are frequently induced in vivo may induce 
GVL whereas others can mediate GVHD. It remains to be investigated whether this 
phenomenon is regulated by high to borderline presence of MiHA specific precursor T-cells 
or by other mechanisms such as tolerance induction to molecular mimicry epitope27;28. 
The identification of LB-NISCH-1A and LB-TEP1-1S in chapter 4 and 5 illustrates that our 
approach allows the identification of highly immunogenic MiHA that are not frequently 
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induced in vivo as no MHC-tetramer positive T-cell populations were observed in the blood 
of patients that were positive for the MiHA and received an allo-SCT and subsequent DLI 
from a donor who was homozygous negative for the SNP encoding MiHA. The identification 
of subdominant MiHA may be restricted to reverse immunology approaches as the T-cell 
repertoire of patients that are screened in forward immunology approaches is skewed 
towards in vivo induced high immunodominant MiHA. If the identified MiHA is restricted to 
a favorable gene expression profile, subdominant MiHA may be of therapeutic interest as 
they can be exploited in potential peptide vaccination or adoptive T-cell therapies.
Increasing the yield of MHC-tetramer pull down and FACS analysis
In our approach the MHC-multimer based enrichment and analysis of the generated T-cell 
lines is crucial for the validation of MiHA and other T-cell epitopes. The absence of MHC-
multimer positive T-cells however, does not necessarily indicate the non-immunogenicity 
of a specific peptide candidate. Precursor frequencies of antigen specific T-cells in an 
unchallenged donor PBMC sample vary and may be so low that the identification of these 
cells may be a matter of chance29;30. In addition, potential antigen specific T-cells may be 
lost during the first 10 days of in vitro culture after MHC-multimer isolation. To prevent 
potential loss of MiHA specific T-cell populations during culture we, as an alternative, 
performed a single cell sort of MHC-tetramer positive T-cell population directly after 
MHC-tetramer pull down. Unpublished results have shown that this approach resulted in 
an increased number of unique MHC-tetramer positive T-cells to be screened. To allow 
selection of high-avidity T-cell clones in a high-throughput manner we isolated T-cells that 
express the surface activation marker CD137 after challenge with endogenously processed 
and presented antigen. This activation marker is in contrast to other activation markers 
upregulated by all T-cells, regardless of differentiation stage, 24 hours after in vitro antigen 
activation. As a consequence, recently activated in vitro primed naïve T-cells can be easily 
isolated  based on their CD137 expression by FACS sorting31;32. 
 The detection efficiency of MHC-multimer positive T-cells by combinatorial coding 
FACS analysis is depending on the number of fluorescent labels with sufficient intrinsic 
fluorescent capacity. The quantum dots that were used in chapter 2, 3, 4 and 5 allowed 
the use of two-color combinations.  The competition for cell surface peptide-MHC complex 
resulted in a decreased intensity for all MHC-multimers combinations. As a consequence, 
the MHC-tetramer staining intensity of antigen-specific T-cell populations with a low affinity 
for the MHC-multimer complex may drop below threshold, especially when combinations 
of the lowest intensity Qdots were used. Although this may serve as an additional selection 
step to bias our selection strategy towards T-cell populations with a moderate to high affinity 
for the MHC-tetramer complex we show in chapter 3 that MHC-tetramer staining was not 
always predictive for T-cell avidity and therefore potential T-cell populations of interest 
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intensities and smaller emission spectra, such as brilliant (ultra)violet dyes33, may be used 
to further expand the complexity of combinatorial coding MHC-tetramer analysis by either 
adding or replacing to the number of fluorochromes used in two-color combinations or 
by designing a three- or four-color combination matrix34. Increasing the complexity of 
combinatorial coding MHC-tetramer analysis will only serve purpose if T-cell recognition of 
large sets of potential clinically relevant peptides needs to be screened in either unbiased 
T-cell repertoires or limited size patient PBMC samples. In the case of dissecting patient-
specific T-cell reactivity towards tumor associated neoantigens, T-cell responses were 
demonstrated to be biased towards a few epitopes derived from highly expressed genes, 
suggesting that it may be feasible to analyze patient-specific T-cell reactivity towards these 
type of antigens with relatively small peptide sets17. If only a few peptide candidates needs 
to be screened, the complexity of combinatorial coding MHC-tetramer analysis may be 
downgraded towards a few optimal fluorescent labels to facilitate analysis of larger groups 
of patient and donor samples and thereby increasing the change of finding rare but useful 
T-cell clones.
Isolation of naïve antigen-specific T-cells by MHC-tetramer pull down
Characterization of antigen specific T-cells within the naïve repertoire can be of clinical 
relevance for various reasons. Detection of naïve T-cell populations may contribute to 
optimize rational vaccine design or to select cord blood samples with pre-existing MiHA 
or tumor specific T-cells prior to umbilical cord transplantation. However, due to extreme 
low frequencies, characterization of naïve T-cell populations requires enrichment of 
MHC-tetramer positive cells prior to analysis, in contrast to memory T-cell populations 
that expanded in vivo after antigen encounter. In chapter 2, 3, 4 and 5 we demonstrate 
the successful isolation of high-avidity MiHA and CMV specific T-cells from an unprimed 
setting. Although direct phenotypic characterization to demonstrate their naïve phenotype 
was lacking due to the low frequency of these cells directly after MHC-tetramer isolation, 
we demonstrate that these cells were not terminally differentiated towards high IFN-γ 
producing T-cells, unlike memory T-cells. The in vitro generated T-cell clones and lines 
were solely selected based on TCR-MHC-tetramer with no subsequent selection for T-cell 
reactivity. As the TCR diversity in the naïve repertoire has been reported to be at least 
100-fold higher compared to the memory T-cell repertoire and high avidity T-cells are 
selectively enriched in the memory subset a substantial part of the isolated T-cells will be 
of low avidity35. The composition of the isolated T-cell populations most likely reflected the 
broad MHC-tetramer positive T-cell repertoire before antigen driven T-cell selection. 
 In chapter 3 we demonstrate that no strict correlation between MHC-tetramer 
reactivity and T-cell avidity exist by studying various A1-pp65-YSE and A1-pp50-VTE 
specific T-cell clones. Although controversial, this discrepancy may be explained by the 
staining with multimerized MHC-peptide complexes. Multimerization of MHC-peptide 
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complexes alter the TCR-MHC-peptide dissociation on- and off-rate kinetics and may result 
in increased binding affinity of the multimerized MHC-peptide complex to surface TCR36. 
This discrepancy may however not be observed when solely monitoring the memory T-cell 
repertoire which is dominated by a few antigen-experienced immunodominant high avidity 
T-cell clones37. 
Currently, the numbers of MiHA that are characterized by forward immunology exceed 
those that are characterized by reverse immunology, but our efforts doubled the number 
of MiHA identified by reverse immunology in only a small time period. Although our 
results did not meet the expectations that were set at the start of this project in 2007, 
they indicate that T-cell epitope predictions are of unexpected complexity and that new 
technical implementations can turn reverse immunology into a more successfully approach. 
In the coming years, it will be interesting to assess how new bioinformatics information can 
be used to improve the efficiency of reverse immunology strategies. If successful, reverse 
immunology based strategies can be of great value to make “off the shelf” personalized 
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Nederlandse samenvatting
Hematopoïese en het ontstaan van leukemie
In het bloed bevinden zich verschillende celpopulaties. Veel van deze populaties hebben 
een relatief korte levensduur en worden constant vernieuwd door nieuwe cellen die 
differentiëren uit hematopoïetische stamcellen (HSC) in de medula van het beenmerg. 
Deze constante vorming van nieuwe bloedcellen wordt hematopoïese genoemd. HSC’s 
hebben de unieke eigenschap om zichzelf te kunnen vernieuwen. Dit houdt in dat er 
na iedere celdeling altijd een nieuwe HSC ontstaat naast een voorlopercel die verder 
kan differentiëren naar een specifiek type bloedcel. Het differentiëren van een ‘onrijpe’ 
voorlopercel naar een ‘rijpe’ functionele bloedcellen gebeurt op specifieke locaties zoals 
het beenmerg, de thymus, lymfklieren en de milt en staat onder stricte regulatie van 
groeifactoren.  Bloedcellen kunnen in verscheidene groepen worden ingedeeld, waaronder 
een myeloïde groep waarin zich onder andere erythrocyten (rode bloedcellen), granulocyten 
en trombocyten (bloedplaatjes) bevinden die nodig zijn voor zuurstoftransport, afweer 
en bloedstolling. Daarnaast de lymfoïde groep waarin zich B-lymfocyten (B-cellen) en 
T-lymfocyten (T-cellen) bevinden die een belangrijke specifieke rol in ons immuunsysteem 
spelen. Dagelijks worden er biljoenen nieuwe bloedcellen aangemaakt. Meestal gaat dit 
goed maar gedurende hematopoïese kunnen er incidenteel op verschillende momenten 
DNA mutaties ontstaan. Deze vorm van DNA schade is een biologisch proces dat kan 
worden veroorzaakt door normale metabolische processen van delende cellen. Daarnaast 
kunnen omgevingsfactoren zoals UV- en radioactieve straling en blootstelling aan toxische 
stoffen hier ook aan bijdragen. Meestal leidt een mutatie tot een abrupte delingsstop van 
de betrokken cel waarna deze in apoptose gaat, een gereguleerde manier van celdood. 
Wanneer een mutatie leidt tot een ongecontroleerde groei van  abnormale, maligne 
cellen in het beenmerg en bloed wordt dit leukemie genoemd. Er zijn verschillende 
verschijningsvormen van leukemie. Bij een opeenhoping van onrijpe snel delende maligne 
cellen noemt men dit acute leukemie en wanneer het rijpere, meer gedifferentieerde 
maligne cellen betreft  ontwikkelt zich een chronisch leukemie.
Allogene stamceltransplantatie als behandeling van leukemie
Afhankelijk van het type leukemie, de leeftijd van de patiënt en de prognose wordt er 
een initiële behandeling gekozen die gericht is op het vernietigen van de maligne cellen. 
Vaak omvat deze behandeling intensieve chemo- en radiotherapie waarbij met behulp 
van medicijnen of straling zoveel mogelijk maligne cellen worden vernietigd. Omdat een 
‘remissie’ van de ziekte zelden compleet is, blijven er vaak lage frequenties van maligne 
cellen achter in het beenmerg of bloed, en is de kans op een recidief (terugkomen van 
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de leukemie) groot.  Er is dan ook vaak nog additionele behandeling nodig. Dit kan 
het uitvoeren van een allogene stamceltransplantatie (alloSCT) zijn. Bij een allogene 
stamceltransplantatie (alloSCT) worden stamcellen uit het beenmerg van een gezonde 
donor naar de patiënt getransplanteerd. De donor kan een verwante donor (directe familie) 
maar ook een niet-verwante donor zijn met een overeenkomende HLA-typering, de genen 
die coderen voor het major histocompatibility complex (MHC). Aan de alloSCT gaat een 
intensieve pre-conditioning vooraf waarin met behulp van chemo- en radiotherapie naast 
achtergebleven maligne cellen ook de gezonde HSC in het beenmerg van de patiënt worden 
vernietigd. Vervolgens worden gezonde HSC van de donor in de patiënt getransplanteerd. De 
toegediende stamcellen zullen de patiënt herkoloniseren en het hematopoïetische systeem 
herstellen. Naast het vervangen van potentiële maligne stamcellen heeft een alloSCT ook 
een aanvullend extra voordeel ten opzichte van een autologe stamceltransplantatie waarin 
de HSC afkomstig zijn van de patiënt zelf T-cellen in het transplantaat kunnen een sterke 
immuunreactie vormen tegen de achtergebleven hematopoiëtische cellen, en wellicht 
chemotherapie resistente maligne cellen van de patiënt opruimen. Deze zogenoemde 
Graft versus Tumor (GvT ofwel transplantaat versus tumor) reactie ontstaat doordat de 
toegediende T-cellen de tumorcellen als lichaamsvreemd herkennen. Daarnaast kunnen 
donor T-cellen in het transplantaat ook een immuunreactie vormen tegen de gezonde 
weefsels van de patiënt. Deze potentieel levensbedreigende Graft versus Host Disease 
(GvHD) manifesteert zich vooral in de  darmen, lever, huid, en longen. Om ernstige GvHD 
te voorkomen wordt gezocht naar een stamceldonor met een zo identiek mogelijke HLA-
typering. Om het risico op GvHD te verminderen kan na alloSCT ervoor gekozen worden 
om donor T-cellen uit het transplantaat te verwijderen (T-cel depletie). Een nadeel van 
deze T-cel depletie is een vergrote kans op een recidief. Naast een vermindering van het 
GvT effect leidt verwijdering van T-cellen ook tot een verhoogde kans op opportunistische 
virale complicaties. Als er geen virus-specifieke T-cellen in het transplantaat van de donor 
aanwezig zijn, kunnen latent in de immuungecompromitteerde patiënt levende virussen 
zoals Epstein-Barr virus (EBV) en Cytomegalovirus (CMV) reactiveren en ernstige, potentiële 
levensbedreigende infecties veroorzaken. Het manipuleren van de immuunrespons na 
alloSCT om gewenste en ongewenste effecten van elkaar te scheiden vormt de basis van 
veel immuuntherapieën.
Donor lymfocyten infusie na allogene stamceltransplantatie
Indien er na een alloSCT nog steeds of opnieuw hematopoïetische cellen van patiënt 
herkomst worden aangetroffen spreekt men van een onvolledig donor chimerisme. Deze 
achtergebleven cellen kunnen leiden tot een recidief van de leukemie en dienen ideaal 
gezien te worden vernietigd. Om dit te bereiken of te voorkomen (profylactisch) dat 
een recidief optreedt, kan de patiënt na alloSCT worden behandeld met T-cellen van de 
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het gewenste effect van een DLI uitblijft, kan meermalig DLI worden toegediend. Als vroeg 
na alloSCT een recidief optreedt of de kans daarop groot is, is de keuze om DLI te geven vaak 
lastig. Aangezien in de patiënt, als gevolg van pre-conditioning geïnduceerde weefselschade 
en infecties, een proinflammatoire cytokine milieu kan zijn gecreëerd is er een verhoogde 
kans op GvHD. Voor het bereiken van het gewenste therapeutische effect na een DLI is het 
dus belangrijk om de goede balans tussen de kansen op het optreden van GvT en GvHD te 
vinden. Veel onderzoek is er op gericht om T-cellen te kunnen selecteren, die uitsluitend 
antigenen herkennen die specifiek door maligne of patïent hematopoïetische cellen 
worden aangeboden. Net zoals het selecteren en toedienen van virus specifieke T-cellen 
kan helpen bij het voorkomen en terugdringen van opportunistische virale infecties, kan 
het toedienen van geselecteerde T-cellen die slechts aan GvT bijdragen, leiden tot een 
langdurige immuunreactie tegen deze kwaadaardige cellen in de afwezigheid van ernstige 
GvHD.
De basis van T-cel reactiviteit
T-cellen kunnen lichaamsvreemde cellen herkennen met behulp van een T-cel receptor 
(TCR). Het TCR repertoire in onze T-cel populatie is enorm divers en elke TCR is in principe 
specifiek voor een bepaald antigeen. Een TCR is een heterodimeer die bestaat uit een 
TCRα en TCRβ keten. In deze ketens vinden willekeurige mutaties en recombinaties plaats 
in de complimentarity determining regions (CDR3) die bepalen welke specifieke structuur 
(epitoop) de betreffende T-cel kan herkennen nadat deze is aangeboden door HLA-
moleculen. Deze TCR gen recombinaties vormen de basis voor de diversiteit in ons TCR 
repertoire en vormen evolutionair gezien een belangrijke overlevingsstrategie. Voordat 
een gematureerde T-cel met zijn unieke TCR de thymus kan verlaten en in de bloedbaan 
kan worden opgenomen, wordt deze gecontroleerd op zijn vermogen om interacties met 
eigen HLA-moleculen aan te kunnen gaan. Herkenning van lichaamsvreemde epitopen, 
zoals die afkomstig van virussen en bacteriën, maar ook die van patiëntenweefsel met 
een vreemd HLA-type, kan de T-cel doen activeren. Vervolgens zal de T-cel de potentieel 
geïnfecteerde cel doorboren met perforines om toegang te verschaffen voor de door de 
T-cel uitgescheiden cytotoxische moleculen zoals granzymes en granulysin. Deze zullen 
vervolgens de geïnfecteerde cel aanzetten tot apoptose.
 T-cellen zijn op basis van de expressie van het type coreceptor molecuul te 
onderscheiden in twee categorieën. Deze coreceptor kan tijdens het herkennen van een 
vreemd HLA-peptide complex door de TCR ook aan het HLA van de geïnfecteerde cel 
binden. Door deze interactie verankert de T-cel zich aan de geïnfecteerde cel en kan er 
een cascade van intracellulaire signalering ontstaan die noodzakelijk is om de T-cel te 
activeren. Onderscheid wordt gemaakt tussen T-cellen die een CD4 of CD8 co-receptor 
op hun oppervlak presenteren. In deze studie wordt gefocust op de CD8 positieve T-cellen 
die beperkt zijn tot het herkennen van epitopen in HLA klasse I. HLA klasse I moleculen 
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komen in tegenstelling tot klasse II constant tot expressie op alle kernhoudende cellen. 
CD8 positieve T-cellen die in de context van HLA klasse I antigenen kunnen herkennen zijn 
overwegend effector T-cellen met een cytotoxische activiteit die vreemde cellen kunnen 
lyseren.
Minor-antigenen
Voor het slagen van een stamceltransplantatie is het relevant om de juiste donor te 
selecteren. Wanneer er een verschil in HLA-typering bestaat tussen patiënt en donor, 
een zogenoemde ‘major mismatch’, zal een groot gedeelte van de geïntroduceerde 
donor T-cel immuniteit zich richten tegen epitopen die worden gepresenteerd door het 
vreemde HLA-molecuul. Het T-cel compartiment van een individu bestaat uit T-cellen 
die alleen lichaamsvreemde en niet lichaameigen epitopen in eigen HLA moleculen 
mogen herkennen. T-cellen zijn tijdens hun selectie in de thymus in de donor niet zijn 
geselecteerd om te voorkomen dat zij lichaamseigen epitopen in de context van vreemd 
patiënt HLA herkennen. Hierdoor kunnen de geïntroduceerde T-cellen de door dit vreemde 
HLA aangeboden lichaamseigen epitopen herkennen als lichaamsvreemd en zodoende 
gezonde cellen aanvallen. Als gevolg hiervan kan er een zeer ernstige GvHD optreden. 
Echter, in de context van een HLA-identieke stamceltransplantatie kan er nog steeds T-cel 
immuniteit optreden tegen cellen van de patiënt. Deze allo-reactiviteit wordt veroorzaakt 
door lichaamsvreemde peptiden afkomstig van de patiënt die in hetzelfde type HLA worden 
aangeboden, en door donor T-cellen kunnen worden herkend.. In dit geval kan de T-cel 
immuniteit worden verklaard door de herkenning van zogenoemde minor-antigenen. Deze 
potentieel immunogene epitopen zijn het product van polymorfe genen, het gevolg van 
kleine variaties in het DNA tussen twee individuen. Er zijn talrijke verschillen in het DNA 
tussen individuen. Verschillen in nucleotide kunnen aminozuurveranderingen opleveren 
met als gevolg dat andere peptides door het HLA gepresenteerd kunnen worden. Wanneer 
een polymorf peptide door T-cellen van een ander individu herkend kan worden spreekt 
men van een minor-antigeen. De zogenoemde single nucleotide polymorphisms (SNP) die 
coderen voor minor-antigenen komen met een bepaalde frequentie in een populatie voor. 
Afhankelijk van deze frequentie, zal een specifieke T-cel populatie gericht tegen dit minor-
antigeen in veel of weinig patiënten te vinden zijn na een alloSCT en DLI. 
 Wanneer een minor-antigeen breed tot expressie komt op gezonde weefsels 
(zowel hematopoïetische als niet-hematopoïetische cellen) van de patiënt kan de T-cel 
reactiviteit van de donor bijdragen aan GvHD omdat de T-cellen deze gezonde cellen als 
vreemd zullen herkennen en lyseren. Als het minor-antigeen alleen gepresenteerd wordt op 
alle hematopoïetische cellen of preferentieel op de maligne cellen van de patiënt kan deze 
echter bijdragen aan GvT. Het elimineren van de hematopoïetische cellen van de patiënt 
waar de leukemiecellen een onderdeel van zijn, leidt namelijk niet tot problemen aangezien 
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donor T-cellen zal worden aangevallen. Therapeutisch relevante minor-antigenen worden 
daarom preferentiël door hematopoïetische of maligne cellen tot expressie gebracht. Om 
de weefseldistributie van minor-antigenen te karakteriseren is een uitgebreide genexpressie 
analyse noodzakelijk. Een infusie van T-cellen die reactief zijn tegen minor-antigenen die 
uitsluitend worden gepresenteerd door het hematopoïetische systeem van de patiënt, en 
zodoende reactief zijn tegen de hematopoïetische cellen, inclusief de maligniteit, is een 
ideale manier om langdurige genezing van leukemie te induceren. Deze minor-antigeen-
specifieke immunotherapie kan, zoals onderzoek heeft aangetoond, effectief zijn. Er zijn 
echter nog maar een beperkt aantal minor-antigenen geïdentificeerd die uitsluitend door 
het hematopoïetische systeem worden gepresenteerd. Om minor-antigeen-specifieke 
immunotherapie tot een realistische optie te maken voor veel patiënten met leukemie 
dienen er meer geschikte minor-antigenen te worden geïdentificeerd.
Dit proefschrift
In dit proefschrift zijn methoden onderzocht om op een innovatieve wijze minor-antigeen-
specifieke CD8 positieve T-cellen te identificeren. De conventionele, ‘voorwaartse methode’ 
om nieuwe minor-antigenen te identificeren is sinds zijn ontdekking drastisch veranderd 
en geoptimaliseerd maar is in essentie niet veranderd. T-cellen met een onbekende 
specificiteit worden geïsoleerd uit het bloed van patiënten die een HLA-identieke 
stamceltransplantatie hebben ondergaan. Met behulp van verschillende moleculaire 
methoden kan vervolgens het herkende minor-antigeen geïdentificeerd worden. Met 
behulp van de voorwaartse methode is er de afgelopen jaren een grote hoeveelheid 
minor-antigenen met uiteenlopende weefseldistributies geïdentificeerd. Helaas zijn er 
hiervan veel niet therapeutisch relevant vanwege een ongunstige weefseldistributie van 
het minor-antigeen coderende gen. Om de identificatie van therapeutisch relevante minor-
antigenen efficiënter te maken is in dit onderzoek de mogelijkheid onderzocht om met 
een ‘terugwaartse methode’ minor-antigenen en de bijbehorende specifieke T-cellen te 
identificeren. Het fundamentele verschil tussen deze en de voorwaartse methode is de 
keuze voor het epitoop dat herkend dient te worden. Het uitgangspunt van deze methode 
is gebaseerd op het kunnen voorspellen van perfecte, hematopoïese-specifieke minor-
antigenen door het gebruik van databanken en bioinformatica. Als een voorspeld minor-
antigeen op theoretische wijze voldoet aan alle opgestelde criteria kan vervolgens in het 
bloed van gezonde donoren gezocht worden naar een T-cel die uitsluitend dit epitoop 
herkend. Het isoleren van deze voorspelde minor-antigeen-specifieke T-cellen is het 
einddoel van deze methode. Gebleken is dat de kans om dit soort T-cellen te isoleren uit 
de totale T-cel populatie erg klein is. Daarom moeten verschillende verrijkingsmethoden 
worden ontwikkeld om tot dit resultaat te komen. Omdat de TCR de specificiteit van de 
minor-antigeen-specifieke T-cellen bepaalt, kan de TCR worden gekloneerd en worden 
gebruikt in een immunotherapie waarin deze wordt geïntroduceerd in donor T-cellen van 
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een ander individu. Door met de terugwaartse methode op grote schaal nieuwe minor-
antigeen-specifieke T-cellen te isoleren kan er een TCR-bank worden aangelegd die in 
de toekomst patiënten die een allogene stamceltransplantatie ondergaan mogelijk kan 
voorzien van een minor-antigeen-specifiek T-cel product met gewenste anti-leukemie 
reactiviteit.
 In hoofdstuk 2 wordt onderzocht of het haalbaar is om met de op dat moment 
beschikbare technieken op een efficiënte manier de specificiteit van grote hoeveelheden 
T-cellen te analyseren. Met behulp van publieke SNP en genexpressie databanken en 
drie verschillende peptide-HLA-binding algoritmes kan een groot aantal minor-antigenen 
worden voorspeld. Vervolgens worden bloedmonsters van patiënten die een succesvolle 
alloSCT en DLI hebben ondergaan geanalyseerd met complexen van vier recombinante 
HLA-moleculen (MHC-tetrameren) die een specifiek voorspeld peptide aanbieden. T-cellen 
die deze zogenoemde ‘MHC-tetrameren’ herkennen kunnen op basis van een fluorescent 
label worden geïdentificeerd. Hoewel het technisch haalbaar blijkt om met de ontwikkelde 
methode op grote schaal peptide-specifieke T-cellen te isoleren – er worden T-cellen 
geïsoleerd voor 71 voorspelde minor-antigenen – blijkt geen van deze T-cellen in staat te 
zijn de door de patiënt van nature gepresenteerde peptiden te herkennen. Op basis van 
dit hoofdstuk kunnen twee belangrijke conclusies getrokken worden die voor het verdere 
verloop van het onderzoek relevant zijn. Allereerst blijkt dat het willekeurig analyseren 
van patiënten op de aanwezigheid van minor-antigeen reactieve T-cellen, in de context 
van een epitoop-gedreven terugwaartse methode, zonder hun SNP status in overweging 
te nemen, een zeer lage efficiëntie op te leveren. Het grootste deel van de geïsoleerde 
MHC-tetrameer positieve T-cellen blijkt niet in staat minor-antigeen presenterende 
cellen te kunnen herkennen. Vermoedelijk komt dit doordat de geïsoleerde T-cellen in de 
thymus van de oorspronkelijke donor zijn geselecteerd om lichaamseigen epitopen niet te 
herkennen. T-cellen geïsoleerd in deze categorie hebben een overwegend lage aviditeit 
voor de voorspelde minor-antigenen. Daarnaast worden er ook T-cellen geïsoleerd uit 
donoren die het voorspelde minor-antigeen wel met een hoge aviditeit herkennen. Dit 
wordt aangetoond door op een artificiële manier dit antigeen door antigeen-negatieve 
cellen tot expressie te laten brengen. Deze cellen worden alleen dan herkend. Omdat cellen 
van de patiënt niet herkend worden geeft dit aan dat een groot deel van de voorspelde 
minor-antigenen niet van nature wordt gepresenteerd door het HLA op de cellen van de 
patiënt.
 In hoofdstuk 3 wordt onderzocht of het met de ontwikkelde MHC-tetrameer 
verrijkingsmethode mogelijk is om laag-frequente peptide-reactieve T-cellen effectiever te 
isoleren uit perifeer bloed en wat hun vermogen is goed hun epitoop te herkennen Van de 
geselecteerde virale peptiden is eerder aangetoond dat ze van nature worden gepresenteerd 
door geïnfecteerde cellen in één van de veel voorkomede HLA allelen; A1, A2, B7, B8 en B40, 
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T-cellen uit het ‘naïeve’ repertoire willen we de gevoeligheid van de isolatiemethode 
bepalen. Voor dit doeleinde zijn donoren met een negatieve serologische status voor 
het humane herpesvirus CMV geselecteerd en is met behulp van de MHC-tetrameer 
verrijkingsmethode getracht CMV-specifieke naïeve T-cellen te isoleren. Het blijkt mogelijk 
om in twee opeenvolgende MHC-tetrameer verrijkingsstappen duidelijk aantoonbare 
MHC-tetrameer-positieve T-cel populaties op te kweken voor 8 van de 10 geselecteerde 
epitopen. Door het V-beta keten gebruik van de TCR van MHC-tetrameer-positieve T-cel 
populaties te analyseren laten we zien dat deze van een complexe samenstelling zijn. Het 
meermaals uitvoeren van een zelfde isolatie experiment laat zien dat de frequentie van 
CMV specifieke voorloper cellen in het naïeve T-cel repertoire een grote invloed heeft op 
de samenstelling van de expanderende T-cel populaties. Door de verschillende populaties 
functioneel te testen op de herkenning van cellen die beladen zijn met peptide of die het 
peptide endogeen presenteren blijkt dat veel geïsoleerde T-cel klonen niet reactief zijn 
tegen het specifieke CMV-peptide. Blijkbaar correleert de MHC-tetrameer aankleuring van 
een T-cel populatie niet altijd met functionele reactiviteit, zeker wanneer T-cellen worden 
verkregen uit het naïeve repertoire aangezien deze nog niet zijn geselecteerd op een hoge 
aviditeit zoals antigeen-ervaren T-cellen. Dit gebrek aan correlatie kan worden verklaard 
door de manier waarop een recombinant MHC-multimeren complex (MHC-tetrameer) zich 
aan een T-cel bindt. Door de associatie- en dissociatiekinetiek van het MHC-peptide-TCR-
complex te bestuderen met behulp van een innovatieve streptameer techniek blijkt dat 
deze kinetiek tussen een TCR en een MHC-tetrameer op een onnatuurlijke wijze verstoord 
is door de multimerisatie van MHC-peptide moleculen. Met behulp van streptameren, 
een complex dat sterk lijkt op een MHC-tetrameer maar waarvan de sterptavidine-biotine 
anker-residuen van het complex na de binding met een T-cel verbroken kunnen worden, 
tonen we aan dat de dissociatiekinetiek van een TCR met een enkel MHC-peptide molecuul 
wel correleert met de functionaliteit van de geïsoleerde T-cel kloon. We laten zien dat 
van vier T-cel klonen met een relatief vergelijkbare hoge MHC-tetrameer aankleuring er 
maar twee daadwerkelijk functioneel zijn. Door deze analyse kunnen functionele en niet-
functionele T-cel klonen in de toekomst van elkaar worden onderscheiden.
 In hoofdstuk 4 wordt een nieuwe methode beschreven die ontwikkeld wordt 
om minor-antigenen te voorspellen en de bijbehorende T-cellen te isoleren. In deze 
methode wordt een andere bron van minor-antigenen geïntegreerd in de terugwaartse 
identificatiemethode. Peptiden die van nature gepresenteerd worden door het HLA van 
cellen worden door een zuurbehandeling geëlueerd en vervolgens geïdentificeerd op 
basis van hun moleculaire massa met behulp van massaspectrometrie. Deze bron van 
geelueerde peptiden garandeert dat de peptiden van nature gepresenteerd kunnen 
worden in het HLA op het celmembraan van cellen. Om minor-antigenen te identificeren 
die van nature door hematopoïetische cellen kunnen worden gepresenteerd is gebruik 
gemaakt van geïmmortaliseerde B-cellijnen als peptidenbron. De identificatie van de 
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biologisch relevante en immunogene LB-NISCH-1A minor-antigeen-specifieke T-cel uit 
het bloed van een gezonde donor toont aan dat deze nieuwe methode haalbaar is. Deze 
nieuwe methode wordt vervolgens in hoofdstuk 5 op grotere schaal gebruikt om vanuit 
een nieuwe databank van geëlueerde peptiden minor-antigenen te voorspellen en daar 
vervolgens immunogene T-cellen voor te isoleren. Dit leidt tot de identificatie van de 
minor-antigenen LB-CLYBL-1Y en LB-TEP1-1S. De klinische relevantie van LB-CLYBL-1Y wordt 
aangetoond door de aanwezigheid van MHC-tetrameer-positieve T-cellen in het bloed 
van een patiënt na alloSCT. Hiermee is de cirkel rond en tonen we aan dat met de in dit 
proefschrift ontwikkelde terugwaartse methode T-cellen met een gewenst minor-antigeen 
herkenningspatroon geïdentificeerd kunnen worden.
 Tot op heden is het aantal minor-antigen dat geïdentificeerd werd met een 
voorwaartse methode groter dan die resulteren uit een terugwaartse methode. In 
dit proefschrift tonen we aan dat het voorspellen van klinisch relevante T-cel epitopen 
onverwacht complex is. De identificatie van drie nieuwe minor-antigen met de in dit 
proefschrift ontwikkelde terugwaartse methode geeft de mogelijkheid aan maar de 
lage efficiëntie maakt deze nog niet tot een volwaardige concurrent van de voorwaartse 
methode. In de komende jaren kan het gebruik van nieuwe bioinformatische informatie de 
efficiëntie van terugwaartse epitoop identificatie methoden verhogen. Hierdoor kan een 
grote collectie van T-cel producten worden aangelegd waardoor het realistischer wordt om 














Op een vroege decemberochtend in 2011 kreeg ik vlak voor mijn eerste praatje op het 
grootste internationale hematologiecongres een belangrijk advies. “Houdt de spanning 
tot het einde vast en laat deze niet direct los bij het uitspreken van je laatste woorden, 
een goed optreden tijdens de vragenronde bepaalt hoe je bij het publiek blijft hangen”. 
Ondanks een grote dosis gezonde spanning ging mijn presentatie inclusief vragenronde 
goed en ik denk nog vaak met plezier terug aan deze indrukwekkende tijd. Dit advies heb 
ik ook proberen te volgen bij het afronden van mijn promotietraject. Het was niet altijd 
eenvoudig om in de twee jaar sinds mijn vertrek uit Leiden mijn energie te doseren en 
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koffiepauze op “de brug” werden naast de dagelijkse belevenissen ook vaak de saillantste 
details besproken.
 Michel Kester wil ik speciaal bedanken voor onze geweldige samenwerking 
gedurende mijn gehele promotietraject. Door onze discussies heb je mijn enthousiasme 
vergroot voor de wetenschap en vooral voor het biochemische “groffuh gooi- en smijtwerk” 
waar je echt een kei in bent. Lorenz Jahn wil ik bedanken voor de enorme berg werk die 
hij verzet heeft tijdens zijn stage en de manier waarop hij hiermee later als PhD student is 
doorgegaan. Heren, naast goede collega’s zijn we ook vrienden geworden en ik ben er trots 
op straks aan jullie zijde op het Rapenburg te mogen staan. 
 Daarnaast wil ik alle co-auteurs danken voor hun belangrijke bijdrage aan het tot 
stand komen van de hoofdstukken. In het bijzonder mijn eerste student Yotam Raz. Ik heb 
je tijdens je “vrijwillige” stage van puber zien opgroeien tot enthousiaste onderzoeker en 
ik weet zeker dat je een groot onderzoeker gaat worden. I thank Sine Reker Hadrup. As an 
experienced Postdoc you took me by the hand during the first difficult phase of my PhD. 
You showed me the great things that can be done using multi-color flow cytometry that I 
am still doing today. Thanks for inviting me at your lab in Copenhagen and for having me as 
a guest at your house.
Mijn ouders wil ik bedanken voor hun onvoorwaardelijke steun en liefde. Ik heb jullie 
geduld op de proef gesteld maar dit leidde alleen maar tot meer aanmoedigingen.
Lieve Liset, met jou is het iedere dag genieten. Fijn dat we elkaar zo goed begrijpen. Zonder 
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